Page last updated: 2024-11-10

quinine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lochnericine: from elicited cell cultures of Catharanthus roseus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lochnericine : An Aspidosperma alkaloid with molecular formula C21H24N2O3 found in the roots of Madagascar periwinkle (Catharanthus roseus, formerly known as Vinca rosea). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
CinchonagenusA genus of rubiaceous South American trees that yields the toxic CINCHONA ALKALOIDS from their bark; QUININE; QUINIDINE; chinconine, cinchonidine and others are used to treat MALARIA and CARDIAC ARRHYTHMIAS.[MeSH]RubiaceaeThe Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH]
AspidospermagenusA plant genus of the family APOCYNACEAE. It contains ellipticine.[MeSH]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]
VincagenusA plant genus of the family Apocynaceae.[MeSH]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]
CinchonagenusA genus of rubiaceous South American trees that yields the toxic CINCHONA ALKALOIDS from their bark; QUININE; QUINIDINE; chinconine, cinchonidine and others are used to treat MALARIA and CARDIAC ARRHYTHMIAS.[MeSH]RubiaceaeThe Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH]

Cross-References

ID SourceID
PubMed CID3034034
CHEMBL ID170
CHEBI ID15854
SCHEMBL ID27031
MeSH IDM0018346
PubMed CID11382599
CHEMBL ID2011514
CHEBI ID6510
SCHEMBL ID6535297
MeSH IDM0018346

Synonyms (123)

Synonym
nsc 192949
cinchonan-9-ol, 6'-methoxy-, (8alpha,9r)-
(8-alpha,9r)-6'-methoxycinchonan-9-ol
quinine anhydrous
cinchonan-9-ol, 6'-methoxy-, (8-alpha,9r)-
ccris 5755
cinchonan-9-ol, 6'-methoxy-
(8s,9r)-6'-methoxycinchonan-9-ol
hsdb 2501
chinin [german]
(r)-(-)-quinine, 6-methoxycinchonidine
einecs 205-003-2
2-quinuclidinemethanol, alpha-(6-methoxy-4-quinolyl)-5-vinyl-
quinine tannate [usp]
unii-26mx5yal2r
quinine, tannate
einecs 215-805-4
AB00375052-12
AB00375052-11
(r)-[(4s,5r,7s)-5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl]-(6-methoxyquinolin-4-yl)methanol
quinine bisulphate
gtpl2510
chinine
6-methoxycinchonine
nsc-192949
nsc192949
(8s,9r)-quinine
chininum
(9r)-6'-methoxy-8alpha-cinchonan-9-ol
chinin
6'-methoxycinchonidine
quinina
CHEBI:15854 ,
(r)-(-)-quinine
(r)-(6-methoxyquinolin-4-yl)((2s,4s,8r)-8-vinylquinuclidin-2-yl)methanol
quinine, suitable for fluorescence, anhydrous, >=98.0% (dried material, nt)
quinsan (*2:1 sulfate salt*), dihydrate
biquinate (*bisulfate heptathydrate*)
cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9r)-, sulfate
dentojel (*bisulfate heptathydrate*)
(8.alpha.,9r)-6'-methoxycinchonan-9-ol
quine (*2:1 sulfate salt*, dihydrate)
(r)-(6-methoxy-4-quinolyl)-[(2s,4s,5r)-5-vinylquinuclidin-2-yl]methanol
quinoline alkaloid
quinamm (*2:1 sulfate salt*), dihydrate
(-)-quinine
quinine ,
130-95-0
DB00468
NCGC00166281-01
quinine, 90%
HMS2089E05
wr297608
chininum purum
rezquin
CHEMBL170 ,
(r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
unii-a7v27phc7a
ec 205-003-2
quinine [ban:nf]
a7v27phc7a ,
cas-130-95-0
dtxsid0044280 ,
tox21_112389
dtxcid60819897
quinine, anhydrous
quinineanhydrous
6'-methoxycinchonine
S4495
bdbm50367247
quinsan
chininum purum [hpus]
quinine [mi]
quinine [hsdb]
quinine [mart.]
quinine [vandf]
quinine [inci]
quinine [who-dd]
EPITOPE ID:131786
AKOS017343662
qi9 ,
SCHEMBL27031
NCGC00274071-01
tox21_112389_1
(r)-(6-methoxyquinolin-4-yl)((1s,2s,4s,5r)-5-vinylquinuclidin-2-yl)methanol
(-)quinine
(r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol
STR03990
cinchonan-9-ol, 6'-methoxy-, (8a,9r)-
AB00375052_13
alpha-(6-methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol
kinder quinina
(r)-[(1s,2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol
quinine, certified reference material, tracecert(r)
Z2235811384
(1r)-(6-methoxyquinolin-4-yl)((2s,4s,5r)-5-vinylquinuclidin-2-yl)methanol
(r)-(6-methoxyquinolin-4-yl)((2s,4s,5r)-5-vinylquinuclidin-2-yl)methanol
(r)-[(2s,4s,5r)-1-aza-5-vinylbicyclo[2.2.2]-oct-2-yl](6-methoxyquinolin-4-yl)methanol
Q189522
Q27166273
(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxy-4-quinolinyl)methanol
BRD-K07940445-003-01-2
O12066
EN300-258513
quinine (mart.)
lochnericine
CHEMBL2011514
(5alpha,6alpha,7alpha,12beta,19alpha)-2,3-didehydro-6,7-epoxyaspidospermidine-3-carboxylic acid methyl ester
methyl 5alpha,6alpha,7alpha,12beta,19alpha-2,3-didehydro-6,7-epoxyaspidospermidine-3-carboxylate
(-)-lochnericine
CHEBI:6510
72058-36-7
SCHEMBL6535297
unii-wy97j4b4am
aspidospermidine-3-carboxylic acid, 2,3-didehydro-6,7-epoxy-, methyl ester, (5alpha,6alpha,7alpha,12r,19alpha)-
aspidospermidine-3-carboxylic acid, 2,3-didehydro-6,7-epoxy-, methyl ester, (5.alpha.,6.alpha.,7.alpha.,12r,19.alpha.)-
WY97J4B4AM ,
lochnericine, (-)-
(5.alpha.,6.alpha.,7.alpha.,12.beta.,19.alpha.)-2,3-didehydro-6,7-epoxyaspidospermidine-3-carboxylic acid methyl ester
lochnericine [mi]
FS-9271
methyl (1r,12s,13r,15s,20r)-12-ethyl-14-oxa-8,17-diazahexacyclo[10.7.1.01,9.02,7.013,15.017,20]icosa-2,4,6,9-tetraene-10-carboxylate
AKOS040752642

Research Excerpts

Overview

Quinine (Qi) is a well-known drug used in malaria therapy. It is also a potential anti-arrhythmic drug used for the treatment of calf cramps, rheumatoid arthritis, colds, and photodermatitis. Quinine is toxic to the auditory system by commonly inducing hearing loss and tinnitus.

ExcerptReferenceRelevance
"Quinine (Qi) is a well-known drug used in malaria therapy; it is also a potential anti-arrhythmic drug used in the treatment of calf cramps, rheumatoid arthritis, colds, and photodermatitis. "( Spectroscopic Analysis of an Antimalarial Drug's (Quinine) Influence on Human Serum Albumin Reduction and Antioxidant Potential.
Kulig, K; Lemańska, O; Maciążek-Jurczyk, M; Muhammetoglu, T; Owczarzy, A; Pożycka, J; Rogóż, W, 2022
)
2.42
"Quinine is an anti-malarial agent belongs to the quinoline alkaloid that can inhibit angiogenesis."( Antiangiogenic Activity of Quinine Alone and in Combination with vitamin C in both ex vivo and in vivo Assays.
Jalil, ZH; Sahib, HB, 2022
)
1.74
"Quinine is an alkaloid with antipyretic and anti-infective properties, and also an ingredient in tonic waters. "( [A drink with an unexpected ending... Adverse reaction by tonic water: A case report].
Bermúdez-Hormigo, C; de Aramburu-Mera, T; Moreno-Lozano, L; Pérez-Darnaudguilhem, GL, 2023
)
2.35
"Quinine is a bitter taste receptor agonist that exhibits antimalarial effects."( Therapeutic effects of quinine in a mouse model of atopic dermatitis.
Chen, S; Huang, J; Jiang, H; Li, X; Liu, M; Lyu, Y; Wang, L; Zhang, Q; Zhou, M, 2021
)
1.65
"Quinine is an antimalarial drug that is toxic to the auditory system by commonly inducing hearing loss and tinnitus, presumably due to its ototoxic effects on disruption of cochlear hair cells and blockade of ion channels of neurons in the auditory system. "( The Effects of Quinine on Neurophysiological Properties of Dopaminergic Neurons.
Heinbockel, T; Jones, M; Xue, Y; Ying, M; Zhan, X; Zou, L, 2018
)
2.28
"Quinine is a bitter compound that is an agonist for several T2Rs also expressed on sinonasal cells, but not for T2R38."( The Role of Quinine-Responsive Taste Receptor Family 2 in Airway Immune Defense and Chronic Rhinosinusitis.
Adappa, ND; Brooks, SG; Cohen, NA; Cowart, BJ; Kennedy, DW; Kohanski, MA; Lee, RJ; Maina, IW; Mansfield, C; Palmer, JN; Reed, DR; Workman, AD, 2018
)
1.58
"Quinine is a drug used for the treatment of malaria and nocturnal leg cramps and is also an important ingredient in some herbal preparations."( Quinine-induced severe thrombocytopenia: the importance of taking a detailed drug history.
Hayes, R; Mohamed, M, 2013
)
2.55
"Quinine is a common food additive and is recognised as a rare cause of FDE."( A case of fixed drug eruption secondary to quinine in tonic water presenting to a sexual health clinic.
Lonsdale-Eccles, E; Wallett, A; Ward, AM, 2014
)
1.39
"Quinine is a common cause of drug-induced thrombocytopenia and the most common cause of drug-induced thrombotic microangiopathy. "( Diversity and severity of adverse reactions to quinine: A systematic review.
George, JN; Liles, AL; Liles, NW; Page, EE; Raskob, GE; Vesely, SK, 2016
)
2.13
"Quinine is a bitter tasting compound that is involved in the regulation of body weight as demonstrated in in vivo animal models and in vitro models of the adipogenic system. "( Regulation of Adipogenesis by Quinine through the ERK/S6 Pathway.
He, J; Ning, X; Shi, X; Yang, G, 2016
)
2.17
"Quinine is a cytochrome P450 isoenzyme 3A4 inhibitor, the very enzyme which is involved in the metabolism of most statins."( Quinine induced simvastatin toxicity through cytochrome inhibition - a case report.
Just, JM; Just, KS; Weckbecker, K, 2016
)
2.6
"Quinine is an alkaloid with powerful antimalarial activity, isolated from the bark of Peru's cinchona trees. "( Intramolecular Hydrogen Bonds in Conformers of Quinine and Quinidine: An HF, MP2 and DFT Study.
Bilonda, MK; Mammino, L, 2017
)
2.15
"Quinine, is an anti-malarial drug that specifically blocks connexin 36 (Cx36) at gap junction channels. "( Antiepileptic effects of quinine in the pentylenetetrazole model of seizure.
Nassiri-Asl, M; Torabinejad, B; Zamansoltani, F, 2009
)
2.1
"IM quinine is a routine procedure in Congo for drug resistant malaria management."( [Intramuscular injections of quinine and tetanus at the Centre Hospitalier Universitaire of Brazzaville, Congo].
Boumandouki, P; Ekouele Mbaki, H; Kounkou, RY; Ndinga, E; Teke-Bagamboula, JN, 2008
)
1.15
"Quinine is a major drug of choice for the treatment of malaria. "( The antimalarial drug quinine disrupts Tat2p-mediated tryptophan transport and causes tryptophan starvation.
Avery, SV; Khozoie, C; Pleass, RJ, 2009
)
2.11
"Quinine is a substrate of the polymorphic p-glycoprotein and CYP3A4/3A5."( Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans.
Aklillu, E; Gustafsson, LL; Mukonzo, JK; Ogwal-Okeng, J; Waako, P, 2010
)
1.32
"Quinine is a standard drug for treating severe malaria in Africa, and it is also increasingly used to treat uncomplicated disease. "( Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda.
Achan, J; Baliraine, FN; Greenhouse, B; Nsobya, SL; Rosenthal, PJ; Talisuna, AO; Tibenderana, JK, 2011
)
2.03
"Quinine is an antimalarial agent whose main mechanism of action on Plasmodium is to inhibit the transformation of toxic haem to polymeric non-toxic haemozoin. "( [Therapeutic drug monitoring of quinine].
Bentué-Ferrer, D; Tribut, O; Verdier, MC,
)
1.86
"Quinine is a natural molecule commonly used as a flavouring agent in tonic water. "( Quinine controls body weight gain without affecting food intake in male C57BL6 mice.
Bezençon, C; Cettour-Rose, P; Damak, S; Darimont, C; le Coutre, J, 2013
)
3.28
"Quinine is an important antimalarial drug that is metabolised mainly by the hepatic mixed-function microsomal enzyme cytochrome P(450). "( Effects of cigarette smoking on quinine pharmacokinetics in malaria.
Jantra, A; Pitisuttithum, P; Pukrittayakamee, S; Wanwimolruk, S; White, NJ; Zhang, H, 2002
)
2.04
"Quinine-induced DIC is a distinct clinical entity, which may present as unexplained thrombocytopenia, coagulopathy, or renal failure. "( Quinine-induced disseminated intravascular coagulation: case report and review of the literature.
Bowton, DL; Dunagan, DP; Knower, MT; Owen, J, 2003
)
3.2
"Quinine is a bitter alkaloid that is used as a flavoring agent in tonic water. "( Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo.
Boulton, D; DeVane, CL; Dodd, S; Donovan, JL; Markowitz, JS, 2003
)
2.1
"Quinine is a common treatment for nocturnal leg cramps but has potential side effects. "( Managing nocturnal leg cramps--calf-stretching exercises and cessation of quinine treatment: a factorial randomised controlled trial.
Coppin, RJ; Little, PS; Wicke, DM, 2005
)
2
"Quinine is an effective and convenient antiarrhythmic drug for the suppression of ventricular arrhythmias in humans."( Antiarrhythmic activity of quinine in humans.
Duff, H; Koshman, ML; Sheldon, R, 1995
)
2.03
"1. Quinine is a front-line antimalarial drug but is prescribed most commonly in nonmalarious countries for cramps. "( The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly.
Annus, T; Davis, TM; Dyer, JR; Garcia-Webb, P; Giele, C; Robson, J, 1994
)
1.17
"Quinine is a useful model substance for reversibly inducing complete loudness recruitment in humans as it acts specifically on some parts of the hearing function."( Quinine reduces the dynamic range of the human auditory system.
Alván, G; Berninger, E; Karlsson, KK, 1998
)
2.46
"Quinine is a widely used medication which has been reported to cause thrombocytopenia on occasion. "( Quinine for cramps.
Pinn, G, 1998
)
3.19
"Quinine is an optical isomer of quinidine. "( Stereospecificity of antibody: quinine, the optical isomer of quinidine and anti-malarial drug chloroquine do not cross-react with quinidine immunoassays.
Dasgupta, A; Paul, A; Wells, A, 2000
)
2.04
"Quinine sulfate is a widely prescribed drug for nocturnal cramps."( [Acral necroses after therapy with quinine sulfate for calf cramps].
Abreu-Gerke, L; Goerz, G; Miller, A; Ruzicka, T, 2000
)
1.31
"Quinine is a suitable model substance for the study of otoacoustic emissions (OAEs) as it reversibly affects the outer hair cells, thus reducing sensitivity, frequency-selectivity and various forms of OAEs. "( Changes in 2f1 - f2 acoustic distortion products in humans during quinine-induced cochlear dysfunction.
Berninger, E; Gustafsson, LL, 2000
)
1.99
"As quinine is a lipophilic drug, this study was conducted to determine whether the pharmacokinetics of quinine is altered in obese subjects."( Pharmacokinetics of quinine in obesity.
Ho, PC; Nachaisit, S; Thitiarchakul, S; Viriyayudhakorn, S; Wanwimolruk, S,
)
0.97
"Quinine is a well-known ototoxic drug which may affect portions of the auditory system with different biochemical effects, causing reversible hearing loss and tinnitus. "( Quinine-induced alterations of electrically evoked otoacoustic emissions and cochlear potentials in guinea pigs.
Nuttall, AL; Parthasarathi, A; Ren, T; Zheng, J, 2001
)
3.2
"Quinine is a common cause of drug-associated TTP-HUS and can cause death and chronic renal failure. "( Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes.
George, JN; Kojouri, K; Vesely, SK, 2001
)
3.2
"Quinine sulfate is a commonly prescribed remedy for idiopathic nocturnal leg cramps and is now available "over the counter." A 24-year-old man ingested 8 g (a commonly dispensed quantity) of quinine sulfate in a suicide attempt. "( Quinine overdose: review of toxicity and treatment.
Goldenberg, AM; Wexler, LF, 1988
)
3.16

Effects

Quinine has an inhibitory effect on tumor and can be utilized as an antiangiogenic agent alone or in combination with vitamin C. Quinine has a side effect profile that cannot be ignored.

Quinine has been used in Western medicine since the 16th century. Quinine has long been used for the treatment of conditions such as malaria and leg cramps. It is also present at low levels in some beverages.

ExcerptReferenceRelevance
"Quinine has an extensive following of users who believe it is salutary and harmless, considering it a food supplement."( Reflections on quinine and its importance in dermatology today.
Gelfman, DM,
)
1.21
"Quinine has a side effect profile that cannot be ignored."( Cinchonism in a patient taking Quinine for leg cramps.
Barrocas, AM; Cymet, T, 2007
)
1.35
"Quinine has an extensive following of users who believe it is salutary and harmless, considering it a food supplement."( Reflections on quinine and its importance in dermatology today.
Gelfman, DM,
)
1.21
"ID quinine has greater effects on plasma gut and pancreatic hormones and pyloric pressures than IG quinine in healthy subjects, consistent with the concept that stimulation of small intestinal bitter receptors is critical to these responses. "( Quinine Effects on Gut and Pancreatic Hormones and Antropyloroduodenal Pressures in Humans-Role of Delivery Site and Sex.
Bitarafan, V; Feinle-Bisset, C; Horowitz, M; Lange, K; Rehfeld, JF; Rezaie, P; Rose, BD, 2022
)
2.79
"Quinine has been used in Western medicine since the 16th century, and far longer in South America. "( Quinine overdose: Not quite gin and tonic.
Bateman, DN, 2023
)
3.8
"Quinine has long been used for the treatment of conditions such as malaria and leg cramps, and is also present at low levels in some beverages; however, it can cause serious side effects. "( A Catastrophic Consequence of Cramp.
Htet, ZM; Karim, M, 2018
)
1.92
"Quinine has been reported to possess anti-spermatogenic activities."( Quinine inhibits ovulation and produces oxidative stress in the ovary of cyclic Sprague-Dawley rats.
Bamisi, OD; Gbotolorun, SC; Inikori, O; Okanlawon, AO; Osinubi, AAA, 2018
)
3.37
"Quinine has been shown to have frequent clinical failures, and yet the mechanisms of action and resistance have not been fully elucidated."( Polymorphisms in Pfmdr1, Pfcrt, and Pfnhe1 genes are associated with reduced in vitro activities of quinine in Plasmodium falciparum isolates from western Kenya.
Akala, HM; Andagalu, B; Angienda, PO; Bidii, NS; Bulimo, WD; Chebon, LJ; Cheruiyot, AC; Cheruiyot, J; Eyase, FL; Ingasia, LA; Johnson, JD; Juma, DW; Kamau, E; Mativo, J; Muiruri, P; Ndegwa, JM; Okudo, C; Omondi, AA; Opot, BH; Yeda, R, 2014
)
1.34
"Quinine has been used to treat cramps of all causes."( Quinine for muscle cramps.
Al Musa, T; Brassington, R; El-Tawil, S; El-Tawil, T; Lunn, MP; Valli, H; Weber, M, 2015
)
2.58
"Quinine has suppressed ictal epileptiform activity in vitro without decreasing neuronal excitability."( Antiepileptic effects of quinine in the pentylenetetrazole model of seizure.
Nassiri-Asl, M; Torabinejad, B; Zamansoltani, F, 2009
)
1.38
"Quinine has been employed in the treatment of malaria for centuries and is still used against severe Plasmodium falciparum malaria. "( Transcriptomic profiling of the Saccharomyces cerevisiae response to quinine reveals a glucose limitation response attributable to drug-induced inhibition of glucose uptake.
Becker, J; dos Santos, SC; Palma, M; Sá-Correia, I; Tenreiro, S, 2009
)
2.03
"Quinine has been used to treat cramps of all causes."( Quinine for muscle cramps.
Al Musa, T; El-Tawil, S; El-Tawil, T; Lunn, MP; Valli, H; Weber, M, 2010
)
2.52
"Quinine has been the only option for parenteral therapy until recently."( Treatment of imported severe malaria with artesunate instead of quinine--more evidence needed?
Burchard, GD; Cramer, JP; de Vries, PJ; Grobusch, MP; López-Vélez, R, 2011
)
1.33
"Quinine sulfate has borderline solubility characteristics and, on the whole, is highly permeable."( Biowaiver monographs for immediate-release solid oral dosage forms: quinine sulfate.
Barends, DM; Dressman, JB; Kopp, S; Polli, JE; Shah, VP; Strauch, S, 2012
)
1.34
"Quinine has been marketed in the United States (U.S.) both over-the-counter (OTC) and by prescription for numerous purposes, including malaria and muscle spasms. "( Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action.
Beitz, J; Brinker, AD, 2002
)
2
"Quinine (QU) has been used worldwide in the suppression and treatment of malaria for more than 350 years. "( Morphometric and stereological assessment of the effects of long-term administration of quinine on the morphology of rat testis.
Noronha, CC; Okanlawon, AO; Osinubi, AA,
)
1.8
"Quinine and quinidine have been cited as drugs that may cause significant morbidity and mortality in toddlers who ingest one or two pills. "( Are one or two dangerous? Quinine and quinidine exposure in toddlers.
Huston, M; Levinson, M, 2006
)
2.08
"Quinine has been increasingly utilized as a placebo in cystic fibrosis (CF) clinical trials, including those leading to FDA approval of inhaled tobramycin, recent studies of anti-inflammatory aerosols such as glutathione, and clinical testing of hypertonic saline aerosols to augment mucous clearance. "( Bioelectric effects of quinine on polarized airway epithelial cells.
Alexander, M; Bates, E; Bebok, Z; Fortenberry, JA; Mazur, M; Miller, S; Rowe, SM; Sorscher, EJ, 2007
)
2.09
"Quinine sulfate has been used with apparent success in some patients, but the Food and Drug Administration recently ordered the cessation of marketing of unapproved quinine formulations and advised consumers to avoid "off-label" use of quinine for cramps."( Quinine--a tonic too bitter for hemodialysis-associated muscle cramps?
Berns, JS; Kobrin, SM,
)
2.3
"Quinine has a side effect profile that cannot be ignored."( Cinchonism in a patient taking Quinine for leg cramps.
Barrocas, AM; Cymet, T, 2007
)
1.35
"Quinine and quinidine have been evaluated with regard to their effects on the electrical activity of neuroblastoma cells. "( Potassium current suppression by quinidine reveals additional calcium currents in neuroblastoma cells.
Fishman, MC; Spector, I, 1981
)
1.71
"Quinine-tetracycline has been used as a second line treatment for uncomplicated falciparum malaria, but duration of treatment varies from place to place."( Quinine-tetracycline for multidrug resistant falciparum malaria.
Bunnag, D; Chittamas, S; Harinasuta, T; Karbwang, J; Na-Bangchang, K; Thanavibul, A, 1996
)
2.46
"Quinine has been shown to inhibit TNF synthesis and cytoadherence in vitro suggesting an additional beneficial effect of quinine on its anti-TNF action."( The effects of quinine and artesunate treatment on plasma tumor necrosis factor levels in malaria-infected patients.
Chotivanich, KT; Ittarat, W; Looareesuwan, S; Udomsangpetch, R, 1999
)
1.38
"Quinine has open conformation typical for Cinchona alkaloids forming intermolecular hydrogen bonds in the crystalline state."( Crystal and molecular structure of a new cobalt complex of quinine.
Oleksy, BJ; Pytel, P; Sliwiński, J, 2001
)
1.28
"Quinine sulfate has been the drug of choice for the treatment of the ever-increasing number of cases of falciparum malaria in tropical countries. "( Drug monitoring of quinine in men with nonsevere falciparum malaria: study in the Amazon region of Brazil.
Midio, AF; Vieira, JL, 2001
)
2.08
"Quinine has been an effective drug for severe chloroquine-resistant falciparum malaria. "( Plasma quinine levels in patients with falciparum malaria when given alone or in combination with tetracycline with or without primaquine.
Bunnag, D; Harinasuta, T; Karbwang, J; Molunto, P, 1991
)
2.18
"Quinine has local anesthetic action but also is an irritant."( Quinine toxicity.
Bateman, DN; Dyson, EH, 1986
)
2.34

Actions

Quinine was chosen because of its action upon the neuromuscular end motor plate. Quinine elicited an increase in the membrane potential along with a concentration-dependent increase in [Ca(2+)]i. The quinine-induced increase in levels was inhibited by thapsigargin (an inhibitor of the Ca2+ pump into intracellular stores), U73122 and omega-conotoxin.

ExcerptReferenceRelevance
"Quinine can cause diverse and severe immune-mediated adverse reactions, including thrombotic microangiopathy (TMA). "( Quinine-Induced Thrombotic Microangiopathy: A Report of 19 Patients.
George, JN; Little, DJ; Page, EE; Vesely, SK, 2017
)
3.34
"Quinine exposure was lower than previously reported in patients who were not pregnant."( Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.
Day, NP; Dhorda, M; Guerin, PJ; Jullien, V; Kloprogge, F; Muwanga, S; Nosten, F; Piola, P; Tarning, J; White, NJ, 2014
)
1.41
"Quinine is a common cause of drug-induced thrombocytopenia and the most common cause of drug-induced thrombotic microangiopathy. "( Diversity and severity of adverse reactions to quinine: A systematic review.
George, JN; Liles, AL; Liles, NW; Page, EE; Raskob, GE; Vesely, SK, 2016
)
2.13
"The quinine-induced increase in hearing threshold and its recovery can be analysed according to 'the psychophysical power function'."( Concentration-Response Relationship of Hearing Impairment Caused by Quinine and Salicylate: Pharmacological Similarities but Different Molecular Mechanisms.
Alvan, G; Berninger, E; Gustafsson, LL; Karlsson, KK; Paintaud, G; Wakelkamp, M, 2017
)
1.17
"The quinine-induced increase in [Ca2+]i levels was inhibited by thapsigargin (an inhibitor of the Ca2+ pump into intracellular stores), U73122 (an inhibitor of phospholipase C) and omega-conotoxin (an N-type Ca2+-channel blocker), but not by nifedipine (an L-type Ca2+-channel blocker)."( Effect of quinine solutions on intracellular Ca2+ levels in neuro-2a cells--conventional physiological method for the evaluation of bitterness.
Akiyoshi, T; Kashiwayanagi, M; Matsuyama, K; Matzno, S; Nakabayashi, T; Nakamura, T; Shinozuka, K; Tanaka, N; Uchida, T, 2003
)
1.2
"Quinine elicited an increase in the membrane potential along with a concentration-dependent increase in [Ca(2+)]i."( Effects of quinine on the intracellular calcium level and membrane potential of PC 12 cultures.
Akiyoshi, T; Matzno, S; Nakamura, T; Shinozuka, K; Tanaka, N; Uchida, T, 2007
)
1.45
"Quinine was chosen because of its action upon the neuromuscular end motor plate."( [Action of quinine sulphate on the incidence of muscle cramps during hemodialysis (author's transl)].
Chacón, JC; Cruz, JM; Garcés, L; Martin Abad, L; Panadero Sandoval, J; Pérez García, A; Piqueras, A, 1980
)
1.37
"Quinine is a common cause of drug-associated TTP-HUS and can cause death and chronic renal failure. "( Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes.
George, JN; Kojouri, K; Vesely, SK, 2001
)
3.2
"Quinine produced an increase in the resistance associated with a depolarization."( Electrical responses to frog taste cells to chemical stimuli.
Akaike, N; Noma, A; Sato, M, 1976
)
0.98
"With quinine, because peak plasma concentrations are very close to the Ki value, there is likely to be inhibition of mefloquine metabolism in patients receiving both drugs."( Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs.
Back, DJ; Bangchang, KN; Karbwang, J, 1992
)
0.74
"Quinine is known to cause nonspecific changes in the membranes of epithelial cells, which may cause alterations of the transport of organic anions by such tissues."( Quinine reduces noxious cochlear effects of furosemide and ethacrynic acid.
Rybak, LP; Whitworth, C,
)
2.3
"Thus quinine may inhibit Na+-amino acid cotransport by blocking conductive K+ channels, thereby decreasing Vm and the transmembrane electrochemical Na+ gradient, and it may deplete the intracellular amino acid pool by disrupting hepatocyte volume regulation."( Quinine decreases hepatocyte transmembrane potential and inhibits amino acid transport.
Castillo, LB; Wondergem, R, 1988
)
2.17
"Quinine also can cause drug-induced thrombocytopenia and purpura."( Quinine toxicity.
Bateman, DN; Dyson, EH, 1986
)
2.34

Treatment

Quinine is a common treatment for nocturnal leg cramps but has potential side effects. Quinine remains the treatment of choice in hospitalized malaria cases. The long treatment duration of 7 days often hamper its adequate use.

ExcerptReferenceRelevance
"Quinine, a treatment used in chloroquine-resistant falciparum malaria, was loaded into poly(ɛ-caprolactone) or Eudragit"( Optimization of Curcuma Oil/Quinine-Loaded Nanocapsules for Malaria Treatment.
Ávila, DS; Colomé, LM; Freddo, RJ; Gomes, GS; Gundel, A; Haas, SE; Maciel, TR; Michels, LR; Piegas, EM, 2018
)
2.22
"Quinine treated rats recorded zero number of ova compared to control. "( Quinine inhibits ovulation and produces oxidative stress in the ovary of cyclic Sprague-Dawley rats.
Bamisi, OD; Gbotolorun, SC; Inikori, O; Okanlawon, AO; Osinubi, AAA, 2018
)
3.37
"Quinine treatment should be restricted to those with severe symptoms, should be subject to regular review and requires discussion of the risks and benefits with patients."( A review of nocturnal leg cramps in older people.
Mulkerrin, EC; O'Keeffe, ST; Rabbitt, L, 2016
)
1.16
"Quinine is a common treatment for nocturnal leg cramps but has potential side effects. "( Managing nocturnal leg cramps--calf-stretching exercises and cessation of quinine treatment: a factorial randomised controlled trial.
Coppin, RJ; Little, PS; Wicke, DM, 2005
)
2
"Quinine remains the treatment of choice in hospitalized malaria cases; however, adverse reactions and the long treatment duration of 7 days often hamper its adequate use. "( Short course of quinine plus a single dose of sulfadoxine/pyrimethamine for Plasmodium falciparum malaria.
Issifou, S; Kremsner, PG; Matsiegui, PB; Missinou, MA; Necek, M, 2006
)
2.12
"In quinine-treated patients, only 38% were ultimately cured."( High efficacy of short-term quinine-antibiotic combinations for treating adult malaria patients in an area in which malaria is hyperendemic.
Bienzle, U; Graninger, W; Kremsner, PG; Metzger, W; Mordmüller, B, 1995
)
1.1
"The quinine based treatment has stemmed mortality by neuropaludism since two years."( [Epidemiological data on children hospitalized with malaria from 1983 to 1992].
Ramialimanana, V; Randriamiharisoa, FA; Razanamparany, MS; Razanamparany, NJ, 1993
)
0.77
"Quinine treatment was associated with a higher risk of hypoglycemia (relative risk, 2.7; 95 percent confidence interval, 1.7 to 4.4; P < 0.001), but there were no other serious side effects in either group."( A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria.
Day, NP; Dinh, XS; Ha, V; Ly, VC; Nguyen, HP; Nguyen, TH; Peto, TE; Pham, PL; Tran, TH; Waller, D; White, NJ, 1996
)
1.29
"Quinine treatment partially reversed the effects of chloroquine in CS P."( Regulation of heme polymerizing activity and the antimalarial action of chloroquine.
Chou, AC; Fitch, CD, 1997
)
1.02
"Quinine treatment resulted in a high rate of gametocyte carriage: person-gametocyte-weeks = 42.5 (95% CI 27.8-62.1) per 1000 woman-weeks."( The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy.
Cho, T; Looareesuwan, S; McGready, R; Nosten, F; Thwai, KL; White, NJ,
)
1.21
"Quinine treatment did not prevent sequestration but did stop subsequent multiplication.(ABSTRACT TRUNCATED AT 250 WORDS)"( The effects of multiplication and synchronicity on the vascular distribution of parasites in falciparum malaria.
Chapman, D; Watt, G; White, NJ,
)
0.85
"In quinine-treated patients, red cell quinine concentration in those with RII failure was significantly lower than that in patients with cure or RI failure (p less than 0.05)."( Red cell and plasma concentrations of combined quinine-quinidine and quinine in falciparum malaria.
Acmor-Apolinar, MM; Attanath, P; Chongsuphajaisiddhi, T; Pojjaroen-Anant, C; Sabchareon, A; Singhasivanon, V, 1991
)
1.05
"5. Quinine treatment of chromaffin cell cultures produced a small but significant decrease in membrane resting potential and a less pronounced depolarization in response to 50 mM K+."( Effect of quinine on the release of catecholamines from bovine cultured chromaffin cells.
Glavinovic, MI; Novas, ML; Tang, R; Trifaró, JM, 1990
)
1.2
"Treatment with quinine (95.3%) was significantly associated with cases (p < 0.001)."( Blackwater fever in Congolese children: a report of clinical, laboratory features and risk factors.
Akilimali, PZ; Aloni, MN; Bodi, JM; Hirayama, K; Kayembe, PK; Longenge, RL; Nsibu, CN; Omar, AH; Tshibassu, PM; Verhaegen, J, 2013
)
0.73
"Treatment with quinine and doxycycline was started and intravenous fluids were administered with close monitoring of the urine output and serum electrolytes."( An imported case of P. falciparum malaria presenting as black water fever with acute renal failure.
Al-Haddad, D; Khan, FY, 2009
)
0.69
"Treatment with quinine dihydrochloride i.v. "( [Successful management of malaria tropica with 50% parasitaemia].
Eiffert, H; Möller, H; Ramadori, G; Reichard, U; Schwörer, H, 2006
)
0.69
"Treatment with quinine was successful in cases in which serum quinine levels could be maintained above MIC for 7 days."( Treatment of quinine resistant falciparum malaria in Thai children.
Attanath, P; Chongsuphajaisiddhi, T; Sabchareon, A, 1983
)
0.97
"Treatment with quinine resulted in a significant reduction in the number of cramps for a four week period compared with placebo (8.83 fewer cramps; 95% confidence interval 4.16 to 13.49)."( Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people.
Man-Son-Hing, M; Wells, G, 1995
)
0.92
"Pretreatment with quinine blocked the cyanide-induced hyperpolarization, whereas glyburide had little effect, showing the hyperpolarization produced by cyanide was due to activation of Ca2+ sensitive K+ channels."( Plasma membrane hyperpolarization by cyanide in chromaffin cells: role of potassium channels.
Borowitz, JL; Isom, GE; Kanthasamy, A; Latha, MV; Yim, GK, 1994
)
0.61
"Treatment with quinine was associated with significantly more episodes of post-admission hypoglycaemia when compared with artemether or chloroquine."( Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance.
Brewster, D; Chapman, D; Craddock, CF; Crawley, J; Holloway, PA; Krishna, S; Kwiatkowski, D; Nosten, F; ter Kuile, F; Waller, DW,
)
0.47
"Pretreatment with quinine, a K+ channel blocker, prevented formation of tumor necrosis factor (TNF) as well as the subsequent hepatic DNA fragmentation and liver enzyme leakage."( Quinine inhibits release of tumor necrosis factor, apoptosis, necrosis and mortality in a murine model of septic liver failure.
Gantner, F; Uhlig, S; Wendel, A, 1995
)
2.06
"Pretreatment with quinine in vivo prevented not only PAF-, but also endotoxin-induced edema formation as assessed by Evans Blue extravasation."( Quinolines attenuate PAF-induced pulmonary pressor responses and edema formation.
Brasch, F; Falk, S; Göggel, R; Heydasch, U; Müller, KM; Uhlig, S; Wendel, A, 1999
)
0.63
"Treatment with quinine is a common practice, but the effectiveness of the drug is doubtful and adverse drug effects are common."( Randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension.
Chan, P; Chen, YJ; Huang, TY; Huang, WP; Liu, YC, 1998
)
0.64
"Treatment with quinine in the presence or absence of the potassium ionophore valinomycin was used to determine whether potassium channels were involved in the reversal of swelling."( Role of quinine-sensitive ion channels in volume regulation in boar and bull spermatozoa.
Harrison, RA; Hebel, M; Petrunkina, AM; Töpfer-Petersen, E; Weitze, KF, 2001
)
1.08
"Treatment with quinine for 14 days of infections in 12 monkeys with the original isolate resulted in cure in 8 monkeys and RI resistance in 4."( Selection of increased quinine resistance in Plasmodium falciparum in Aotus monkeys.
Collins, WE; Glew, RH; Miller, LH, 1978
)
0.91
"Pretreatment with quinine also potentiated the 5-HT2-mediated head-twitch in the mouse but had no effect on the hypothermia in the mouse, induced by 8-OH-DPAT (0.5 mg/kg, s.c.)."( The effects of rubidium, caesium and quinine on 5-HT-mediated behaviour in rat and mouse--3. Quinine.
Grahame-Smith, DG; Wang, H, 1992
)
0.88

Toxicity

There were 290 adverse events in the quinine group and 141 in the artemether-lumefantrine group. In the second and third trimesters, AL was not associated with increased adverse pregnancy outcomes. AL showed improved tolerability relative toQuinine, and its efficacy was non-inferior to Quinine.

ExcerptReferenceRelevance
" The comprehensive toxic screen, which provides multiple modalities of drug analysis, will be a key diagnostic tool in the further investigation of these inherently toxic agents and their impact on syndromes of cocaine intoxication."( Clinical toxicity of cocaine adulterants.
Shannon, M, 1988
)
0.27
"The currently recognized toxic effects of quinine in humans are identified and the problems of management of overdosage of quinine are discussed."( Quinine toxicity.
Bateman, DN; Dyson, EH, 1986
)
1.98
" One adverse reaction of chloroquine that has an important bearing on its use is pruritus."( Toxicity and side-effects of antimalarials in Africa: a critical review.
Salako, LA, 1984
)
0.27
" Safe and effective drugs, capable of being administered as a single-dose or short-course treatment, are urgently needed to control the adaptable malaria parasite."( Falciparum malaria: the urgent need for safe and effective drugs.
Rieckmann, KH, 1983
)
0.27
" These data indicate that there is an early direct toxic effect of quinine on the retinal cells."( Ocular quinine toxicity followed by electroretinogram, electro-oculogram, and pattern visually evoked potential.
Brinton, GF; Norton, E; Zahn, JR, 1981
)
0.95
" Generally, adverse effects reported in association with the fluoroquinolones have been those that could have been predicted by previous experience with non-fluorinated derivatives and by animal toxicity studies."( Safety and tolerability of fluoroquinolones.
Lietman, PS; Norrby, SR, 1993
)
0.29
" The purpose of this study was to define the toxic effect and excretion of cisplatin in the chicken, a species widely applied to the study of tubular transport mechanisms but little used for toxicology studies."( Toxicity and excretion of cisplatin in the avian kidney.
Cacini, W; Fink, IM, 1995
)
0.29
"Praneem Vilci (PV), purified neem oil was reported to exercise a reversible antifertility effect after a single intrauterine instillation in rodents and primates without any adverse effects."( Safety of intrauterine administration of purified neem seed oil (Praneem Vilci) in women & effect of its co-administration with the heterospecies dimer birth control vaccine on antibody response to human chorionic gonadotropin.
Garg, S; Gopalan, S; Jain, V; Kaur, J; Pal, R; Sehgal, S; Singh, O; Taluja, V; Talwar, GP; Upadhyay, SN, 1995
)
0.29
" Limited awareness of quinine-induced hepatotoxicity may result in an unrecognized adverse effect."( Quinine-induced hepatotoxicity.
Farver, DK; Lavin, MN, 1999
)
2.06
" The pharmacokinetic data, however, showed that they are of similar profile, except in adverse features and contraindications, and values like their half-life (t1/2) where the long (t1/2) in drugs like sulphadoxine-pyrimethamine endows them with suppressive-cure feature, especially against recrudescent strains."( Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries.
Makonnen, E; Mengesha, T, 1999
)
0.3
" Pharmacokinetic profile demonstrates that all these drugs have similar therapeutic effects, but differ in their adverse reactions, contraindications, and half-life."( Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries.
Makonnen, E; Mengesha, T, 1999
)
0.3
" Treatment with quinine is a common practice, but the effectiveness of the drug is doubtful and adverse drug effects are common."( Randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension.
Chan, P; Chen, YJ; Huang, TY; Huang, WP; Liu, YC, 1998
)
0.65
" This case highlights the potential toxic effects of quinine, the dangers of its bulk prescription, and the lack of strict guidelines with regard to its prescription."( Acute confusion and blindness from quinine toxicity.
Cho, M; Khuraijam, GS; Kodali, VR; Prasad, RS; Travers, JP, 2003
)
0.85
" The outcome measures were parasite clearance time, fever clearance time, efficacy, and adverse events profile."( A randomized open label clinical trial to compare the efficacy and safety of intravenous quinine followed by oral malarone vs. intravenous quinine followed by oral quinine in the treatment of severe malaria.
Ayuo, PO; Esamai, F; Jakait, B; Obala, A; Ong'or, WO; Tenge, CN, 2005
)
0.55
" There were no serious adverse events."( Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in Pune, India.
B, KK; Bharucha, K; Godbole, S; Joshi, SN; Katti, U; Kulkarni, S; Mehendale, S; Risbud, A, 2005
)
0.33
" The pathophysiology, clinical manifestations and risk factors and risk minimisation strategies regarding the ototoxicity associated with these drugs are presented in order to highlight this problem and reduce the incidence of adverse outcomes."( Systemic ototoxicity: a review.
Coates, H; Shine, NP, 2005
)
0.33
" Daily intravaginal use of this pessary for 7 days had no adverse effects on cervical cytology or on metabolic and organ functions."( A polyherbal vaginal pessary with spermicidal and antimicrobial action: evaluation of its safety.
Bagga, R; Baweja, R; Das, SK; Gopalan, S; Khare, S; Malhotra, D; Raghuvanshi, P; Suri, S; Talwar, GP, 2006
)
0.33
"Cyclosporine nephrotoxicity remains a major side effect in solid organ transplantation, and can be exacerbated by concomitant administration of sirolimus."( Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction.
Anglicheau, D; Beaune, P; Cassinat, B; Legendre, C; Marquet, P; Méria, P; Pallet, N; Rabant, M; Thervet, E, 2006
)
0.33
" This included possible health system failures, adverse reactions to antimalarials, inappropriate medicine use and failing to respond to treatment."( Malaria deaths as sentinel events to monitor healthcare delivery and antimalarial drug safety.
Barnes, KI; Blumberg, L; Donohue, S; Durrheim, DN; Gumede, JK; Hansford, F; Hugo, JJ; Immelman, E; Kruger, P; Mabuza, A; Mehta, U; Sánchez Canal, A; Swart, G, 2007
)
0.34
" There were 32 suspected adverse reactions to antimalarial therapy."( Malaria deaths as sentinel events to monitor healthcare delivery and antimalarial drug safety.
Barnes, KI; Blumberg, L; Donohue, S; Durrheim, DN; Gumede, JK; Hansford, F; Hugo, JJ; Immelman, E; Kruger, P; Mabuza, A; Mehta, U; Sánchez Canal, A; Swart, G, 2007
)
0.34
"A confidential enquiry into malaria-related deaths is a useful tool for identifying preventable factors, health system failures and adverse events affecting malaria case management."( Malaria deaths as sentinel events to monitor healthcare delivery and antimalarial drug safety.
Barnes, KI; Blumberg, L; Donohue, S; Durrheim, DN; Gumede, JK; Hansford, F; Hugo, JJ; Immelman, E; Kruger, P; Mabuza, A; Mehta, U; Sánchez Canal, A; Swart, G, 2007
)
0.34
" Although transient genital discomfort was the main reported adverse experience, none of the study participants discontinued product use."( Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: a phase II clinical trial report.
Dutta, S; Joshi, SN; Katti, U; Kulkarni, S; Kumar, BK; Mehendale, S; Risbud, A, 2008
)
0.35
"Praneem polyherbal tablet was safe for vaginal use up to 6 months with each act of sex among low-risk women."( Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: a phase II clinical trial report.
Dutta, S; Joshi, SN; Katti, U; Kulkarni, S; Kumar, BK; Mehendale, S; Risbud, A, 2008
)
0.35
" These findings suggest that HepG2 cells were more sensitive to the cytotoxicity of ginkgolic acid than primary rat hepatocytes, and CYP1A and CYP3A could metabolize ginkgolic acid to more toxic compounds."( Cytotoxicity of ginkgolic acid in HepG2 cells and primary rat hepatocytes.
Liu, ZH; Zeng, S, 2009
)
0.35
" ET may be safely executed in a setting with intensive care facilities and availability of safe blood products and should be considered as a beneficial adjunct treatment to parenteral antimalarial therapy."( Efficacy and safety of exchange transfusion as an adjunct therapy for severe Plasmodium falciparum malaria in nonimmune travelers: a 10-year single-center experience with a standardized treatment protocol.
Bezemer, JM; Hesselink, DA; Overbosch, D; van Genderen, PJ; Wismans, PJ, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" There were 290 adverse events in the quinine group and 141 in the artemether-lumefantrine group."( Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial.
Ashley, EA; Dhorda, M; Guerin, PJ; Lindegardh, N; McGready, R; Nabasumba, C; Nosten, F; Nyehangane, D; Piola, P; Snounou, G; Turyakira, E, 2010
)
0.87
" The two groups were compared in terms of reduction of parasite load, resolution of fever, recovery of consciousness and incidence of adverse effects."( Efficacy and safety of quinine loading dose in patients with severe falciparum malaria at a tertiary care hospital in Pakistan.
Akhtar, J; Ayaz, SI; Beg, MA; Kazmi, SH; Mehraj, V; Patel, MJ; Riaz, M; Saleem, T; Samdani, AJ; Tariq, M; Ullah, H, 2011
)
0.68
" In the second and third trimesters, AL was not associated with increased adverse pregnancy outcomes as compared with quinine or sulphadoxine-pyrimethamine, showed improved tolerability relative to quinine, and its efficacy was non-inferior to quinine."( A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy.
D'Alessandro, U; Hamed, K; Juma, E; Kayentao, K; Manyando, C; Okafor, HU, 2012
)
0.59
" As secondary endpoint, the proportion of any adverse event was assessed."( Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis.
Burchard, GD; Cramer, JP; Kluge, S; Rolling, T; Schmiedel, S; Wichmann, D, 2013
)
0.72
"While adverse events observed in patients treated with artesunate were limited to delayed haemolysis (three patients, 60%) and temporary deterioration in renal function (three patients, 60%), patients treated with quinine showed a more diverse picture of side effects with 22 patients (71%) experiencing at least one adverse event."( Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis.
Burchard, GD; Cramer, JP; Kluge, S; Rolling, T; Schmiedel, S; Wichmann, D, 2013
)
0.91
" Quinine exposure was associated with adverse pregnancy outcomes which was not the case following other anti-malarial intake."( Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort.
Abdulla, S; Genton, B; Mazuguni, F; Mosha, D; Mrema, S; Sevene, E, 2014
)
1.31
" Predators learn about the toxic content of aposematic prey and reduce their attacks on them."( Better the devil you know: avian predators find variation in prey toxicity aversive.
Barnett, CA; Bateson, M; Rowe, C, 2014
)
0.4
" More research is needed to determine its effect in patients with toxic retinal damage."( An experimental treatment of ocular quinine toxicity with high-dose 9-cis Beta-carotene.
Assia, EI; Belkin, A; Kornhouser, T; Koval, T; Meshi, A; Rotenstreich, Y, 2015
)
0.69
" Adverse drug effects may be responsible for a fraction of nocturnal leg cramps but often go unrecognized, resulting in additional prescribing intended to deal with adverse effects that might be better addressed by reduction, substitution, or discontinuation of the offending agent."( Quinine induced simvastatin toxicity through cytochrome inhibition - a case report.
Just, JM; Just, KS; Weckbecker, K, 2016
)
1.88
"Given the high morbidity for mother and fetus associated with malaria in pregnancy, safe and efficacious drugs are needed for treatment."( The Safety of Artemisinin Derivatives for the Treatment of Malaria in the 2nd or 3rd Trimester of Pregnancy: A Systematic Review and Meta-Analysis.
Dellicour, S; Emerson, S; Kovacs, SD; Sevene, E; Steketee, R; Stergachis, A; Ter Kuile, FO; van Eijk, AM; Weiss, NS, 2016
)
0.43
" For quinine, clindamycin, and mefloquine and the combinations of sulfadoxine+pyrimethamine and artemether+lumefantrine, there are reports (including studies without internal comparison groups) that combined describe 304 to >1100 exposures of women in the first trimester for each drug with no conclusive evidence of adverse effects on pregnancy at therapeutic doses."( Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester.
Clark, RL, 2017
)
0.97
" Other common risk factors for adverse pregnancy outcomes were not well-reported."( Methodology of assessment and reporting of safety in anti-malarial treatment efficacy studies of uncomplicated falciparum malaria in pregnancy: a systematic literature review.
Gilder, ME; Guérin, PJ; McGready, R; Nosten, F; Saito, M, 2017
)
0.46
"0%) patients experienced at least one drug-related adverse event (AE)."( Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo.
Fungula, B; Inocencio da Luz, R; Kalabuanga, M; Lula Ntamba, Y; Lutumba, P; Muhindo Mavoko, H; Ntamabyaliro Nsengi, PM; Tona Lutete, G; Van Geertruyden, JP, 2019
)
0.74
" Adverse events both solicited and unsolicited are recorded all through the study post-randomization."( Efficacy and safety of dual intravenous artesunate plus quinine compared to intravenous artesunate for cerebral malaria in a triple blinded parallel multisite randomized controlled trial in Nigerian children: DUAL PAQ TRIAL Protocol.
Alao, MA; Asinobi, AO; Gbadero, DA; Ibrahim, OR; Nna, EO; Okoye, IJ; Orimadegun, AE; Oyenuga, AO, 2021
)
0.87
" Separate network meta-analyses in the frequentist framework, using a random effects model, with quinine as reference, were conducted for adults and children, and rankings were produced using p-scores to assess mortality, parasite clearance, coma recovery, fever clearance, neurological sequela and adverse events."( Comparative efficacy and safety of the artemisinin derivatives compared to quinine for treating severe malaria in children and adults: A systematic update of literature and network meta-analysis.
Amoh, G; Amuzu, DSY; Andoh, NE; Ansong, M; Hirst, J; Nyaaba, N; Ordóñez-Mena, JM, 2022
)
1.17

Pharmacokinetics

Pharmacokinetic parameters of quinine during the acute phase of the infection were not different from those during the recovery phase. Neither the estimated gestational age nor the trimester influenced the pharmacokinetic properties ofQuinine significantly.

ExcerptReferenceRelevance
" Peak plasma quinine concentration and the time of peak concentration were similar in the young and elderly subjects."( Pharmacokinetics of quinine in young and elderly subjects.
Campbell, AJ; Chalcroft, S; Coville, PF; Wanwimolruk, S,
)
0.82
" The mean elimination half-life of quinine in the PMs (10."( Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.
Chalcroft, S; Wanwimolruk, S, 1991
)
0.78
" Marked differences were observed in the pharmacokinetic parameters."( Effect of oral activated charcoal on the pharmacokinetics of quinidine and quinine administered intravenously to rabbits.
Hasan, MM; Hassan, MA; Rawashdeh, NM, 1990
)
0.51
" Parameters such as half-life distribution volume, clearance and bioavailability, are defined."( [Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines].
Blayo, MC; Pussard, E; Verdier, F,
)
0.41
" Besides the alpha-MPS causes an increases Cmax and a shorter tmax of the quinine blood levels."( [The effect of ion pair formation on the pharmacokinetic properties of drugs. 1. The effect of alpha-methylpalmitic acid on the pharmacokinetics of quinine in rabbits].
Fürst, W; Jirka, M; Loh, HJ; Müller, H; Neubert, R; Schneider, S, 1987
)
0.7
"The influence of the hexylsalicylic acid (2) on the pharmacokinetic of the quinine (1), was studied using rabbits."( [The effect of ion pair formation on the pharmacokinetics of drugs. 2. The effect of hexylsalicylic acid on the pharmacokinetics of quinine].
Fürst, W; Jirka, M; Loh, HJ; Neubert, R; Schulze, P; Wenzel, U, 1987
)
0.71
" Peak plasma quinine concentration and the time of peak concentration were not altered after cimetidine or ranitidine pretreatment."( Effects of cimetidine and ranitidine on the pharmacokinetics of quinine.
Patamasucon, P; Pongmarutai, M; Sunbhanich, M; Wanwimolruk, S, 1986
)
0.88
" The mean (+/- SD) half-life of quinine was 11."( Pharmacokinetics of quinine in children.
Edstein, M; Shann, F; Stace, J, 1985
)
0.88
"For the past 300 years antimalarial dosage regimens have not been based on pharmacokinetic information."( Clinical pharmacokinetics of antimalarial drugs.
White, NJ,
)
0.13
"The pharmacokinetic parameters of quinidine and quinine were determined and compared in seven mongrel dogs."( Comparison of pharmacokinetic parameters of intravenous quinidine and quinine in dogs.
Clohisy, DR; Gibson, TP,
)
0.62
" QUI possesses a statistical significant influence on the EPR serum concentrations and, as a consequence, on the pharmacokinetic parameters for the initial distribution phase of EPR."( Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine.
Bandak, S; Czejka, M; Schernhammer, E; Schüller, J; Simon, D; Weiss, C,
)
0.35
" A one-compartment open pharmacokinetic model was fitted to serum quinine concentrations."( The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly.
Annus, T; Davis, TM; Dyer, JR; Garcia-Webb, P; Giele, C; Robson, J, 1994
)
0.79
" Similarly, evaluation of the pharmacokinetic properties of halofantrine has led to the demonstration that poor and erratic absorption could be just as likely to explain therapeutic failure as resistance of the parasite to effects of this drug."( Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.
Edwards, G; Ward, SA; Winstanley, PA, 1994
)
0.29
" This is consistent with a prolongation in the elimination half-life of antipyrine in animals pretreated with capsaicin (2."( Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats.
Clark, CR; Ferry, DG; Kepple, M; Nyika, S; Wanwimolruk, S, 1993
)
0.51
" Cmax and the initial rate of RVD (Vo) were both linear functions of the increase in cell volume."( Cell volume regulation in rat thymocytes.
Arrazola, A; Garay, RP; Hannaert, P; Rota, R; Soler, A, 1993
)
0.29
" Pharmacokinetic parameters of quinine during the acute phase of the infection were not different from those during the recovery phase."( The pharmacokinetics of quinine in patients with hepatitis.
Karbwang, J; Molunto, P; Na Bangchang, K; Thanavibul, A, 1993
)
0.88
" tmax and t1/2."( Pharmacokinetics of quinine in chronic liver disease.
Auprayoon, P; Banmairuroi, V; Karbwang, J; Molunto, P; Na-Bangchang, K; Sukontason, K, 1995
)
0.61
" A marked alteration in the pharmacokinetics of Qn was found in patients with CRF compared to healthy subjects; there were six significant changes in the pharmacokinetic parameters."( Pharmacokinetics of quinine in patients with chronic renal failure.
Banmairuroi, V; Karbwang, J; Molunto, P; Na-Bangchang, K; Rimchala, P; Sukontason, K, 1996
)
0.62
" The tmax occurred later after intrarectal (4."( Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria.
Barennes, H; Clavier, F; Granic, G; Henzel, D; Kahiatani, F; Mahaman Sani, A; Pussard, E; Ravinet, L; Verdier, F, 1996
)
0.55
" Chloroquine is extensively distributed with an enormous total apparent volume of distribution (Vd) more than 100 L/kg, and a terminal elimination half-life of 1 to 2 months."( Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.
Krishna, S; White, NJ, 1996
)
0.62
" The pharmacokinetic properties of dihydroquinine were generally similar to those of quinine, although dihydroquinine clearance was less affected by acute malaria."( A study of the factors affecting the metabolic clearance of quinine in malaria.
Davis, TM; Keeratithakul, D; Kyle, D; Looareesuwan, S; Nagachinta, B; Pukrittayakamee, S; Smith, AL; Teja-Isavadharm, P; Weber, A; White, NJ, 1997
)
0.8
"To study the pharmacokinetic behaviour of quinine in Caucasians with and without malaria."( Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria.
Claessen, FA; Kager, PA; Perenboom, RM; Tange, RA; van Boxtel, CJ; Wetsteijn, JC, 1998
)
2.01
" There were no significant differences among the three treatment periods with regard to pharmacokinetic parameters of quinine, including the peak plasma drug concentration (Cmax), the time to reach Cmax (tmax), the terminal elimination half-life (t1/2), the area under the concentration-time curve and the apparent oral clearance."( Grapefruit juice has no effect on quinine pharmacokinetics.
Chalcroft, SC; Coville, PF; Ho, PC; Wanwimolruk, S, 1999
)
0.79
" The estimated 3OHQn terminal elimination half-life was 21 h (16."( Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure.
Keeratithakul, D; Kyle, D; Newton, P; Pukrittayakamee, S; Teja-Isavadharm, P; White, N,
)
0.45
"This study was carried out to investigate the pharmacokinetic and pharmacodynamic interactions between two antimalarial drugs, mefloquine and quinine."( Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine.
Karbwang, J; Na-Bangchang, K; Riengchainam, S; Shrestha, SB; Tan-Ariya, P; Thanavibul, A, 1999
)
0.74
" Several models were tested, but the best model was a monoexponential decline of the parasitemia in which the mean parasite elimination half-life was shorter after artemisinin (5."( Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics.
Anh, TK; Bich, NN; de Vries, PJ; Heisterkamp, SH; Hung, LN; Kager, PA; Van Thien, H, 2000
)
0.59
" There were no significant differences in time to reach the peak plasma concentration, half-life and total clearance of quinine between the 2 groups."( Pharmacokinetics of quinine in obesity.
Ho, PC; Nachaisit, S; Thitiarchakul, S; Viriyayudhakorn, S; Wanwimolruk, S,
)
0.66
" The animals were divided into two groups, one served as control and the other group was pretreated with 25 mg/kg naringin once a day for 7 consecutive days before the pharmacokinetic study."( Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats.
Coville, PF; Wanwimolruk, S; Wong, CW; Zhang, H, 2000
)
0.54
"We present the first population pharmacokinetic analysis of quinine in patients with Plasmodium falciparum malaria."( Population pharmacokinetics of intramuscular quinine in children with severe malaria.
Agbenyega, T; Ansong, D; Bedo-Addo, G; Derendorf, H; Henderson, G; Hutson, A; Krishna, S; Nagaraja, NV; Owusu-Ofori, A; Planche, T; Shroads, AL; Stacpoole, PW, 2001
)
0.81
"The pharmacokinetic properties of oral quinine sulphate (600 mg salt) were investigated in seven healthy Caucasian volunteers, in a randomised, crossover study, on low- and high-salt diets."( Oral quinine pharmacokinetics and dietary salt intake.
Kuypers, D; Maliakal, P; Newton, P; Simpson, A; Villegas, L; Wanwimolruk, S; White, NJ, 2001
)
1.09
"Although the 24-h urine sodium excretion was significantly higher when the volunteers were on a high-salt diet, there were no significant differences in quinine AUC0-infinity, tmax, and Cmax after the two diets."( Oral quinine pharmacokinetics and dietary salt intake.
Kuypers, D; Maliakal, P; Newton, P; Simpson, A; Villegas, L; Wanwimolruk, S; White, NJ, 2001
)
1.02
"The study was carried out to investigate the pharmacokinetic and pharmacodynamic interactions between artemether (ARTEM) and quinoline antimalarials namely mefloquine (MQ), quinine (QN) and primaquine (PQ) when given concurrently."( Absence of significant pharmacokinetic and pharmacodynamic interactions between artemether and quinoline antimalarials.
Karbwang, J; Na-Bangchang, K; Saenglertsilapachai, S; Thanavibul, A; Ubalee, R,
)
0.32
" There were no significant differences in any pharmacokinetic variables for the parent compound or metabolite between the two groups."( Effects of cigarette smoking on quinine pharmacokinetics in malaria.
Jantra, A; Pitisuttithum, P; Pukrittayakamee, S; Wanwimolruk, S; White, NJ; Zhang, H, 2002
)
0.6
"The relationships between the pharmacokinetic properties of quinine during a 7-day treatment course and the therapeutic response were studied in 30 adult patients with uncomplicated falciparum malaria monitored for > or = 28 days."( Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria.
Huyakorn, S; Jantra, A; Looareesuwan, S; Pukrittayakamee, S; Stepniewska, K; Wanwimolruk, S; White, NJ, 2003
)
2
" The pharmacokinetic parameters AUC (relative bioavailability) and c(max) of quinine were significantly decreased by micellar systems in rabbits."( The influence of bile salts and mixed micelles on the pharmacokinetics of quinine in rabbits.
Dongowski, G; Fritzsch, B; Giessler, J; Härtl, A; Kuhlmann, O; Neubert, RH, 2005
)
0.79
" Since beta-arthemeter is now available, an open-label pharmacodynamic analysis was performed in 73 adults with uncomplicated Plasmodium falciparum malaria."( Pharmacodynamic analysis of antimalarials used in Plasmodium falciparum imported malaria in northern Italy.
Calleri, G; Canta, F; Caramello, P; Cavecchia, I; Di Perri, G; Gobbi, F; Lipani, F; Sergi, G,
)
0.13
" According to the pharmacodynamic parameters measured, no significant differences were recorded among patients with or without prior exposure to malaria."( Pharmacodynamic analysis of antimalarials used in Plasmodium falciparum imported malaria in northern Italy.
Calleri, G; Canta, F; Caramello, P; Cavecchia, I; Di Perri, G; Gobbi, F; Lipani, F; Sergi, G,
)
0.13
" Pharmacokinetic and pharmacodynamic data were analyzed by population approaches by using NONMEM and WinBugs, respectively."( Quinine pharmacokinetics and pharmacodynamics in children with malaria caused by Plasmodium falciparum.
Jullien, V; Le Jouan, M; Pons, G; Rey, E; Tetanye, E; Tod, M; Tran, A; Tréluyer, JM, 2005
)
1.77
" There was no significant difference in the mean maximum plasma concentration attained (C(max)), the mean time at which C(max) was attained, the elimination half-life (t(1/2)) and the total area under the plasma concentration vs."( Pharmacokinetics of quinine and its metabolites in pregnant Sudanese women with uncomplicated Plasmodium falciparum malaria.
Abdelrahim, II; Adam, I; Elbashir, MI; Elghazali, G; Gustafsson, LL; Mirghani, RA, 2007
)
0.66
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"These findings could help explain possible pharmacokinetic changes of furosemide in various rat disease models (where CYP2C11, 2E1, 3A1 and/or CYP3A2 are altered) and drug-drug interactions between furosemide and other drugs (mainly metabolized via CYP2C11, 2E1, 3A1 and/or 3A2)."( Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism.
Choi, YH; Lee, JH; Lee, MG; Lee, U; Yang, KH, 2009
)
0.35
"To evaluate the pharmacokinetic interactions between ritonavir and quinine in healthy volunteers."( Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.
Cook, JM; Omoruyi, SI; Onyeji, CO; Owolabi, AR; Sarma, PV; Soyinka, JO, 2010
)
0.85
"Ten healthy volunteers were each given 600-mg single oral doses of quinine alone, ritonavir alone (200 mg every 12 h for 9 days), and quinine in combination with ritonavir, in a three-period pharmacokinetic nonrandomized sequential design study."( Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.
Cook, JM; Omoruyi, SI; Onyeji, CO; Owolabi, AR; Sarma, PV; Soyinka, JO, 2010
)
0.85
"01) in the elimination half-life (11."( Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.
Cook, JM; Omoruyi, SI; Onyeji, CO; Owolabi, AR; Sarma, PV; Soyinka, JO, 2010
)
0.61
" Identified articles were included in the review if the study had at least one group that reported at least one pharmacokinetic parameter of interest in pregnant women."( Pharmacokinetics of antimalarials in pregnancy: a systematic review.
Ensom, MH; Wilby, KJ, 2011
)
0.37
" Thus, this study was performed to investigate the pharmacokinetic and pharmacodynamic interactions between nifedipine and metformin, since both drugs were commonly metabolized via hepatic CYP2C and 3A subfamilies in rats."( Pharmacokinetic and pharmacodynamic interaction between nifedipine and metformin in rats: competitive inhibition for metabolism of nifedipine and metformin by each other via CYP isozymes.
Choi, YH; Lee, MG, 2012
)
0.38
" A phase I pharmacokinetic study was conducted to assess the impact of long-term use of ritonavir-boosted lopinavir (LPV/r) on quinine pharmacokinetics in healthy volunteers."( Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine.
El-Gasim, M; Hendrix, CW; Lu, Y; Nyunt, MM; Parsons, TL; Petty, BG, 2012
)
0.82
" A population pharmacokinetic study was conducted with 75 Tanzanian children aged 4 months to 8 years with severe malaria who received quinine intramuscularly; 69 patients received a loading dose of 20 mg quinine dihydrochloride (salt)/kg of body weight."( Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria.
Day, NP; Dondorp, AM; Gesase, S; Hendriksen, IC; Lemnge, MM; Lindegardh, N; Maiga, D; Mtove, G; Reyburn, H; Tarning, J; von Seidlein, L; White, NJ, 2013
)
0.82
"Pregnancy alters the pharmacokinetic properties of many drugs used in the treatment of malaria, usually resulting in lower drug exposures."( Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.
Dhorda, M; Guerin, PJ; Jullien, V; Kloprogge, F; Nosten, F; Piola, P; Tarning, J; White, NJ, 2013
)
0.62
" Computed descriptors often used to predict absorption, distribution, metabolism, elimination and toxicity (ADMET) were used to assess the pharmacokinetic profiles of the isolated compounds."( New antimalarial hits from Dacryodes edulis (Burseraceae)--part I: isolation, in vitro activity, in silico "drug-likeness" and pharmacokinetic profiles.
Ngemenya, MN; Ntie-Kang, F; Tane, P; Tematio, EL; Tene, M; Titanji, VP; Zofou, D, 2013
)
0.39
"Oral quinine is used for the treatment of uncomplicated malaria during pregnancy, but few pharmacokinetic data are available for this population."( Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.
Day, NP; Dhorda, M; Guerin, PJ; Jullien, V; Kloprogge, F; Muwanga, S; Nosten, F; Piola, P; Tarning, J; White, NJ, 2014
)
1.2
" A population pharmacokinetic model for quinine was developed accounting for different disposition, absorption, error and covariate models."( Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.
Day, NP; Dhorda, M; Guerin, PJ; Jullien, V; Kloprogge, F; Muwanga, S; Nosten, F; Piola, P; Tarning, J; White, NJ, 2014
)
0.96
" Neither the estimated gestational age nor the trimester influenced the pharmacokinetic properties of quinine significantly."( Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.
Day, NP; Dhorda, M; Guerin, PJ; Jullien, V; Kloprogge, F; Muwanga, S; Nosten, F; Piola, P; Tarning, J; White, NJ, 2014
)
0.9
" kola reduced quinine tmax by 48% (group A), mean Cmax by 19% and 26% in groups A and B, respectively, and slight reduction in mean AUC0- ∞ of quinine in both groups."( Effect of dehusked Garcinia kola seeds on the overall pharmacokinetics of quinine in healthy Nigerian volunteers.
Akanmu, MA; Cook, JM; Igbinoba, SI; Nathaniel, TI; Onyeji, CO; Pullela, SS; Soyinka, JO, 2015
)
1.01
" Primary aims included examination of the plasma and urinary pharmacokinetic profile of once-daily quinine; secondary aims assessed pharmacokinetic/pharmacodynamic interactions with oxycodone (a CYP3A and CYP2D substrate)."( Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans.
Babalonis, S; Hampson, AJ; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2015
)
2.08
"This study aimed to investigate the pharmacokinetic interactions between quinine and lopinavir boosted with ritonavir (LPV/r) in healthy Thai adults (8 males and 12 females)."( Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults.
Cressey, TR; Kongjam, P; Na-Bangchang, K; Rattanapunya, S; Rueangweerayut, R; Tawon, Y, 2015
)
0.92
" The objective of the study was to apply physiologically-based pharmacokinetic (PBPK) modeling to predict optimal dosage regimens of quinine when coadministered with lopinavir/ritonavir in malaria and HIV coinfected patients with different conditions."( Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir.
Karbwang, J; Na-Bangchang, K; Rajoli, RKR; Saeheng, T; Siccardi, M, 2020
)
0.99
" The whole-body physiologically based pharmacokinetic (PBPK) models for quinine, phenobarbital, and quinine-phenobarbital coadministration were constructed based on the previously published information using Simbiology®."( Physiologically based pharmacokinetic modeling for dose optimization of quinine-phenobarbital coadministration in patients with cerebral malaria.
Karbwang, J; Na-Bangchang, K; Rajoli, RKR; Sae-Heng, T; Siccardi, M, 2022
)
1.19

Compound-Compound Interactions

The efficacy and toxicity of oral quinine combined with oral chloroquine were studied in 50 Thai men with uncomplicated falciparum malaria. The effect of 16 alpha-acetoxy-26-hydroxycholest-4-ene-3,22-dione (SN-1) isolated from Solanum nudum Dunal (a Solanaceae traditionally used for treating fever in Colombia) was studied.

ExcerptReferenceRelevance
" We have compared plasma quinine levels on day 2, day 5 and day 7 (before and at 2 hours after dosing) in twenty-one patients with acute falciparum malaria who were treated with quinine alone (8 patients) or quinine in combination with tetracycline (8 patients) or quinine with tetracycline and primaquine (5 patients)."( Plasma quinine levels in patients with falciparum malaria when given alone or in combination with tetracycline with or without primaquine.
Bunnag, D; Harinasuta, T; Karbwang, J; Molunto, P, 1991
)
1.04
" In the present study, ten patients with falciparum malaria were given large doses of erythromycin, combined with standard doses of chloroquine; the cure rate was 0 out of 10 (4 RIII failures, 6 RII failures)."( Failure of large-dose erythromycin in combination with a standard dose of chloroquine or quinine in the treatment of human falciparum malaria.
Boudreau, EF; Childs, GE; Pang, LW; Somutsakorn, P; Supanantalerk, C; Webster, HK, 1985
)
0.49
" Noise present in recreational or occupational environment may also be potentially damaging to the auditory system when combined with some ototoxic therapeutic agents."( Ototoxicity and noise-drug interaction.
Bhattacharyya, TK; Dayal, VS, 1984
)
0.27
"The activity of chloroquine and quinine, alone and in combination with desferrioxamine (7 mumol/liter), was evaluated in vitro against susceptible and resistant clones of Plasmodium falciparum by a semimicroassay system."( In vitro activity of chloroquine and quinine in combination with desferrioxamine against Plasmodium falciparum.
Basco, LK; Le Bras, J, 1993
)
0.84
"The efficacy and toxicity of oral quinine combined with oral chloroquine were studied in 50 Thai men with uncomplicated falciparum malaria."( Therapeutic effects of chloroquine in combination with quinine in uncomplicated falciparum malaria.
Chantra, A; Chindanond, D; Clemens, R; Phophak, N; Pukrittayakamee, S; Vanijanonta, S, 1996
)
0.82
"We report the ability of azithromycin in combination with quinine to eliminate the Babesia infection in a native Taiwanese woman."( Ability of azithromycin in combination with quinine for the elimination of babesial infection in humans.
Shih, CM; Wang, CC, 1998
)
0.81
"The reversal effects of quinine (Quin) in combination with cyclosporin A (CsA), dipyridamole (DPM) or tamoxifen (Tam), respectively on the drug resistance of K562/HHT were studied by MTT, flow cytometry and median-effect principle."( [Synergistic reversal effect of quinine in combination with modulators on multidrug resistant cell line K562/HHT].
Bian, S; Feng, M; Luo, M, 1998
)
0.89
" Quin combined with CsA increased intracellular DNR accumulation significantly as compared with either of them alone."( [Synergistic reversal effect of quinine in combination with modulators on multidrug resistant cell line K562/HHT].
Bian, S; Feng, M; Luo, M, 1998
)
0.58
"Dynamic drop-to-drop solvent microextraction (DDSME) combined with atmospheric pressure-matrix assisted laser desorption/ionization mass spectrometry (AP-MALDI/MS) has been successfully applied on the bioanalysis of quinine using micro liter volume (30 microL) of human urine and plasma samples."( Quantitative bioanalysis of quinine by atmospheric pressure-matrix assisted laser desorption/ionization mass spectrometry combined with dynamic drop-to-drop solvent microextraction.
Shrivas, K; Wu, HF, 2007
)
0.82
"The effect of 16 alpha-acetoxy-26-hydroxycholest-4-ene-3,22-dione (SN-1) isolated from Solanum nudum Dunal (a Solanaceae traditionally used for treating fever in Colombia) on Plasmodium falciparum erythrocyte stages and its in vitro antiplasmodial activity when combined with the following conventional drugs was studied: chloroquine (CQ), amodiaquine (AQ), desethylamodiaquine (desethyl-AQ), quinine (QN), artemisinin (AR), atovaquone (ATV) and quinine (QN)."( Plasmodium falciparum: Solanum nudum SN-1 steroid antiplasmodial activity when combined with antimalarial drugs.
Blair, S; Deharo, E; Pabón, A, 2011
)
0.54
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"The effectiveness of methylene blue (MB) combined with pyrimethamine (PYR), chloroquine (CQ) or quinine (Q) was examined in a classical four-day suppressive test against a causative agent of rodent malaria, Plasmodium berghei."( The in vivo antimalarial activity of methylene blue combined with pyrimethamine, chloroquine and quinine.
Aldana, I; Bertani, S; Deharo, E; Garavito, G; Quiliano, M; Valentin, A, 2012
)
0.81
" Oxycodone and noroxycodone parameters (Tmax , Cmax , t1/2 ) were similar with or without quinine present, although drug exposure (AUC) was slightly greater when combined with quinine."( Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans.
Babalonis, S; Hampson, AJ; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2015
)
2.08
"The coformulated lopinavir/ritonavir significantly reduces quinine concentration in healthy volunteers due to potential drug-drug interactions (DDIs)."( Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir.
Karbwang, J; Na-Bangchang, K; Rajoli, RKR; Saeheng, T; Siccardi, M, 2020
)
1.03
"The study was aimed at investigating the effect of quinine alone and in combination with vitamin C on angiogenesis process."( Antiangiogenic Activity of Quinine Alone and in Combination with vitamin C in both ex vivo and in vivo Assays.
Jalil, ZH; Sahib, HB, 2022
)
1.27

Bioavailability

The effects of methimazole (MTZ), metyrapone (MTP) and quinine (QNE) on the pharmacokinetics and bioavailability of parenterally administered netobimin (NTB) and its major metabolites were studied in sheep. Quinine sulphate was well absorbed in uncomplicated falciparum malaria.

ExcerptReferenceRelevance
"53 h, a tmax of 1-3 h and a bioavailability of 88%."( Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans.
Salako, LA; Sowunmi, A, 1992
)
0.64
"The effects of methimazole (MTZ), metyrapone (MTP) and quinine (QNE) on the pharmacokinetics and bioavailability of parenterally administered netobimin (NTB) and its major metabolites, albendazole sulphoxide (ABZSO) and albendazole sulphone (ABZSO2), were studied in sheep."( Enhancement of the plasma concentration of albendazole sulphoxide in sheep following coadministration of parenteral netobimin and liver oxidase inhibitors.
Lanusse, CE; Prichard, RK, 1991
)
0.53
" Oral quinine sulphate was well absorbed in uncomplicated falciparum malaria."( Disposition of oral quinine in acute falciparum malaria.
Chanond, L; Davis, TM; Karbwang, J; Molunto, P; Pukrittayakamee, S; Silamut, K; Supanaranond, W; White, NJ, 1991
)
1.09
" Quinine was well absorbed reaching mean peak concentrations of 15."( The pharmacokinetic properties of intramuscular quinine in Gambian children with severe falciparum malaria.
Brewster, D; Craddock, C; Jammeh, A; Karbwang, J; Krishna, S; Kwiatkowski, D; Molunto, P; Waller, D; White, NJ,
)
1.3
" Compared to the intramuscular route, intrarectal Quinimax bioavailability was 40%."( Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics.
Barennes, H; Clavier, F; Kahiatani, F; Meynard, D; Njifountawouo, S; Pussard, E; Verdier, F,
)
0.13
" The nature of the salt associated to the active principle can give some advantages in the field of activity, bioavailability and toxicity."( Plasmodium berghei mouse model: antimalarial activity of new alkaloid salts and of thiosemicarbazone and acridine derivatives.
Loiseau, PM; Nguyen, DX, 1996
)
0.29
" The approximate bioavailability of intrarectal quinine from 0 to 8 h was 36% vs intravenous quinine and 51% vs intramuscular quinine."( Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria.
Barennes, H; Clavier, F; Granic, G; Henzel, D; Kahiatani, F; Mahaman Sani, A; Pussard, E; Ravinet, L; Verdier, F, 1996
)
0.8
" Quinine is well absorbed by mouth or following intramuscular injection even in severe cases of malaria (estimated bioavailability more than 85%)."( Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.
Krishna, S; White, NJ, 1996
)
1.53
" VACV demonstrates an oral bioavailability that is three to five time greater than acyclovir, concentration dependent, and saturable in humans."( Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats.
Balimane, PV; Sinko, PJ, 1998
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"The objective was to determine whether or not dietary salt intake affects the relative bioavailability of oral quinine."( Oral quinine pharmacokinetics and dietary salt intake.
Kuypers, D; Maliakal, P; Newton, P; Simpson, A; Villegas, L; Wanwimolruk, S; White, NJ, 2001
)
1.04
"Dietary salt does not affect the relative oral bioavailability of quinine sulphate."( Oral quinine pharmacokinetics and dietary salt intake.
Kuypers, D; Maliakal, P; Newton, P; Simpson, A; Villegas, L; Wanwimolruk, S; White, NJ, 2001
)
1.06
" Kaolin reduced the bioavailability of each compound by < or =30%."( Adaptive function of soil consumption: an in vitro study modeling the human stomach and small intestine.
Davoust, E; Dominy, NJ; Minekus, M, 2004
)
0.32
"This study compared the absolute bioavailability of quinine sulphate as capsule and as tablet against the intravenous (i."( Absolute bioavailability of quinine formulations in Nigeria.
Babalola, CP; Bolaji, OO; Ezeomah, E; Ogunbona, FA, 2004
)
0.87
"The bioavailability of orally administered drugs can be influenced by interactions with food components and by physico-chemical conditions in the upper gastrointestinal tract."( The influence of bile salts and mixed micelles on the pharmacokinetics of quinine in rabbits.
Dongowski, G; Fritzsch, B; Giessler, J; Härtl, A; Kuhlmann, O; Neubert, RH, 2005
)
0.56
"The aim of this work was to improve the rectal bioavailability of quinine hydrochloride by designing thermosensitive and mucoadhesive gels intended for rectal delivery."( In vitro and in vivo characteristics of a thermogelling and bioadhesive delivery system intended for rectal administration of quinine in children.
Agnely, F; Besnard, M; Grossiord, JL; Kablan Brou, J; Koffi, AA; Ponchel, G, 2008
)
0.79
" The results indicate the suitability of this technique in antimalarial drug quality and bioavailability studies."( A simple technique for the detection of anti-malarial drug formulations and their presence in human urine.
Akida, JA; Lemnge, MM; Lugimbana, L; Malebo, HM; Malle, LN; Segeja, MD, 2006
)
0.33
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" The physical properties of tablets were evaluated in vitro, as well as the quinine bioavailability in healthy adults (n=18) and the efficacy for treatment of children with uncomplicated Plasmodium falciparum malaria (n=56) using a 7-day regimen of 8 mg quinine/kg."( Taste-masked quinine pamoate tablets for treatment of children with uncomplicated Plasmodium falciparum malaria.
Bortel, V; Karema, C; Kayitare, E; Kayumba, PC; Mehuys, E; Ntawukulilyayo, JD; Remon, JP; Vervaet, C, 2010
)
0.96
" Despite being fast metabolizers, women display higher quinine bioavailability than men in Uganda."( Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans.
Aklillu, E; Gustafsson, LL; Mukonzo, JK; Ogwal-Okeng, J; Waako, P, 2010
)
0.85
"The efficacy of anti-malarial drugs is determined by the level of parasite susceptibility, anti-malarial drug bioavailability and pharmacokinetics, and host factors including immunity."( Modulating effects of plasma containing anti-malarial antibodies on in vitro anti-malarial drug susceptibility in Plasmodium falciparum.
Chotivanich, K; Dondorp, AM; Krudsood, S; Monatrakul, P; Mungthin, M; Udomsangpetch, R; White, NJ; Wilairatana, P, 2010
)
0.36
"Quinine therefore, reduced the bioavailability and the antimicrobial activity of ampicillin-cloxacillin upon co-administration, which may have therapeutic implications."( Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination.
Babalola, CP; Ezeasor, C; Falade, OB; Falusi, AG; Kwasi, DA; Olaniyi, AA, 2016
)
2.13
" The ADME properties of these active molecules were also predicted to enhance the knowhow of the oral bioavailability, indicating good bioavailability of the active entities."( Ionic liquid mediated stereoselective synthesis of alanine linked hybrid quinazoline-4(3H)-one derivatives perturbing the malarial reductase activity in folate pathway.
Bhatt, JD; Chudasama, CJ; Dixit, BC; Dixit, RB; Patel, BD; Patel, TS; Patel, UH; Vanparia, SF, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Seletalisib is an orally bioavailable selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ) in clinical development for the treatment of immune-mediated inflammatory diseases."( Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions.
Bonnaillie, P; Brouta, F; Chanteux, H; Gillent, E; Helmer, E; Long, J; Mathy, FX; Nicolaï, J; Nicolas, JM; Rosseels, ML; Viot, D, 2020
)
0.56

Dosage Studied

Hydroxyethylapoquinine (HEAQ), used at 8 g a day for dosing in humans in the 1930s and halving mortality from bacterial pneumonias, was shown to cure bird malaria in the 1940s. The current study evaluated providers' knowledge and practices of treatment policy and dosing regimens with AL and quinine.

ExcerptRelevanceReference
" Guidelines for cholorquine or quinine dosage in severe disease are proposed; each drug is given at a dose of 5 to 10 mg/kg in 10 ml/kg of fluid as an intravenous infusion in four hours at a frequency of dosing every 12 to 24 hours."( The treatment of severe falciparum malaria.
Hall, AP, 1977
)
0.54
" These observations suggest that quinine dosage should be modified during the initial period of treatment, when symptoms and fever are greatest, in acute falciparum malaria."( Quinine disposition during malaria and during induced fever.
Carson, PE; Frischer, H; Rieckmann, KH; Trenholme, GM; Williams, RL, 1976
)
1.98
"Rats 24-hr water deprived were injected IP with a fixed amount (10 ml/kg) of solution of various concentrations of LiCl and NaCl in dosage ranges which in previous experiments either increased or had no effect on water intake."( NaCl and LiCl efficacy in the induction of aversion for quinine and saccharin solutions immediately following injection.
Kutscher, CL; Lisch, M; Wright, WA, 1977
)
0.5
" Combination therapy with full-dose quinine and clindamycin for three days cured all four patients so treated who were followed up, and with half dosage three out of five patients were cured."( Falciparum malaria semi-resistant to clindamycin.
Doberstyn, EB; Hall, AP; Nanokorn, A; Sonkom, P, 1975
)
0.53
" Lewis rats (n = 7 or 8) were dosed with methoxyphenamine with and without prior administration of various doses of either quinine or its diastereomer quinidine."( Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.
Hawes, EM; McKay, G; Midha, KK; Muralidharan, G, 1991
)
1.93
"The pharmacokinetics and effectiveness of three dosage regimens of quinine were studied in a group of 59 children with severe malaria."( Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens.
Marsh, K; Newton, CR; Pasvol, G; Peshu, NM; Warrell, DA; Watkins, WM; Were, JB; Winstanley, PA, 1991
)
1.96
" After simultaneous dosage of quinine and quinidine, Cf:Cm (0."( Disposition of the diastereoisomers quinine and quinidine in the ovine fetus.
Ching, MS; Czuba, MA; Ghabrial, H; Hardy, KJ; Mihaly, GW; Morgan, DJ; Smallwood, RA, 1991
)
0.84
" falciparum infection is potentially lethal, we suggest that the treatment of malaria attacks be optimized, by systematically dosing serum quinine levels, in order to adjust the administered doses, and, as a first-line therapy, by prescribing a combination of drugs to patients at high risk of resistance."( [Ideal treatment of malaria attack: more questions than answers? Experience of a department of infectious diseases].
Biron, F; Boibieux, A; Chi, NH; Muron, T; Peyramond, D; Piens, MA, 1991
)
0.48
" The dose-response curves for the two isomers followed a similar course both for induction and elicitation."( Quinine and quinidine cross-react after systemic photosensitization in the mouse.
Ljunggren, B; Wirestrand, LE, 1990
)
1.72
" So, at the dosage of 25 mg/kg, quinine was found to be very effective in the Congo in 1989 against both pernicious and non pernicious malaria."( [Efficacy of quinine in children hospitalized for malaria attacks in Brazzaville (Congo) in 1989].
Carme, B; Dhellot, H; Nzingoula, S; Plassart, H; Senga, J, 1991
)
0.93
"Twenty eight adult male patients with acute uncomplicated falciparum malaria which showed RI or RII responses to quinine sulfate at the dosage of 600 mg 8 hourly for 7, 10 or 14 days were treated with a single dose of mefloquine (Lariam); 25 patients received 1000 mg, 2 received 750 mg and 1 received 500 mg."( Quinine resistant falciparum malaria treated with mefloquine.
Bunnag, D; Harinasuta, T; Lasserre, R, 1990
)
1.93
"Twenty-five Malwaian children with Plasmodium falciparum infection were studied for response to quinine in an eight-hourly dosage of 10 mg salt kg-1 body weight."( In vivo efficacy of quinine treatment for Plasmodium falciparum malaria in Malawian children.
Campbell, CC; Heymann, DL; Khormana, CO; Macheso, AF; Wirima, JJ, 1990
)
0.82
"8 nmol/l) of PGE2 on the mefloquine- and quinine-induced inhibition of the ACh cumulative dose-response curves were also investigated."( Action of mefloquine on agonist-induced contractions of the guinea-pig isolated ileum.
Go, ML; Lee, HS, 1988
)
0.54
" For prophylaxis, it has been suggested that the dosage of 10 mg/kg/wk should be spread over the week (3."( [Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines].
Blayo, MC; Pussard, E; Verdier, F,
)
0.41
" In general, these data indicated that malaise may be an important influence of 2DG; but dosage and time course parameters associated with post-drug reductions in drinking suggested that a separable consummatory inhibition effect may also occur."( Inhibited drinking and pica in rats following 2-deoxy-D-glucose.
Bartles, RR; Beatey, S; Hawkins, C; McKinney, J; Rhea, K; Watson, PJ, 1987
)
0.27
"For the past 300 years antimalarial dosage regimens have not been based on pharmacokinetic information."( Clinical pharmacokinetics of antimalarial drugs.
White, NJ,
)
0.13
" Used in high dosage by the intraventricular as well as the intravenous route, this drug might be successful in the treatment of further cases of primary amoebic meningoencephalitis."( Sensitivity to amphotericin B of a Naegleria sp. isolated from a case of primary amoebic meningoencephalitis.
Carter, RF, 1969
)
0.25
" Group II: 26 children were treated with quinine at the dosage adjusted to the body surface area based on an adult dose of 500 mg base eight hourly for 14 days."( In vivo and in vitro sensitivity of Falciparum malaria to quinine in Thai children.
Attanath, P; Chongsuphajaisiddhi, T; Sabcharoen, A, 1981
)
0.77
"A study was carried out to assess the efficacy of a modified 7 day course of quinine in children with falciparum malaria, in comparison with those of a 7 day course of quinine at standard dosage and a combination of a 7 day course of quinine and sulfadoxine-pyrimethamine, and in relation to the MIC, and to the serum levels of quinine during the course of treatment."( Treatment of quinine resistant falciparum malaria in Thai children.
Attanath, P; Chongsuphajaisiddhi, T; Sabchareon, A, 1983
)
0.86
" Reappraisal of quinine therapy has led to important modifications in dosage recommendations and recognition of a major complication of severe malaria associated with its use--hypoglycaemia."( Management of Plasmodium falciparum malaria.
Phillips, RE, 1984
)
0.61
" These phospholipase A2 inhibitors also inhibited the cellular uptake of 45Ca2+ evoked by carbamylcholine with similar dose-response curves to those for inhibition of catecholamine secretion."( Suppression by phospholipase A2 inhibitors of secretion of catecholamines from isolated adrenal medullary cells by suppression of cellular calcium uptake.
Izumi, F; Kobayashi, H; Sakurai, S; Wada, A; Yanagihara, N, 1983
)
0.27
" Birds in one group, which acted as a control, were dosed orally with retinyl palmitate in corn oil, whereas the other group (experimental) was given corn oil only throughout the experiment."( The effects of vitamin A deficiency of oral gustatory behaviour in chicks.
Dewar, WA; Gentle, MJ, 1981
)
0.26
" Salicylate (an anion) and quinine (a cation), in dosage which inhibited allantoin uptake, also inhibit the uptake of the para-aminohippuric acid (an anion) and tetraethylammonium bromide (a cation)."( Renal handling of [14C]allantoin in the rabbit.
Roch-Ramel, F; Schäli, C, 1980
)
0.56
"Patients underwent open-label, dose-ranging trials of quinine with daily doses of 600, 1200, and 1800 mg in a twice-daily dosing regimen."( Antiarrhythmic activity of quinine in humans.
Duff, H; Koshman, ML; Sheldon, R, 1995
)
0.84
" Further, a dosage of 200 to 300 mg of quinine every night has not been shown to cause significant side effects."( Is quinine effective and safe in leg cramps?
Abernathy, T; Mandal, AK; Nelluri, SN; Stitzel, V, 1995
)
1.18
"In recent years major advances have been made in the clinical pharmacology of many drugs used for the treatment of tropical diseases, particularly in the design and development of dosage regimens for the treatment of severe malaria."( Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.
Edwards, G; Ward, SA; Winstanley, PA, 1994
)
0.29
" The selected combination formulated into a suitable dosage form is likely to offer dual benefit of a potent contraceptive and an antimicrobial preparation."( Synergistic spermicidal activity of neem seed extract, reetha saponins and quinine hydrochloride.
Chabra, S; Doncel, G; Garg, S; Talwar, GP; Upadhyay, SN, 1994
)
0.52
" With the use of the tail flick model, dose-response curves were constructed to codeine, morphine, oxycodone and oxymorphone (the O-demethylated metabolite of oxycodone) in both rat strains."( The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model.
Bochner, F; Cleary, J; Mikus, G; Somogyi, A, 1994
)
0.29
" The peak plasma quinine concentration after rapid intravenous dosing was 12."( Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: the importance of unbound quinine concentration.
Mberu, E; Mwangi, I; Newton, C; Pasvol, G; Ward, S; Warn, P; Warrell, D; Waruiru, C; Watkins, W; Winstanley, P,
)
0.74
" Before dosing and at regular intervals during dosing, blood and urine samples were collected and analysed for quinine HCl."( Toxicity threshold of quinine hydrochloride following low-level repeated dosing in healthy volunteers.
Butterworth, KR; Drewitt, PN; Raglan, EM; Springall, CD; Walters, DG, 1993
)
0.81
" The present data suggest that current dosage regimens of quinine used in the treatment of falciparum malaria may not be suitable for malaria patients with acute hepatitis or those who have had hepatitis within the past 3 months."( The pharmacokinetics of quinine in patients with hepatitis.
Karbwang, J; Molunto, P; Na Bangchang, K; Thanavibul, A, 1993
)
0.84
"006 at 2 hr and 4 hr, respectively), whereas this was not observed in a control group of nine older children (age range = 24 months to 10 years) receiving the same im dosage regimen."( Quinine pharmacokinetics in young children with severe malaria.
Hoek, FJ; Kager, PA; Kwiatkowski, D; van Boxtel, CJ; van den Berg, B; van Hensbroek, MB, 1996
)
1.74
" This suggests that dosage adjustment of Qn during haemodialysis is unnecessary."( Plasma quinine concentrations in falciparum malaria with acute renal failure.
Banmairuroi, V; Bunnag, D; Karbwang, J; Na-Bangchang, K; Rimchala, W; Sukontason, K; Tin, T, 1996
)
0.75
"To describe a case involving the removal of quinine by continuous venovenous hemofiltration (CVVH) in a patient with malaria and acute renal failure and to present recommendations on the dosing of quinine in such patients."( Quinine clearance in continuous venovenous hemofiltration.
Davies, JG; Greenwood, EF; Kingswood, JC; Sharpstone, P; Street, MK, 1996
)
2
" Dose-response studies showed that expression of wild-type pfmdr1 causes cellular resistance to quinine, quinacrine, mefloquine, and halofantrine in yeast cells."( The pfmdr1 gene of Plasmodium falciparum confers cellular resistance to antimalarial drugs in yeast cells.
Brault, M; Delling, U; Gros, P; Ruetz, S; Schurr, E, 1996
)
0.51
" A safe and effective dosing strategy is postulated."( Metabolism of quinine in children with global malnutrition.
Flouvat, B; Lagardère, B; Mugnier, C; Roux, A; Tréluyer, JM, 1996
)
0.65
" The decline in plasma concentration following multiple dosing was monoexponential with a terminal half-life of 12."( Disposition of oral quinine in African patients suffering from acute uncomplicated falciparum malaria.
Sowunmi, A, 1996
)
0.62
" A new dosage of halofantrine is proposed for the second injection due to cardiac toxicity."( [Malaria in expatriates in Africa. 154 cases. Clinical problems and therapeutic difficulties].
Gorge, O; Nicolas, F; Nicolas, X; Perret, JL; Touze, JE, 1997
)
0.3
" Dosing twice daily for at least 5 days was also critical."( Repetitive dosing of artemisinin and quinine against Plasmodium falciparum in vitro: a simulation of the in vivo pharmacokinetics.
Abbas, N; Björkman, A; Bwijo, B; Eriksson, O; Hassan Alin, M, 1997
)
0.57
" A dose-response to varying concentrations of bitter tastants can be measured."( Response of pigs to bitter-tasting compounds.
Nelson, SL; Sanregret, JD, 1997
)
0.3
" Probit analysis of log dose-response was used to determine effective concentrations EC50, EC90 and EC99 to the studied drugs."( In vivo and in vitro Plasmodium falciparum resistance to chloroquine, amodiaquine and quinine in the Brazilian Amazon.
di Santi, SM; Segurado, AA; Shiroma, M,
)
0.35
" The present data suggest that malaria parasites in African patients are still very sensitive to quinine and that the current dosage of quinine is effective for the treatment of acute falciparum malaria in African patients without augmenting therapy with any other drug such as tetracycline or sulphadoxine-pyrimethamine."( Pharmacokinetics of quinine in African patients with acute falciparum malaria.
Babalola, CP; Bolaji, OO; Ogunbona, FA; Sowunmi, A; Walker, O, 1998
)
0.84
" The fact that in malaria patients there was no correlation between body weight and quinine VD as calculated during the elimination phase renders questionable the usefulness of dosing quinine according to body weight."( Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria.
Claessen, FA; Kager, PA; Perenboom, RM; Tange, RA; van Boxtel, CJ; Wetsteijn, JC, 1998
)
1.97
" All sanctioned providers limited their first choices of antimalarial drug to those recommended by the national malaria control program and reported using correct dosing regimens."( Use of antimalarial drugs in Mali: policy versus reality.
Dicko, A; Diop, S; Djimde, A; Doumbo, O; Plowe, CV; Wellems, TE, 1998
)
0.3
" Reasons for compliance included the desire to be cured and to follow the advice of malaria staff/employer, and the simple dosing regimen."( Compliance with artesunate and quinine + tetracycline treatment of uncomplicated falciparum malaria in Thailand.
Fungladda, W; Honrado, ER; Kamolratanakul, P; Karbwang, J; Kitayaporn, D; Masngammueng, R; Thimasarn, K, 1998
)
0.59
"A gas chromatographic-mass spectrometric method was used to separate quinine and its metabolites present in urine after oral dosing of 300 mg quinine in humans."( Identification of quinine metabolites in urine after oral dosing in humans.
Bannon, P; Cook, JM; Roy, L; Villeneuve, JP; Yu, P, 1998
)
0.87
" While most patients with tertian malaria were cured with the standard chloroquine and primaquine regimen, a higher dosage was required for one case acquired in Papua New Guinea."( Imported malaria: successful treatment of 31 patients in the era of chloroquine resistance.
Chang, HL; Chang, SC; Chen, YC; Fang, CT; Hsieh, WC; Hsueh, PR; Hung, CC, 1999
)
0.3
" Further studies are required to establish its role and the optimal dosage regimen of charcoal to be administered."( Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists.
, 1999
)
0.3
" Dosage reduction to 5 mg/kg body weight in the patients seem to be safer."( Experience with quinine in falciparum malaria.
Adhikari, P; Padmaja, UK; Periera, P, 1999
)
0.65
") dosing of quinine was investigated."( Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats.
Coville, PF; Wanwimolruk, S; Wong, CW; Zhang, H, 2000
)
0.92
" The four drivers had been treated with chloroquine and proguanil but the dosage may have been insufficient with regard to their body weight (average weight = 110 kg)."( [A collective malarial infestation during a humanitarian mission in west Africa].
Beytout, J; Caumon, L; Chouaki, M; Cueto, T; Delort, P; Dufraise, S; Monchard, F; Philippe, JM; Rimeize, H, 2002
)
0.31
" Pharmacokinetic parameters were determined on repeated whole blood samples from caudal vein (experiment 1) and quinine distribution was evaluated in tissues and blood fractions from mice sacrificed two hours post dosing (experiment 2)."( Quinine distribution in mice with Plasmodium berghei malaria.
Bernier, A; Bouree, P; Fouquet, E; Pussard, E,
)
1.79
" Developed dosage forms must be able to assure a prolonged release in the rectum but not too much so as to avoid product expulsion by the child anus."( Comparative in vitro-in vivo study of two quinine rectal gel formulations.
Fawaz, F; Guyot, M; Koffi, A; Millet, P, 2004
)
0.59
" and oral dosage forms varied between 10 and 13."( Absolute bioavailability of quinine formulations in Nigeria.
Babalola, CP; Bolaji, OO; Ezeomah, E; Ogunbona, FA, 2004
)
0.62
" To inform dosage recommendations we assessed the pharmacokinetics of intravenous artesunate after the first dose."( The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria.
Barnes, KI; Chierakul, W; Evans, AC; Newton, PN; Ruangveerayuth, R; Smith, PJ; White, NJ, 2006
)
0.33
"The purpose of this study was to develop a taste-masked quinine sulphate dosage form as a flexible pediatric formulation tool."( Quinine sulphate pellets for flexible pediatric drug dosing: formulation development and evaluation of taste-masking efficiency using the electronic tongue.
Cordella, C; Huyghebaert, N; Kayumba, PC; Ntawukuliryayo, JD; Remon, JP; Vervaet, C, 2007
)
2.03
" To further characterize the effects of PCP on sucrose consumption, we examined the dose-response relationship between PCP and sucrose consumption, the longevity of the effect, the effects of repeated injections of PCP, variation of the PCP effect across sucrose concentrations, and the effects of PCP on gustatory hedonic responses."( Behavioral processes mediating phencyclidine-induced decreases in voluntary sucrose consumption.
Baird, JP; Hulick, V; Turgeon, S; Wallman, A, 2008
)
0.35
" We observed a moderate dose-response effect for thiabendazole, whereby spore count decreased as drug consumption increased."( Effect of four antimicrobials against an Encephalitozoon sp. (Microsporidia) in a grasshopper host.
Johny, S; Whitman, DW, 2008
)
0.35
" QS taste-masked pellets have been developed which offer more flexibility in adapting dosage to a child's weight."( Taste-masked quinine sulphate pellets: bio-availability in adults and steady-state plasma concentrations in children with uncomplicated Plasmodium falciparum malaria.
Huyghebaert, N; Kayumba, PC; Ntawukuliryayo, JD; Remon, JP; Twagirumukiza, M; van Bortel, L; Vervaet, C, 2008
)
0.72
" Permeation studies were carried out with Franz diffusion cells containing sublingual mucosa membranes with PBS receptor phase and dosed with solutions of quinine hydrochloride or quinine/2-hydroxypropyl-beta-cyclodextrin complexes."( Permeation of quinine across sublingual mucosa, in vitro.
Heard, CM; Ong, CM, 2009
)
0.91
"01) in the total area under the concentration-time curve (AUC(T)), maximum plasma concentration (C(max)) and terminal elimination half-life (T((1/2)beta)) of quinine compared with values with quinine dosing alone (AUC: 53."( Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers.
Cook, JM; Omoruyi, SI; Onyeji, CO; Owolabi, AR; Sarma, PV; Soyinka, JO, 2009
)
0.78
" Plasmodium berghei-infected Wistar rats were used to evaluate the efficacy of QN-loaded nanocapsules using different dosing regimens."( Nanoencapsulation increases quinine antimalarial efficacy against Plasmodium berghei in vivo.
Bettoni, CC; Dalla Costa, T; de Oliveira, LK; Guterres, SS; Haas, SE, 2009
)
0.65
" This study aimed to develop taste-masked quinine tablets suitable for children and offering dosing flexibility to adjust the quinine dose in function of body weight."( Taste-masked quinine pamoate tablets for treatment of children with uncomplicated Plasmodium falciparum malaria.
Bortel, V; Karema, C; Kayitare, E; Kayumba, PC; Mehuys, E; Ntawukulilyayo, JD; Remon, JP; Vervaet, C, 2010
)
0.99
"Insoluble quinine pamoate was used to formulate fast-disintegrating tablets, using a specific tablet design (rectangular tablet which can be divided into 8 subunits) to allow dosing flexibility."( Taste-masked quinine pamoate tablets for treatment of children with uncomplicated Plasmodium falciparum malaria.
Bortel, V; Karema, C; Kayitare, E; Kayumba, PC; Mehuys, E; Ntawukulilyayo, JD; Remon, JP; Vervaet, C, 2010
)
1.13
"Fast-dispersible and taste-masked quinine pamoate tablets improved dosing accuracy, allowed easy administration and resulted in a high efficacy during the treatment of children with uncomplicated malaria."( Taste-masked quinine pamoate tablets for treatment of children with uncomplicated Plasmodium falciparum malaria.
Bortel, V; Karema, C; Kayitare, E; Kayumba, PC; Mehuys, E; Ntawukulilyayo, JD; Remon, JP; Vervaet, C, 2010
)
1.01
"Downward dosage adjustment of quinine appears necessary when concurrently administered with ritonavir."( Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.
Cook, JM; Omoruyi, SI; Onyeji, CO; Owolabi, AR; Sarma, PV; Soyinka, JO, 2010
)
0.9
" Finally, a dose-response for quinine taste preference in IAA and continuous-access animals was determined."( Motivation for alcohol becomes resistant to quinine adulteration after 3 to 4 months of intermittent alcohol self-administration.
Bonci, A; Bowers, MS; Chang, SJ; Hopf, FW; Sparta, DR, 2010
)
0.91
" The system covered stocks of the four different dosage packs of artemether-lumefantrine (AL) and quinine injectable."( SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology.
Barrington, J; Kungulwe, S; Mwafongo, W; Ward, P; Wereko-Brobby, O, 2010
)
0.58
" Conducting a training programme for nurses and the provision of working aids, such as a dosage table and a wall chart, are recommended."( Assessing the performance of nurses in the management of malaria patients in Tanzania.
Kanamori, S; Kohi, TW; Mkude, S; Nyamhanga, T, 2011
)
0.37
" The most commonly used quinine dosage was 300 mg/day (range 200 to 500 mg)."( Quinine for muscle cramps.
Al Musa, T; El-Tawil, S; El-Tawil, T; Lunn, MP; Valli, H; Weber, M, 2010
)
2.11
" However, its continued use is challenged by its poor tolerability, poor compliance with complex dosing regimens, and the availability of more efficacious anti-malarial drugs."( Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria.
Achan, J; Baliraine, FN; D'Alessandro, U; Erhart, A; Rosenthal, PJ; Talisuna, AO; Tibenderana, JK; Yeka, A, 2011
)
1.81
" With respect to content uniformity of dosage forms, 1mm mini-tablets containing 80% quinine hydrochloride met the requirements of the European Pharmacopeia (AV=6."( Development of mini-tablets with 1mm and 2mm diameter.
Breitkreutz, J; Kleinebudde, P; Tissen, C; Woertz, K, 2011
)
0.59
" Quinine injected at a dosage of 60 mg kg(-1) body weight resulted in a significantly lower number of trophonts."( Efficacy of quinine against ichthyophthiriasis in common carp Cyprinus carpio.
El-Matbouli, M; Schumacher, IV; Wedekind, H, 2011
)
1.66
" Quinine is metabolized primarily by CYP3A4, implying changing the dosage when combined with inhibitors or inducers of CYP."( [Therapeutic drug monitoring of quinine].
Bentué-Ferrer, D; Tribut, O; Verdier, MC,
)
1.33
" There was no evidence of dose-related drug toxicity with the loading dosing regimen."( Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria.
Day, NP; Dondorp, AM; Gesase, S; Hendriksen, IC; Lemnge, MM; Lindegardh, N; Maiga, D; Mtove, G; Reyburn, H; Tarning, J; von Seidlein, L; White, NJ, 2013
)
0.62
" The current study evaluated providers' knowledge and practices of treatment policy and dosing regimens with AL and quinine in the public, private and not-for-profit drug outlets."( Provider knowledge of treatment policy and dosing regimen with artemether-lumefantrine and quinine in malaria-endemic areas of western Kenya.
Abong'o, BO; Ombaka, JH; Onyango, RO; Ouma, C; Watsierah, CA, 2012
)
0.81
" Information on provider in-service training, knowledge (qualification, treatment policy, dosing regimen, recently banned anti-malarials) and on practices (request for written prescription, prescription of AL, selling partial packs and advice given to patients after prescription), was collected."( Provider knowledge of treatment policy and dosing regimen with artemether-lumefantrine and quinine in malaria-endemic areas of western Kenya.
Abong'o, BO; Ombaka, JH; Onyango, RO; Ouma, C; Watsierah, CA, 2012
)
0.6
"Public-sector providers have higher knowledge on treatment policy and dosing regimen on recommended anti-malarials."( Provider knowledge of treatment policy and dosing regimen with artemether-lumefantrine and quinine in malaria-endemic areas of western Kenya.
Abong'o, BO; Ombaka, JH; Onyango, RO; Ouma, C; Watsierah, CA, 2012
)
0.6
" More studies with appropriate control groups in larger series are needed to characterize the degree to which pregnant women are underdosed with current antimalarial dosing regimens."( Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.
Dhorda, M; Guerin, PJ; Jullien, V; Kloprogge, F; Nosten, F; Piola, P; Tarning, J; White, NJ, 2013
)
0.62
" Hydroxyethylapoquinine (HEAQ), used at 8 g a day for dosing in humans in the 1930s and halving mortality from bacterial pneumonias, was shown to cure bird malaria in the 1940s and was also reported as treatment for human malaria cases."( Antimalarial efficacy of hydroxyethylapoquinine (SN-119) and its derivatives.
Meyers, DJ; Sanders, NG; Sullivan, DJ, 2014
)
1.02
"6 for the three dosing groups (10, 20 and 100 mg)."( Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
Andersson, TB; Bäckström, T; Bertilsson, L; Björkhem-Bergman, L; Bredberg, E; Diczfalusy, U; Nylén, H; Rönquist-Nii, Y, 2014
)
1.85
" These factors determine the adherence to the dosing schedules during the treatment course and thus the evaluation of the subsidy policy, its implementation and role in malaria burden in this region is compulsory."( Access to artemisinin-based combination therapy (ACT) and quinine in malaria holoendemic regions of western Kenya.
Ouma, C; Watsierah, CA, 2014
)
0.65
"05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27."( Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration.
Adeagbo, BA; Adegbola, AJ; Igbinoba, SI; Nathaniel, TI; Soyinka, JO,
)
0.61
" The most commonly used quinine dosage was 300 mg/day (range 200 to 500 mg)."( Quinine for muscle cramps.
Al Musa, T; Brassington, R; El-Tawil, S; El-Tawil, T; Lunn, MP; Valli, H; Weber, M, 2015
)
2.17
"There is no evidence to judge optimal dosage or duration of quinine treatment."( Quinine for muscle cramps.
Al Musa, T; Brassington, R; El-Tawil, S; El-Tawil, T; Lunn, MP; Valli, H; Weber, M, 2015
)
2.1
"The 3D printing technique of fused deposition modeling® (FDM) has lately come into focus as a potential fabrication technique for pharmaceutical dosage forms and medical devices that allows the preparation of delivery systems with nearly any shape."( Assessment of different polymers and drug loads for fused deposition modeling of drug loaded implants.
Bogdahn, M; Franz, C; Kempin, W; Koster, LC; Schneider, F; Seidlitz, A; Weitschies, W, 2017
)
0.46
" This may soon change to recommending artemisinin-based combination therapies (standard duration of dosing = 3 days)."( Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester.
Clark, RL, 2017
)
0.46
" The objective of the study was to apply physiologically-based pharmacokinetic (PBPK) modeling to predict optimal dosage regimens of quinine when coadministered with lopinavir/ritonavir in malaria and HIV coinfected patients with different conditions."( Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir.
Karbwang, J; Na-Bangchang, K; Rajoli, RKR; Saeheng, T; Siccardi, M, 2020
)
0.99
"Considering the low day 7 concentrations of piperaquine reported in the patients studied here, we suggest to adopt the recently recommended higher dose of DP in young children or a prolonged 5-day dosing in children living in malaria endemic areas who have suffered an initial episode of severe malaria in order to achieve adequate drug exposures for effective post-treatment prophylactic effects."( Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine.
Blessborn, D; Byakika-Kibwika, P; Lamorde, M; Ssenyonga, R; Tarning, J, 2019
)
0.72
"Standard dosage regimens of quinine formulated for adult patients with uncomplicated and complicated malaria have been applied for clinical uses in children, pregnant women, and elderly."( Clinical pharmacokinetics of quinine and its relationship with treatment outcomes in children, pregnant women, and elderly patients, with uncomplicated and complicated malaria: a systematic review.
Na-Bangchang, K; Saeheng, T, 2022
)
1.31
" Robust training on appropriate anti-malarial and dosage is needed, particularly given the recent change in recommendation for artemether-lumefantrine use in the first trimester."( Healthcare provider and drug dispenser knowledge and adherence to guidelines for the case management of malaria in pregnancy in the context of multiple first-line artemisinin-based combination therapy in western Kenya.
Dellicour, S; Gutman, JR; Hill, J; Ochodo, E; Osoro, CB; Ter Kuile, F; Young, T, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (74 Items)

ItemProcessFrequency
Beveragescore-ingredient101
Sodascore-ingredient65
Waterscore-ingredient54
Carbonated drinkscore-ingredient42
Boissonscore-ingredient25
Tonic watercore-ingredient22
gazeusescore-ingredient21
Eau toniquecore-ingredient20
Boissons avec sucre ajoutécore-ingredient19
Alcoholic beveragescore-ingredient14
Sweetened beveragescore-ingredient9
Boissons édulcoréescore-ingredient4
en:Tonic drink with sugarcore-ingredient4
Bebidas azucaradascore-ingredient4
Bebidas con saborcore-ingredient4
Tónicacore-ingredient4
Bebidas no alcohólicascore-ingredient4
Bebidascore-ingredient4
carbonatadascore-ingredient3
Fraiscore-ingredient3
Artificially sweetened beveragescore-ingredient3
Non-alcoholic beveragescore-ingredient3
Unsweetened beveragescore-ingredient2
en:sweetened-beveragescore-ingredient2
Carbonated soft drinks without fruit juicecore-ingredient2
Tonic drink without sugar with artificial sweetenerscore-ingredient2
Flavoured Drinkscore-ingredient2
Beverages and beverages preparationscore-ingredient1
Plant-based beveragescore-ingredient1
Plant-based foods and beveragescore-ingredient1
Diet gin and toniccore-ingredient1
Ginscore-ingredient1
Hard liquorscore-ingredient1
Distilled beveragescore-ingredient1
Diet sodascore-ingredient1
Diet beveragescore-ingredient1
Vins aromatiséscore-ingredient1
Vinscore-ingredient1
Frozen foodscore-ingredient1
Surgeléscore-ingredient1
Apéritif sans alcoolcore-ingredient1
alcooliséescore-ingredient1
Boissons froidescore-ingredient1
TONIC SANS SUCRES SANS ASPARTAMEcore-ingredient1
Sodas lightcore-ingredient1
Boissons lightcore-ingredient1
Tonic sucrécore-ingredient1
Tonic sucré avec édulcorantscore-ingredient1
en:ginscore-ingredient1
Carbonated soft drinks without fruit juice with sugar and artificial sweetenerscore-ingredient1
en:artificially-sweetened-beveragescore-ingredient1
Gesuikerde drankencore-ingredient1
Tonicscore-ingredient1
Frisdrankencore-ingredient1
Koolzuurhoudende drankencore-ingredient1
Drankencore-ingredient1
Productos sin glutencore-ingredient1
en:Products for specific dietscore-ingredient1
Bebidas carbonatadascore-ingredient1
en:Specific productscore-ingredient1
Energy drinkscore-ingredient1
Boissons à l'orangecore-ingredient1
Boissons aux fruitscore-ingredient1
Boissons gazeusescore-ingredient1
Boissons à base de végétauxcore-ingredient1
Aliments et boissons à base de végétauxcore-ingredient1
en:tonic-watercore-ingredient1
Tonic drink with sugar and artificial sweetenerscore-ingredient1
Tonic drink with sugar and artificial sweetenerstrace-ingredient1
Sweetened beveragestrace-ingredient1
Tonic watertrace-ingredient1
Sodastrace-ingredient1
Carbonated drinkstrace-ingredient1
Beveragestrace-ingredient1

Roles (4)

RoleDescription
antimalarialA drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
muscle relaxantA drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
cinchona alkaloidAn alkaloid based on a cinchonan skeleton.
monoterpenoid indole alkaloidA terpenoid indole alkaloid which is biosynthesised from L-tryptophan and diisoprenoid (usually secolaganin) building blocks.
organic heterohexacyclic compound
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
Aspidosperma alkaloidAny member of a group of indole alkaloids based on a C19 or C20 skeleton formed by condensation of tryptamine with a rearranged seconloganin-derived C9 or C10 unit. The Aspidosperma alkaloids constitute the largest group of indole alkaloids (currently ca. 220 alkaloids) and may be divided into several sub-groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency25.16180.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency8.69090.000714.592883.7951AID1259369; AID1259392
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency7.09010.001022.650876.6163AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency19.49710.01237.983543.2770AID1645841
farnesoid X nuclear receptorHomo sapiens (human)Potency23.70830.375827.485161.6524AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.21780.000229.305416,493.5996AID743080; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency2.18760.00108.379861.1304AID1645840
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency9.52050.001019.414170.9645AID743094
aryl hydrocarbon receptorHomo sapiens (human)Potency17.79660.000723.06741,258.9301AID743085; AID743122
thyroid stimulating hormone receptorHomo sapiens (human)Potency26.60320.001628.015177.1139AID1224895
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency33.49150.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency26.60110.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1Mus musculus (house mouse)IC50 (µMol)0.28000.28001.32753.9000AID678794
Solute carrier family 22 member 2Homo sapiens (human)Ki3.40000.10001.52203.4000AID681171
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)51.60000.21005.553710.0000AID386625
Solute carrier family 22 member 1 Homo sapiens (human)Ki22.90000.55004.26507.4600AID681146
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Solute carrier organic anion transporter family member 1A4Rattus norvegicus (Norway rat)Ki3.81000.03702.34107.3000AID679493
Solute carrier family 22 member 2Mus musculus (house mouse)IC50 (µMol)2.80002.80004.76678.0000AID678785
Potassium channel subfamily K member 2Homo sapiens (human)IC50 (µMol)3.85000.40003.92279.0000AID1802150
Bile salt export pumpHomo sapiens (human)IC50 (µMol)122.27670.11007.190310.0000AID1443980; AID1449628; AID1473738
Histidine-rich protein PFHRP-IIPlasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)7,400,000.00000.07651.12552.9000AID401645
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)137.85560.00022.318510.0000AID150618; AID1555759; AID681126; AID681127; AID681131; AID681579; AID681580; AID681581; AID681582
ATP-dependent translocase ABCB1Homo sapiens (human)Ki12.00000.02002.35948.5900AID150735
Cytochrome P450 2D26Rattus norvegicus (Norway rat)IC50 (µMol)0.09400.09402.16285.6000AID54564
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)0.62850.00002.015110.0000AID1520028; AID262947; AID54564; AID54570
Cytochrome P450 2D6Homo sapiens (human)Ki15.00000.00011.19868.0000AID150607
Solute carrier organic anion transporter family member 1A1Rattus norvegicus (Norway rat)Ki76.70001.10004.51259.8000AID682052
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)IC50 (µMol)51.60002.03005.53139.9000AID386625
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)IC50 (µMol)2.03330.18003.68578.8000AID678995; AID678996; AID681159
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Ki2.61500.13002.37856.9000AID681157; AID681376
Cytochrome P450 2D4Rattus norvegicus (Norway rat)IC50 (µMol)1.70001.70001.70001.7000AID54566
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)IC50 (µMol)25.50001.00004.446710.0000AID678968; AID678969
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)Ki55.00000.39002.32959.4000AID681632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AlbuminHomo sapiens (human)Kd309.03000.08933.31358.0000AID327170
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)Km2.60000.02891.04072.6000AID679159
ATP-dependent translocase ABCB1Homo sapiens (human)Km10.00000.01403.717210.0000AID681163
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Km0.27000.27005.695010.0000AID681573
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (120)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cardiac ventricle developmentPotassium channel subfamily K member 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayPotassium channel subfamily K member 2Homo sapiens (human)
memoryPotassium channel subfamily K member 2Homo sapiens (human)
response to mechanical stimulusPotassium channel subfamily K member 2Homo sapiens (human)
response to axon injuryPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of cardiac muscle cell proliferationPotassium channel subfamily K member 2Homo sapiens (human)
cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium channel subfamily K member 2Homo sapiens (human)
cochlea developmentPotassium channel subfamily K member 2Homo sapiens (human)
positive regulation of cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of DNA biosynthetic processPotassium channel subfamily K member 2Homo sapiens (human)
stabilization of membrane potentialPotassium channel subfamily K member 2Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (70)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
outward rectifier potassium channel activityPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion leak channel activityPotassium channel subfamily K member 2Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
endoplasmic reticulum membranePotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
cell surfacePotassium channel subfamily K member 2Homo sapiens (human)
apical plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
neuronal cell bodyPotassium channel subfamily K member 2Homo sapiens (human)
calyx of HeldPotassium channel subfamily K member 2Homo sapiens (human)
astrocyte projectionPotassium channel subfamily K member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (791)

Assay IDTitleYearJournalArticle
AID477940Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum Voll infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID562271Antimalarial activity against Plasmodium falciparum isolates assessed as parasite growth inhibition after 72 hrs by ELISA based histidine-rich protein 2 in vitro drug susceptibility assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Antimalarial activity of tigecycline, a novel glycylcycline antibiotic.
AID361170Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-resistant Plasmodium falciparum W22001Journal of natural products, Jun, Volume: 64, Issue:6
Antimalarial compounds from Rhaphidophora decursiva.
AID335153Selectivity index, ED50 for human KB cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID547339Antimalarial activity against Plasmodium falciparum harboring pfcrt-76 mutant gene with 2 DNNND repeat2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID524782Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by 96-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID337542Selectivity index, ratio of ED50 for human KB-V1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID477946Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum K2 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID1145674Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID125789Inhibitory effect on Bufuralol 1'-hydroxylation by human liver microsomes (Ki = apparent inhibition constant)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
AID547327Antimalarial activity against Plasmodium falciparum isolate 89732010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID575590Antimicrobial activity against Plasmodium falciparum F08B40 harboring pfnhe1 ms4760 haplotype 21 carrying 1 copy of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID682003TP_TRANSPORTER: inhibition of Choline uptake (Choline: 10 uM, Quinine: 200 uM) in Xenopus laevis oocytes2001The Journal of biological chemistry, Nov-09, Volume: 276, Issue:45
Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus.
AID575580Antimicrobial activity against Plasmodium falciparum F09N44 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1593290Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID298287Antiprion activity in ScN2a cells assessed as inhibition of protease-resistant prion protein accumulation2007Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
New series of antiprion compounds: pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation.
AID472815Inhibition of HCV genotype 1b NS5B polymerase deltaC21 mutant at 50 uM2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Allosteric inhibitors of hepatitis C virus NS5B polymerase thumb domain site II: structure-based design and synthesis of new templates.
AID575429Antimicrobial activity against Plasmodium falciparum F07-23 harboring pfnhe1 ms4760 haplotype 1 carrying 2 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes aft2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID764199Antiplasmodial activity against erythrocytic stage of chloroquine-sensitive Plasmodium falciparum 3D7 assessed as parasite LDH activity by three-fold serial dilution method2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID334843Antimalarial activity after 24 hrs against Plasmodium falciparum W2 infected in type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxic and antimalarial alkaloids from the bulbs of Crinum amabile.
AID575735Antimicrobial activity against Plasmodium falciparum 7G8 harboring pfnhe1 ms4760 haplotype 1 carrying 2 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034C 1042D 1246Y and pfcrt 72-76 SVMNT 220S infected in human erythrocytes after 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID511256Antimicrobial activity against Plasmodium falciparum harboring mdr1 N86Y/D1246Y/Y184F mutant gene by ELISA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID1145676Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 to IC50 for sensitive Lactobacillus casei ATCC 74691977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID678968TP_TRANSPORTER: inhibition of TEA uptake (in the presence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID477943Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum Bres infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID547331Antimalarial activity against Plasmodium falciparum harboring 3 DNNND repeat2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID234946Selectivity is the ratio of mean EC50 value against FA3A cells to that of EC50 value against Plasmodium falciparum2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Synthesis of novel ferrocenyl sugars and their antimalarial activities.
AID754530Inhibition of hemozoin formation in 8 M acetate buffer at pH 5 after 18 hrs by microtiter plate-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID337517Antimalarial activity after 24 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID335152Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum W2 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID575432Antimicrobial activity against Plasmodium falciparum F08B53 harboring pfnhe1 ms4760 haplotype 1 carrying 2 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes aft2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1209582Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID588988Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OCT12010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID211647Compound was evaluated for toxicity on Human kidney epithelial (Graham cells) at a dose of 100 ug/mL; Not toxic2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Antimalarial compounds from Parinari capensis.
AID358505Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 Indochina by [3H]hypoxanthine uptake2001Journal of natural products, Jan, Volume: 64, Issue:1
Strychnogucines A and B, two new antiplasmodial bisindole alkaloids from Strychnos icaja.
AID393144Antitubercular activity against Mycobacterium tuberculosis H37Rv after 5 days by microplate alamar blue assay2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Synthesis and in vitro antitubercular activity of a series of quinoline derivatives.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID299663Antibacterial activity against methicillin-resistant Staphylococcus aureus CMAH 0504 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Synthesis and evaluation of amphiphilic cationic quinine-derived for antibacterial activity against methicillin-resistant Staphylococcus aureus.
AID158038Inhibitory concentration against multidrug-resistant Plasmodium falciparum Dd2.2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Structure-activity relationships of novel anti-malarial agents. Part 4: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides.
AID575572Antimicrobial activity against Plasmodium falciparum F09A10 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID279385Growth inhibition of Plasmodium falciparum as reduced [3H]hypoxanthine incorporation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
AID290778Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcB1 after 48 hrs by pLDH assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
A novel artemisinin-quinine hybrid with potent antimalarial activity.
AID1873790Cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as inhibition of calcein-AM efflux at 20 uM incubated for 15 mins by calcein-AM staining based flow cytometry analysis2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines.
AID681573TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes1996The Journal of biological chemistry, Dec-20, Volume: 271, Issue:51
Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1.
AID377944Cytotoxicity against human KB cells after 72 hrs by SRB assay1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID337528Cytotoxicity against human LNCAP cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID442261Therapeutic index, ratio of IC50 for concanavalin-stimulated BALB/c mice (Mus musculus) splenocytes to IC50 for Plasmodium falciparum 3D72009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID158845Inhibitory activity against Plasmodium falciparum K12002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID1123507Antimalarial activity against Plasmodium berghei1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Quantitative structure-activity relationships in 1-aryl-2-(alkylamino)ethanol antimalarials.
AID558054Antimicrobial activity against Plasmodium falciparum harboring SVMNT genotype after 72 hrs by SYBR green I assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria.
AID683685Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate alamar blue assay2012European journal of medicinal chemistry, Nov, Volume: 57The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.
AID150607Inhibition of partially purified cytochrome P450 2D6 1'-hydroxybufuralol formation1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
AID1593288Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring M133I/A138T double mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID337529Cytotoxicity against human ZR-75-1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID678995TP_TRANSPORTER: inhibition of TEA uptake (in the presence of bicarbonate) (TEA: 20 uM) in OCT1-expressing HEK293 cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID477947Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum K14 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID575569Antimicrobial activity against Plasmodium falciparum F08B61 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID563688Antimalarial activity against Plasmodium falciparum assessed as resistant isolates2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility.
AID524776Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by 96-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID337525Cytotoxicity against human KBV1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID749413Hemolytic activity in human RBC at 100 uM after 48 hrs relative to control2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Synthesis and evaluation of 7-chloro-4-(piperazin-1-yl)quinoline-sulfonamide as hybrid antiprotozoal agents.
AID547310Antimalarial activity against Plasmodium falciparum isolate AK150 D-02010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID554629Antimicrobial activity against Plasmodium falciparum IMT 10336 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID1873782Cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibition incubated for 144 hrs by fluorescence microplate reader assay2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines.
AID1145688Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as active dose required to increase of 100% in mean survival time1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID680279TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Quinine: 20 uM) in MDR1-expressing NIH-3T3 cells2004Biochemical and biophysical research communications, Mar-19, Volume: 315, Issue:4
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
AID575434Antimicrobial activity against Plasmodium falciparum F09N18 harboring pfnhe1 ms4760 haplotype 1 carrying 2 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes aft2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID337533Selectivity index, ratio of ED50 for human HT1080 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID755528Cytotoxicity against human 5637 cells assessed as growth inhibition after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID299661Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Synthesis and evaluation of amphiphilic cationic quinine-derived for antibacterial activity against methicillin-resistant Staphylococcus aureus.
AID299678Toxicity in human erythrocytes assessed as hemolytic activity at 250 ug/ml after 1 hr2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Synthesis and evaluation of amphiphilic cationic quinine-derived for antibacterial activity against methicillin-resistant Staphylococcus aureus.
AID554624Antimicrobial activity against Plasmodium falciparum IMT 16332 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID558845Antimalarial activity against Plasmodium falciparum IMT K4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID333950Phototoxicity against CHO cells at 25 ppm
AID575563Antimicrobial activity against Plasmodium falciparum F07-42 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID749412Inhibition of beta-haematin formation after 24 hrs by microtiter plate assay2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Synthesis and evaluation of 7-chloro-4-(piperazin-1-yl)quinoline-sulfonamide as hybrid antiprotozoal agents.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID322135Antimalarial activity against Plasmodium falciparum W2 as reduced [3H]hypoxanthine uptake after 72 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID337550Selectivity index, ratio of ED50 for human ZR-75-1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID575591Antimicrobial activity against Plasmodium falciparum SM harboring pfnhe1 ms4760 haplotype 6 carrying 2 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86Y 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after 72 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID524778Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by 96-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID227386Antiplasmodial potency relative to chloroquine in ferriprotoporphyrin biomineralisation assay2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
The imidazo[2,1-a]isoindole system. A new skeletal basis for antiplasmodial compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID337549Selectivity index, ratio of ED50 for human LNCaP cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID378395Antimalarial activity against chloroquine-resistant Plasmodium falciparum W22006Journal of natural products, Aug, Volume: 69, Issue:8
Biological activities and 3D QSAR studies of a series of Delisea pulchra (cf. fimbriata) derived natural products.
AID575586Antimicrobial activity against Plasmodium falciparum F08B7 harboring pfnhe1 ms4760 haplotype 9 carrying 3 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes afte2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1145608Drug absorption in anesthetized rat colon at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID564297Antimalarial activity against Plasmodium falciparum IMT 9881 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID357907Antimalarial activity against chloroquine-resistant Plasmodium falciparum W22001Journal of natural products, Sep, Volume: 64, Issue:9
Synthesis of new artemisinin analogues from artemisinic acid modified at C-3 and C-13 and their antimalarial activity.
AID1364941Antiviral activity against Chikungunya virus infected in African green monkey Vero cells2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID72013Cytotoxicity against mouse mammary tumor FM3A cells representing a model of host2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Rhodacyanine dyes as antimalarials. 1. Preliminary evaluation of their activity and toxicity.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID337518Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum W2 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID119229Antimalarial activity against trophozoite-induced Plasmodium berghei in mice (Mus musculus)1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID554635Antimicrobial activity against Plasmodium falciparum IMT L1 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID1126676Antimalarial activity against chloroquine/quinine sensitive Plasmodium falciparum assessed as parasite growth inhibition after 48 hrs2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.
AID519975Antimalarial activity against early trophozoite-stage Plasmodium falciparum 3D7 infected in erythrocyte assessed as reduction in parasite hemoglobin content at 5 times IC50 after 8 hrs in presence of 40 uM protease inhibitor ALLN2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparum.
AID316376Antimalarial activity against Plasmodium falciparum D6 in MSF assay2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis and heme-binding correlation with antimalarial activity of 3,6-bis-(omega-N,N-diethylaminoamyloxy)-4,5-difluoroxanthone.
AID554444Antimicrobial activity against Plasmodium falciparum IMT 9881 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID564304Antimalarial activity against Plasmodium falciparum IMT K4 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID519978Antimalarial activity against Plasmodium falciparum 3D7 infected in erythrocyte assessed as reduction in endocytic vesicle content after 8 hrs by immunofluorescence microscopy2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparum.
AID1593296Inhibition of Plasmodium falciparum cytochrome b-c12019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1422833Binding affinity to hemin assessed as protection against H2O2-induced hemin degradation up to 100 uM at pH 5.2 preincubated followed by H2O2 addition measured after 120 mins2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Potent Antimalarial Activity of Two Arenes Linked with Triamine Designed To Have Multiple Interactions with Heme.
AID575581Antimicrobial activity against Plasmodium falciparum F09N64 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID564286Antimalarial activity against Plasmodium falciparum D6 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID477948Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum FCM29 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID116254Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 640 mg/kg subcutaneous dose1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID575562Antimicrobial activity against Plasmodium falciparum F07-40 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86Y 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220A infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID29140Apparent value (pKa) calculated with ACD/pKa (experimental pKa value)2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
AID575738Antimicrobial activity against Plasmodium falciparum HB3 harboring pfnhe1 ms4760 haplotype 5 carrying 4 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042D 1246D and pfcrt 72-76 CVMNK 220A infected in human erythrocytes after 722010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID337541Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID575442Antimicrobial activity against Plasmodium falciparum F07-11 harboring pfnhe1 ms4760 haplotype 6 carrying 2 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID547317Antimalarial activity against Plasmodium falciparum isolate 68162010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID1201059Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K12015European journal of medicinal chemistry, Apr-13, Volume: 94Synthesis of isocryptolepine analogues and their structure-activity relationship studies as antiplasmodial and antiproliferative agents.
AID158671Effective dose ED90 against Plasmodium berghei N in mice (Mus musculus) malaria model after peroral administration2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID377947Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID322130In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID290777Antimalarial activity against Plasmodium falciparum 3D7 after 72 hrs by pLDH assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
A novel artemisinin-quinine hybrid with potent antimalarial activity.
AID558846Antimalarial activity against Plasmodium falciparum IMT L1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1873786Resistance ratio of IC50 for cytotoxicity against multidrug resistance human MES-SA/Dx5 cells in presence of P-gp inhibitor Tariquidar to IC50 for cytotoxicity against human MES-SA cells in presence of P-gp inhibitor Tariquidar2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines.
AID678969TP_TRANSPORTER: inhibition of TEA uptake (in the absence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID477937Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum 3D7 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID1209581Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID337524Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID575564Antimicrobial activity against Plasmodium falciparum F07-58 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID554628Antimicrobial activity against Plasmodium falciparum IMT 10500 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID159026Inhibitory ratio on proliferation of Plasmodium falciparum at 0.1 uM2001Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18
New anti-malarial flavonol glycoside from Hydrangeae Dulcis Folium.
AID233780The ratio of SD90 of the quinine hydrochloride, to the SD90 of the test substance for the Dose of 74.5 mg/kg1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID361155Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2/Indochina by [3H]hypoxanthine uptake2002Journal of natural products, Oct, Volume: 65, Issue:10
Antiplasmodial activity of alkaloids from various strychnos species.
AID1209593Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID477939Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum 8425 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID150736Fraction of high affinity at binding site of human P-Glycoprotein (P-gp) in two-affinity model2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID575737Antimicrobial activity against Plasmodium falciparum K1 harboring pfnhe1 ms4760 haplotype 5 carrying 4 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86Y 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after 72 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID337523Cytotoxicity against human Col1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID581964Antimicrobial activity against wild type Plasmodium falciparum HB3 infected in erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I-based fluorescence assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID558840Antimalarial activity against Plasmodium falciparum IMT 10336 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID681131TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID116238Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after 20 mg/kg subcutaneous dose1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID388306Inhibition of Plasmodium falciparum recombinant carbonic anhydrase2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Carbonic anhydrase inhibitors: inhibition of Plasmodium falciparum carbonic anhydrase with aromatic/heterocyclic sulfonamides-in vitro and in vivo studies.
AID547328Antimalarial activity against Plasmodium falciparum harboring 1 DNNND repeat2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID575446Antimicrobial activity against Plasmodium falciparum F09N35 harboring pfnhe1 ms4760 haplotype 6 carrying 2 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1239624Antiplasmodial activity against CQ-sensitive Plasmodium falciparum 3D72015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Quinoline-based antimalarial hybrid compounds.
AID158844Inhibitory activity against Plasmodium falciparum D62002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID524777Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by 1536-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID575568Antimicrobial activity against Plasmodium falciparum F08B41 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID477938Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum D6 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID547302Antimalarial activity against Plasmodium falciparum isolate AK1442010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID564295Antimalarial activity against Plasmodium falciparum IMT 31 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID681376TP_TRANSPORTER: inhibition of MPP+ uptake in OCT1-expressing HEK293 cells
AID334844Selectivity index, ratio of ED50 for human KB cells to ED50 for Plasmodium falciparum D61993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxic and antimalarial alkaloids from the bulbs of Crinum amabile.
AID575560Antimicrobial activity against Plasmodium falciparum F07-31 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1145675Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID337515Cytotoxicity against human multidrug-resistant KBV1 cells1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Cyclea barbata.
AID764202Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream form assessed as parasite LDH activity by three-fold serial dilution method2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID401070Activation of LPS-induced NO production in BCG-treated ICR mouse macrophages at 1 mg/kg/day, po administered for 3 days before BCG immunization measured after 24 hrs of LPS challenge by Griess reagent method1998Journal of natural products, Jun-26, Volume: 61, Issue:6
Enhancement of NO production in activated macrophages in vivo by an antimalarial crude drug, Dichroa febrifuga.
AID1656233Antimalarial activity against chloroquine and quinine sensitive Plasmodium falciparum2019European journal of medicinal chemistry, Feb-15, Volume: 164Green recipes to quinoline: A review.
AID547318Antimalarial activity against Plasmodium falciparum isolate 89662010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID547313Antimalarial activity against Plasmodium falciparum isolate AK1822010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID150618Concentration required for 50% inhibition at binding site of human P-Glycoprotein (P-gp) in one-affinity model2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
AID575570Antimicrobial activity against Plasmodium falciparum F08B63 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID337534Selectivity index, ratio of ED50 for human LUC1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1145607Octanol-aqueous phase distribution coefficient, log D of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID337522Cytotoxicity against human SK-MEL-2 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1520028Inhibition of human CYP2D6 preincubated for 5 mins followed by NADPH addition and measured after 45 mins by luminescence based microplate reader analysis
AID547305Antimalarial activity against Plasmodium falciparum isolate AK1672010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID477945Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum W2 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID402143Antimalarial activity against Plasmodium falciparum W2 by [3H]hypoxanthine uptake relative to gedunin1997Journal of natural products, Apr, Volume: 60, Issue:4
Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives.
AID554633Antimicrobial activity against Plasmodium falciparum IMT 6311 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID324385Induction of light chain 3-GFP level in human H4 cells at 6.9 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID159840Compound was evaluated for its antimalarial activity in vitro on Plasmodium falciparum2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Antimalarial compounds from Parinari capensis.
AID1593253Antimalarial activity against multidrug-resistant Plasmodium falciparum Dd2 infected in human erythrocytes by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID402124Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes by [3H]hypoxanthine uptake1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID575445Antimicrobial activity against Plasmodium falciparum F08B32 harboring pfnhe1 ms4760 haplotype 6 carrying 2 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID558837Antimalarial activity against Plasmodium falciparum IMT 31 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID337532Selectivity index, ratio of ED50 for human HT1080 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID575449Antimicrobial activity against Plasmodium falciparum F09N68 harboring pfnhe1 ms4760 haplotype 6 carrying 2 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID116376Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 80 mg/kg subcutaneous dose1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID322129In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID158848Inhibitory activity against Plasmodium falciparum W22002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID575734Antimicrobial activity against Plasmodium falciparum 3D7 harboring pfnhe1 ms4760 haplotype 2 carrying 1 copy of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVMNK 220A infected in human erythrocytes after 722010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID461608Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 14 days post infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID660170Antimalarial activity against chloroquine sensitive Plasmodium falciparum HB3 after 72 hrs by SYBP Green I dye staining2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum.
AID324583Increase in long-lived protein degradation in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID547333Antimalarial activity against Plasmodium falciparum harboring pfcrt-76 mutant gene2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID547337Antimalarial activity against Plasmodium falciparum harboring pfmdr1-86 mutant gene with 2 DNNND repeat2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID575736Antimicrobial activity against Plasmodium falciparum Dd2 harboring pfnhe1 ms4760 haplotype 1 carrying 2 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86Y 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID554642Antimicrobial activity against Plasmodium falciparum IMT 9996 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID299676Toxicity in human erythrocytes assessed as hemolytic activity at 1000 ug/ml after 1 hr2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Synthesis and evaluation of amphiphilic cationic quinine-derived for antibacterial activity against methicillin-resistant Staphylococcus aureus.
AID116250Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after 40 mg/kg subcutaneous dose1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID386625Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID337527Cytotoxicity against human A431 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID54564Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D2 expressed in Saccharomyces cerevisiae2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
AID337531Selectivity index, ratio of ED50 for human BCA1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID575561Antimicrobial activity against Plasmodium falciparum F07-35 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1201065Antiplasmodial activity against chloroquine/mefloquine-resistant Plasmodium falciparum SRIV352015European journal of medicinal chemistry, Apr-13, Volume: 94Synthesis of isocryptolepine analogues and their structure-activity relationship studies as antiplasmodial and antiproliferative agents.
AID755549Hemolytic activity in mouse RBC at 100 uM after 1 hr by ELISA relative to control2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID558834Antimalarial activity against Plasmodium falciparum IMT Bres assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID337520Cytotoxicity against human HT1080 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID558838Antimalarial activity against Plasmodium falciparum IMT 8425 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID158877In vitro inhibition of parasite development of Plasmodium falciparum W2 in human erythrocytes2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Synthesis and evaluation of new antimalarial analogues of quinoline alkaloids derived from Cinchona ledgeriana Moens ex Trimen.
AID337540Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1145606Octanol-aqueous phase partition coefficient, log P of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID333895Genotoxicity in CHO cells assessed as chromosomal aberrations at 50 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID564302Antimalarial activity against Plasmodium falciparum IMT K14 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID279313Inhibition of Plasmodium falciparum in HRP2 ELISA2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.
AID575453Antimicrobial activity against Plasmodium falciparum F07-27 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1434536Cytotoxicity against HEK293 cells measured after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
New antiprotozoal agents: Synthesis and biological evaluation of different 4-(7-chloroquinolin-4-yl) piperazin-1-yl)pyrrolidin-2-yl)methanone derivatives.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID442269Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMT K2 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID575567Antimicrobial activity against Plasmodium falciparum F08B27 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID575433Antimicrobial activity against Plasmodium falciparum F09N1 harboring pfnhe1 ms4760 haplotype 1 carrying 2 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042D 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes afte2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1602676Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID680392TP_TRANSPORTER: inhibition of TEA uptake (TEA: 60 uM, Quinine: 1000 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, May, Volume: 289, Issue:2
Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations.
AID683687Kinetic solubility of the compound at pH 7.42012European journal of medicinal chemistry, Nov, Volume: 57The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.
AID54566Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D4 expressed in Saccharomyces cerevisiae2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
AID575558Antimicrobial activity against Plasmodium falciparum F07-28 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID322134Antimalarial activity against Plasmodium falciparum D6 as reduced [3H]hypoxanthine uptake after 72 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID575451Antimicrobial activity against Plasmodium falciparum F07-8 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042D 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1145685Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1732408Antimalarial activity against synchronized ring stage chloroquine-sensitive Plasmodium falciparum assessed as parasite growth inhibition incubated for 48 hrs in presence of 10% human plasma by hypoxanthine assay2021Bioorganic & medicinal chemistry letters, 04-15, Volume: 38Design, synthesis and biological evaluation of mono- and bisquinoline methanamine derivatives as potential antiplasmodial agents.
AID279317Inhibition of Plasmodium falciparum AZ10011022 isolate in HRP2 ELISA2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.
AID564305Antimalarial activity against Plasmodium falciparum IMT L1 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID116230Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 160 mg/kg subcutaneous dose1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID1525556Inhibition of human TASK3 expressed in Xenopus oocytes at 100 uM by whole cell patch clamp assay relative to control2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
TASK Channels Pharmacology: New Challenges in Drug Design.
AID324576Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID442256Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID563687Antimalarial activity against Plasmodium falciparum assessed as parasite growth inhibition after 48 hrs by [3H]hypoxanthin incorporation assay2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility.
AID1290449Antimalarial activity against Plasmodium falciparum after 48 hrs2016European journal of medicinal chemistry, Apr-13, Volume: 112Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
AID354810Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum W21996Journal of natural products, Jul, Volume: 59, Issue:7
Antimalarial activity: the search for marine-derived natural products with selective antimalarial activity.
AID316377Antimalarial activity against Plasmodium falciparum W2 in MSF assay2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis and heme-binding correlation with antimalarial activity of 3,6-bis-(omega-N,N-diethylaminoamyloxy)-4,5-difluoroxanthone.
AID322127In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID158642Effective dose ED50 against Plasmodium berghei N in mice (Mus musculus) malaria model after subcutaneous administration2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID547304Antimalarial activity against Plasmodium falciparum isolate AK152 D-562010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID1593289Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring M133I mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1233560Selectivity index, ratio of IC50 against human WI38 cells to IC50 for Plasmodium falciparum 3D72015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID681126TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID461611Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 21 days post infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID547332Antimalarial activity against Plasmodium falciparum harboring pfcrt gene2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID337514Cytotoxicity against human multidrug-sensitive KB3 cells1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Cyclea barbata.
AID337544Selectivity index, ratio of ED50 for mice (Mus musculus) P388 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1201063Antiplasmodial activity against chloroquine/mefloquine-resistant Plasmodium falciparum SKF582015European journal of medicinal chemistry, Apr-13, Volume: 94Synthesis of isocryptolepine analogues and their structure-activity relationship studies as antiplasmodial and antiproliferative agents.
AID681634TP_TRANSPORTER: inhibition of TEA uptake (apical to cell)(TEA: 100 uM, Quinine: 200 uM) in OCT2-expressing MDCK cells1999The American journal of physiology, 12, Volume: 277, Issue:6
rOCT2 is a basolateral potential-driven carrier, not an organic cation/proton exchanger.
AID558841Antimalarial activity against Plasmodium falciparum IMT 10500 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID524786Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by 1536-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID547311Antimalarial activity against Plasmodium falciparum isolate AK2272010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID54562Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D1 expressed in Saccharomyces cerevisiae2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
AID524779Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by 1536-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID575438Antimicrobial activity against Plasmodium falciparum F09A9 harboring pfnhe1 ms4760 haplotype 5 carrying 4 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID358504Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum FCA 20 Ghana by [3H]hypoxanthine uptake2001Journal of natural products, Jan, Volume: 64, Issue:1
Strychnogucines A and B, two new antiplasmodial bisindole alkaloids from Strychnos icaja.
AID681171TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes1997DNA and cell biology, Jul, Volume: 16, Issue:7
Cloning and characterization of two human polyspecific organic cation transporters.
AID1453045Antimalarial activity against ring stage chloroquine-resistant Plasmodium falciparum W2 preincubated for 48 hrs measured after 48 hrs in presence of 10% human serum by YOYO-1 dye-based FACS analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Synthesis, characterization, molecular docking and in vitro antimalarial properties of new carboxamides bearing sulphonamide.
AID461599Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 5 days post infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID322131In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID679493TP_TRANSPORTER: inhibition of Digoxin uptake in Oatp2-expressing LLC-PK1 cells2002Pharmaceutical research, Feb, Volume: 19, Issue:2
Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.
AID354808Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum D61996Journal of natural products, Jul, Volume: 59, Issue:7
Antimalarial activity: the search for marine-derived natural products with selective antimalarial activity.
AID333946Genotoxicity in CHO cells assessed as chromosomal aberrations at 100 ppm after 90 mins in dark
AID562110Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID575575Antimicrobial activity against Plasmodium falciparum F09N6 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042D 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID359665Cytotoxicity against human KB cells1992Journal of natural products, Dec, Volume: 55, Issue:12
Antimalarial activity of sesquiterpenes from the marine sponge Acanthella klethra.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID558832Antimalarial activity against Plasmodium falciparum HB3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID681579TP_TRANSPORTER: inhibition of Tetramethylrosamine efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID575441Antimicrobial activity against Plasmodium falciparum F07-9 harboring pfnhe1 ms4760 haplotype 6 carrying 2 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID554626Antimicrobial activity against Plasmodium falciparum IMT 8425 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID547309Antimalarial activity against Plasmodium falciparum isolate AK2492010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID554637Antimicrobial activity against Plasmodium falciparum IMT K2 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID564287Antimalarial activity against Plasmodium falciparum FCM29 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID547326Antimalarial activity against Plasmodium falciparum isolate AK022 D-282010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID575746Antimicrobial activity against Plasmodium falciparum harboring pfnhe1 ms4760 haplotype 3 carrying 1 copy of DNNND repeat and His/Asp ratio 6:2 infected in human erythrocytes after 72 hrs by SYBR green I-based fluorescence assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID575745Antimicrobial activity against Plasmodium falciparum harboring pfnhe1 ms4760 haplotype 35 carrying 1 copy of DNNND repeat and His/Asp ratio 5:2 infected in human erythrocytes after 72 hrs by SYBR green I-based fluorescence assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID554632Antimicrobial activity against Plasmodium falciparum IMT Vol harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID359666Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D61992Journal of natural products, Dec, Volume: 55, Issue:12
Antimalarial activity of sesquiterpenes from the marine sponge Acanthella klethra.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1183264Antimalarial activity against chloroquine ane quinine-sensitive ring stage of Plasmodium falciparum assessed as inhibition of parasite growth after 48 hrs2014European journal of medicinal chemistry, Sep-12, Volume: 84Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.
AID554622Antimicrobial activity against Plasmodium falciparum IMT 10354 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID586924Antileishmanial activity against tafenoquine-resistant promastigotes of Leishmania major R4 assessed as inhibition of parasite growth after 72 hrs by MTT assay2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID575428Antimicrobial activity against Plasmodium falciparum F07-10 harboring pfnhe1 ms4760 haplotype 1 carrying 2 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes aft2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID279384Growth inhibition of Plasmodium falciparum ring stage in infected erythrocytes by DAPI growth assay2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
AID575744Antimicrobial activity against Plasmodium falciparum harboring pfnhe1 ms4760 haplotypes1,18 carrying 2 copies of DNNND repeat and His/Asp ratio 7:4 infected in human erythrocytes after 72 hrs by SYBR green I-based fluorescence assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1555759Inhibition of P-gp-mediated Rhodamine-123 efflux in human MCF-7/DOX cells assessed as Rhodamine-123 accumulation preincubated for 15 mins followed by Rhodamine-123 addition measured after 0.5 to 4 hrs by fluorescence assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Natural products as multidrug resistance modulators in cancer.
AID554623Antimicrobial activity against Plasmodium falciparum D6 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID233027Relative activity against FM3A cells and Plasmodium falciparum FCR32004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Pi-delocalized beta-carbolinium cations as potential antimalarials.
AID1148823Antimalarial activity against Plasmodium berghei infected in mouse assessed as change in mean survival time at 160 mg/kg, sc1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Synthesis, antimalarial activity, and phototoxicity of some benzo(h)quinoline-4-methanols.
AID327169Apparent permeability across parallel artificial membrane2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.
AID524788Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by 1536-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID755527Cytotoxicity against human EJ cells assessed as growth inhibition after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID361157Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum FCA 20/ Ghana by [3H]hypoxanthine uptake2002Journal of natural products, Oct, Volume: 65, Issue:10
Antiplasmodial activity of alkaloids from various strychnos species.
AID335154Selectivity index, ED50 for human KB cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID337539Selectivity index, ratio of ED50 for human COL1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID547322Antimalarial activity against Plasmodium falciparum isolate 89772010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID575448Antimicrobial activity against Plasmodium falciparum F09N66 harboring pfnhe1 ms4760 haplotype 6 carrying 2 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID354806Cytotoxicity against human KB cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Antimalarial activity: the search for marine-derived natural products with selective antimalarial activity.
AID681950TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.85 uM, Quinine: 1000 uM) in Xenopus laevis oocytes1997Molecular pharmacology, Jun, Volume: 51, Issue:6
Cloning and functional expression of a human liver organic cation transporter.
AID754534Inhibition of hemozoin formation in parasite digestive vacuole extract by microtiter plate-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID1758487Cytotoxicity against human HEK293 cells incubated for 48 hrs by MTT assay2021European journal of medicinal chemistry, May-05, Volume: 217Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors.
AID513158Inhibition of heme crystallization after 16 hrs2006Nature chemical biology, Aug, Volume: 2, Issue:8
A clinical drug library screen identifies astemizole as an antimalarial agent.
AID575577Antimicrobial activity against Plasmodium falciparum F09N29 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042D 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID472817Inhibition of HCV genotype 1b NS5B polymerase deltaC21 M423K mutant at 50 uM2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Allosteric inhibitors of hepatitis C virus NS5B polymerase thumb domain site II: structure-based design and synthesis of new templates.
AID324582Increase in long-lived protein degradation in human H4 cells after 1 hr relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1145679Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 to IC50 for sensitive Pediococcus cerevisiae ATCC 8081977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID158865Antimalarial activity against Plasmodium falciparum Dd2 in erythrocytes2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.
AID683684Antiplasmodial against chloroquine-rsistant Plasmodium falciparum W2 after 2 days by flow cytometry2012European journal of medicinal chemistry, Nov, Volume: 57The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.
AID442260Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID335151Antimalarial activity after 24 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID575739Antimicrobial activity against Plasmodium falciparum harboring pfnhe1 ms4760 haplotypes 5,34 carrying4 copies of DNNND repeat and His/Asp ratio 5:8 infected in human erythrocytes after 72 hrs by SYBR green I-based fluorescence assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID279383Growth inhibition of Plasmodium falciparum ring stage in infected erythrocytes by DAPI growth assay2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
AID754535Inhibition of hemozoin formation in 0.5 M acetate buffer at pH 4.8 after 12 hrs by microtiter plate-based high-throughput assay in presence of trophozoite lysate2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID575582Antimicrobial activity against Plasmodium falciparum F09N78 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1758486Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in erythrocytes assessed as reduction in parasite growth incubated for 48 hrs by lactate dehydrogenase assay2021European journal of medicinal chemistry, May-05, Volume: 217Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors.
AID324584Increase in long-lived protein degradation in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID547303Antimalarial activity against Plasmodium falciparum isolate AK0622010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID264019Cytotoxicity against mouse FM3A cell line2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Antimalarial effect of bis-pyridinium salts, N,N'-hexamethylenebis(4-carbamoyl-1-alkylpyridinium bromide).
AID333755Antimalarial activity as reduced heme degradation in Plasmodium falciparum infected human erythrocytes2004Journal of natural products, Dec, Volume: 67, Issue:12
New eudesmane derivatives from Melampodium camphoratum from the Suriname rainforest.
AID417167Cytotoxicity against human A2780 cells2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Antiproliferative and antimalarial anthraquinones of Scutia myrtina from the Madagascar forest.
AID680503TP_TRANSPORTER: inhibition of Doxorubicin transepithelial transport (basal to apical) (Doxorubicin: 3 uM, Quinidine: 50 uM) in MDR1-expressing LLC-PK1 cells2000European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Sep, Volume: 11, Issue:3
Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
AID442265Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMTL1 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID337530Selectivity index, ratio of ED50 for human BCA1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID472820Cytotoxicity against human HBI10A cells at 20 uM2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Allosteric inhibitors of hepatitis C virus NS5B polymerase thumb domain site II: structure-based design and synthesis of new templates.
AID558842Antimalarial activity against Plasmodium falciparum IMT 16332 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID378393Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D62006Journal of natural products, Aug, Volume: 69, Issue:8
Biological activities and 3D QSAR studies of a series of Delisea pulchra (cf. fimbriata) derived natural products.
AID402140Antimalarial activity against Plasmodium falciparum D6 by [3H]hypoxanthine uptake1997Journal of natural products, Apr, Volume: 60, Issue:4
Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives.
AID755551Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID1599407Antiviral activity against Dengue virus infected in human HepG2 cells assessed as viral production at 150 uM after 1 hrs by flow cytometry analysis relative to control2019European journal of medicinal chemistry, Aug-15, Volume: 176Recent update on anti-dengue drug discovery.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID337671Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61994Journal of natural products, Oct, Volume: 57, Issue:10
Thalifaberidine, a cytotoxic aporphine-benzylisoquinoline alkaloid from Thalictrum faberi.
AID575565Antimicrobial activity against Plasmodium falciparum F08B2 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID442266Antimalarial activity against chloroquine-sensitive Plasmodium falciparum PA infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID575440Antimicrobial activity against Plasmodium falciparum F07-3 harboring pfnhe1 ms4760 haplotype 6 carrying 2 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID558828Antimalarial activity against Plasmodium falciparum D6 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1148831Phototoxicity in ip dosed mouse1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Synthesis, antimalarial activity, and phototoxicity of some benzo(h)quinoline-4-methanols.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID511251Antimicrobial activity against Plasmodium falciparum by ELISA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID337526Cytotoxicity against mouse P388 cells after 2 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1060786Antiplasmodial activity against chloroquine-resistant ring stage Plasmodium falciparum W2 assessed as parasitemia after 48 hrs by flow cytometry2014European journal of medicinal chemistry, Jan, Volume: 71Urea/oxalamide tethered β-lactam-7-chloroquinoline conjugates: synthesis and in vitro antimalarial evaluation.
AID547297Antimalarial activity against Plasmodium falciparum isolate AK1832010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID337672Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-resistant Plasmodium falciparum W21994Journal of natural products, Oct, Volume: 57, Issue:10
Thalifaberidine, a cytotoxic aporphine-benzylisoquinoline alkaloid from Thalictrum faberi.
AID442268Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCM29 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID333948Genotoxicity in CHO cells assessed as chromosomal aberrations at 12.5 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID575585Antimicrobial activity against Plasmodium falciparum F07-34 harboring pfnhe1 ms4760 haplotype 9 carrying 3 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes aft2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1434537Selectivity index, ratio of IC50 for cytotoxicity against HEK293 cells to IC50 for anti-malarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in erythrocytes2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
New antiprotozoal agents: Synthesis and biological evaluation of different 4-(7-chloroquinolin-4-yl) piperazin-1-yl)pyrrolidin-2-yl)methanone derivatives.
AID575592Antimicrobial activity against Plasmodium falciparum FCC1/HN harboring pfnhe1 ms4760 haplotype 6 carrying 2 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes afte2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID575439Antimicrobial activity against Plasmodium falciparum F09N72 harboring pfnhe1 ms4760 haplotype 5 carrying 4 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID749414Antimalarial activity against chloroquine-resistant Plasmodium falciparum FCR-3 assessed as growth inhibition after 24 hrs by [3H]-hypoxanthine incorporation assay2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Synthesis and evaluation of 7-chloro-4-(piperazin-1-yl)quinoline-sulfonamide as hybrid antiprotozoal agents.
AID299664Antibacterial activity against methicillin-resistant Staphylococcus aureus CMAH 0515 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Synthesis and evaluation of amphiphilic cationic quinine-derived for antibacterial activity against methicillin-resistant Staphylococcus aureus.
AID72015In vitro cytotoxic activity against mouse mammary tumor FM3A cells2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Synthesis of novel ferrocenyl sugars and their antimalarial activities.
AID461605Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 10 days post infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID377948Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum W21999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID554645Antimicrobial activity against Plasmodium falciparum ms4760-3 assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID324541Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 6.9 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID658767Inhibition of beta-hematin formation assessed as Ferriprotoporphyrin IX biomineralisation after 24 hrs2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID54570Inhibition of MAMC O-dealkylation mediated by human Cytochrome P450 2D6 expressed in human lymphoblastoid cell line2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID547325Antimalarial activity against Plasmodium falciparum isolate 89482010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID683683Antiplasmodial against chloroquine-rsistant Plasmodium falciparum K1 assessed as inhibition of [3H]hypoxanthine incorporation after 24 hrs by scintillation counting2012European journal of medicinal chemistry, Nov, Volume: 57The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.
AID1145613Drug absorption in rat small intestine1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID322133In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID547314Antimalarial activity against Plasmodium falciparum isolate AK1272010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID402141Antimalarial activity against Plasmodium falciparum W2 by [3H]hypoxanthine uptake1997Journal of natural products, Apr, Volume: 60, Issue:4
Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives.
AID554630Antimicrobial activity against Plasmodium falciparum FCR3 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID511255Antimicrobial activity against chloroquine-resistant Plasmodium falciparum K1 by ELISA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID575742Antimicrobial activity against Plasmodium falciparum harboring pfnhe1 ms4760 haplotype 9 carrying 3 copies of DNNND repeat and His/Asp ratio 7:6 infected in human erythrocytes after 72 hrs by SYBR green I-based fluorescence assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID564298Antimalarial activity against Plasmodium falciparum IMT 10336 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID279314Inhibition of Plasmodium falciparum AZ10011003 isolate in HRP2 ELISA2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.
AID1145671Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID511254Antimicrobial activity against chloroquine-resistant Plasmodium falciparum HB3 by ELISA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID547336Antimalarial activity against Plasmodium falciparum harboring pfmdr1 gene with 2 DNNND repeat2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID678785TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in Xenopus laevis oocytes2002Biochemical and biophysical research communications, Aug-23, Volume: 296, Issue:3
Functional characterization of mouse cation transporter mOCT2 compared with mOCT1.
AID378977Antimalarial activity after 48 hrs against Plasmodium falciparum W2 by [3H]hypoxanthine uptake2006Journal of natural products, Jan, Volume: 69, Issue:1
Lupeol long-chain fatty acid esters with antimalarial activity from Holarrhena floribunda.
AID337512Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Cyclea barbata.
AID681159TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID666967Antimalarial activity against trophozoite stage of chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocytes after 48 hrs2012European journal of medicinal chemistry, Aug, Volume: 54New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.
AID600551Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of [3H] hypoxanthine incorporation after 24 hrs by scintillation counting2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Antiprotozoal activity of chloroquinoline based chalcones.
AID558839Antimalarial activity against Plasmodium falciparum IMT 9881 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID547298Antimalarial activity against Plasmodium falciparum isolate 88852010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID334845Selectivity index, ratio of ED50 for human KB cells to ED50 for Plasmodium falciparum W21993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxic and antimalarial alkaloids from the bulbs of Crinum amabile.
AID378979Antimalarial activity after 48 hrs against Plasmodium falciparum D6 by [3H]hypoxanthine uptake2006Journal of natural products, Jan, Volume: 69, Issue:1
Lupeol long-chain fatty acid esters with antimalarial activity from Holarrhena floribunda.
AID575427Antimicrobial activity against Plasmodium falciparum F07-7 harboring pfnhe1 ms4760 haplotype 1 carrying 2 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes afte2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID575579Antimicrobial activity against Plasmodium falciparum F09N40 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID158037Inhibitory concentration against Plasmodium falciparum W2 infected erythrocytes1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID29139Calculated dissociation constant (pKa, calculated with ACD/pKa)2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
AID547329Antimalarial activity against Plasmodium falciparum harboring 1 DDNHNDHHNND repeat2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID754527Inhibition of hemozoin formation in 12.9 M acetate buffer at pH 4.5 at 60 degC after 1 hr by microtiter-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID1873785Cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibition incubated for 144 hrs in presence of P-gp inhibitor Tariquidar by fluorescence microplate reader assay2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines.
AID377946Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum D61999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID564300Antimalarial activity against Plasmodium falciparum IMT 10500 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID564306Antimalarial activity against Plasmodium falciparum IMT Vol assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1233552Cytotoxicity against human WI38 cells by MTT assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID554643Antimicrobial activity against Plasmodium falciparum IMT K14 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID1538873Antimalarial activity against Plasmodium falciparum FCR3 infected in human erythrocytes by Giemsa staining analysis2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Green synthesis, biological evaluation, molecular docking studies and 3D-QSAR analysis of novel phenylalanine linked quinazoline-4(3H)-one-sulphonamide hybrid entities distorting the malarial reductase activity in folate pathway.
AID262947Inhibition of human CYP2D6 expressed in Escherichia coli JM1092006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking.
AID337536Selectivity index, ratio of ED50 for human MEL2 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID324577Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1525572Inhibition of human TASK1 expressed in Xenopus oocytes at 100 uM by whole cell voltage clamp assay2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
TASK Channels Pharmacology: New Challenges in Drug Design.
AID360936Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 by [3H]hypoxanthine uptake2001Journal of natural products, Jun, Volume: 64, Issue:6
Antimalarial compounds from Rhaphidophora decursiva.
AID564285Antimalarial activity against Plasmodium falciparum W2 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID158864Antimalarial activity against Plasmodium falciparum 3D7 in erythrocytes2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.
AID524783Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by 1536-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID158846Inhibitory activity against Plasmodium falciparum NF542002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID158674Effective dose ED90 against Plasmodium berghei N in mice (Mus musculus) malaria model after subcutaneous administration2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID1688324Antimalarial activity against Plasmodium falciparum 3D7A asexual forms assessed as inhibition of [G-3H]hypoxanthine uptake incubated for 24 hrs followed by [G-3H]hypoxanthine addition and measured after 18 hrs by liquid scintillation spectrometry2020European journal of medicinal chemistry, Feb-15, Volume: 188Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
AID575450Antimicrobial activity against Plasmodium falciparum F07-6 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID519976Antimalarial activity against early trophozoite-stage Plasmodium falciparum 3D7 infected in erythrocyte assessed as reduction in parasite hemoglobin content at 5 times IC50 after 8 hrs in presence of 40 uM protease inhibitor E642008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparum.
AID1148828Antimalarial activity against Plasmodium berghei infected in mouse assessed as change in mean survival time at 640 mg/kg, sc1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Synthesis, antimalarial activity, and phototoxicity of some benzo(h)quinoline-4-methanols.
AID524789Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by 96-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID575743Antimicrobial activity against Plasmodium falciparum harboring pfnhe1 ms4760 haplotype 6 carrying 2 copies of DNNND repeat and His/Asp ratio 5:4 infected in human erythrocytes after 72 hrs by SYBR green I-based fluorescence assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID754528Inhibition of hemozoin formation in 0.1 M acetate buffer at pH 4.8 after 12 hrs by tube-based high-throughput assay in presence of Plasmodium yoelii homogenate2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID378082Cytotoxicity against human KB cells2006Journal of natural products, Aug, Volume: 69, Issue:8
Biological activities and 3D QSAR studies of a series of Delisea pulchra (cf. fimbriata) derived natural products.
AID1758488Selectivity index, ratio of IC50 for human HEK293 cells to IC50 for Plasmodium falciparum NF542021European journal of medicinal chemistry, May-05, Volume: 217Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors.
AID754531Inhibition of hemozoin formation in 0.5 M acetate buffer at pH 4.8 after 12 hrs by tube-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID575430Antimicrobial activity against Plasmodium falciparum F07-50 harboring pfnhe1 ms4760 haplotype 1 carrying 2 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes aft2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1145677Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID337551Selectivity index, ratio of ED50 for human ZR-75-1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1233554Selectivity index, ratio of IC50 against human WI38 cells to IC50 for Trypanosoma brucei brucei Lister 427 bloodstream forms2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1434534Anti-amoebic activity against trophozoites of Entamoeba histolytica HM-1:IMSS gassed with nitrogen for 10 mins measured after 72 hrs by eosin staining based micro dilution method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
New antiprotozoal agents: Synthesis and biological evaluation of different 4-(7-chloroquinolin-4-yl) piperazin-1-yl)pyrrolidin-2-yl)methanone derivatives.
AID279315Inhibition of Plasmodium falciparum AZ10011008 isolate in HRP2 ELISA2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.
AID558844Antimalarial activity against Plasmodium falciparum IMT K2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID337519Cytotoxicity against human BCA1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID547299Antimalarial activity against Plasmodium falciparum isolate 90672010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID1145678Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1145680Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID681582TP_TRANSPORTER: inhibition of Calcein-AM efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID402125Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes by [3H]hypoxanthine uptake1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID336325Antimalarial activity against mefloquine-resistant Plasmodium falciparum D6 (Sierra Leone) after 24 to 60 hrs by [G-H3]hypoxanthine uptake1993Journal of natural products, Nov, Volume: 56, Issue:11
A new antimalarial quassinoid from Simaba guianensis.
AID151998In vitro antimalarial activity against Plasmodium falciparum D6 (Sierra Leone)1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Antimalarial activity of new water-soluble dihydroartemisinin derivatives. 2. Stereospecificity of the ether side chain.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID377945Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID338768Antimalarial activity against Plasmodium falciparum W2 in human erythrocytes after 24 hrs by [3H]hypoxanthine uptake
AID322132In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID681580TP_TRANSPORTER: inhibition of JC-1 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID461596Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as inhibition of parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 5 days post infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID337548Selectivity index, ratio of ED50 for human LNCaP cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID547320Antimalarial activity against Plasmodium falciparum isolate AK022D-02010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID402142Antimalarial activity against Plasmodium falciparum D6 by [3H]hypoxanthine uptake relative to gedunin1997Journal of natural products, Apr, Volume: 60, Issue:4
Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives.
AID681643TP_TRANSPORTER: TEA uptake (TEA: 200 uM, Quinine: 200 uM) in Xenopus laevis oocytes1999The American journal of physiology, 12, Volume: 277, Issue:6
rOCT2 is a basolateral potential-driven carrier, not an organic cation/proton exchanger.
AID1148830Toxicity in mouse infected with Plasmodium berghei assessed as animal death at 640 mg/kg, sc1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Synthesis, antimalarial activity, and phototoxicity of some benzo(h)quinoline-4-methanols.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID558053Antimicrobial activity against Plasmodium falciparum harboring CVMNT genotype after 72 hrs by SYBR green I assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1551790Antiplasmodial activity against Plasmodium falciparum2019European journal of medicinal chemistry, Jul-01, Volume: 173Antibacterial activity study of 1,2,4-triazole derivatives.
AID1368006Antimalarial activity against Plasmodium falciparum in infected in human RBC2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Ionic liquid mediated stereoselective synthesis of alanine linked hybrid quinazoline-4(3H)-one derivatives perturbing the malarial reductase activity in folate pathway.
AID547300Antimalarial activity against Plasmodium falciparum isolate AK0182010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID575740Antimicrobial activity against Plasmodium falciparum harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND repeat and His/Asp ratio 5:6 infected in human erythrocytes after 72 hrs by SYBR green I-based fluorescence assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID159899Effective subcutaneous dose ED50 against Plasmodium yoelii sspNS2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID547321Antimalarial activity against Plasmodium falciparum isolate 90702010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID354809Antiplasmodial activity against Plasmodium falciparum W21996Journal of natural products, Jul, Volume: 59, Issue:7
Antimalarial activity: the search for marine-derived natural products with selective antimalarial activity.
AID600554Inhibition of beta-haematin formation after 24 hrs by microtiter plate assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Antiprotozoal activity of chloroquinoline based chalcones.
AID554644Antimicrobial activity against Plasmodium falciparum ms4760-2 assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID564289Antimalarial activity against Plasmodium falciparum PA assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID575447Antimicrobial activity against Plasmodium falciparum F09N58 harboring pfnhe1 ms4760 haplotype 6 carrying 2 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID575588Antimicrobial activity against Plasmodium falciparum F09A21 harboring pfnhe1 ms4760 haplotype 18 carrying 2 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes af2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID299662Antibacterial activity against methicillin-resistant Staphylococcus aureus CMAH 0430 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Synthesis and evaluation of amphiphilic cationic quinine-derived for antibacterial activity against methicillin-resistant Staphylococcus aureus.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1873784Cytotoxicity against human MES-SA cells assessed as cell growth inhibition incubated for 144 hrs in presence of P-gp inhibitor Tariquidar by fluorescence microplate reader assay2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines.
AID1145612Dissociation constant, pKa of the compound at pH 5.31977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID564296Antimalarial activity against Plasmodium falciparum IMT 8425 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID754525Inhibition of hemozoin formation in 1 M acetate buffer at pH 4.8 after 4.17 hrs by microtiter-based high-throughput assay in presence of 0.012 mg/mL Tween 202013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID754536Inhibition of hemozoin formation in 0.5 M acetate buffer at pH 4.8 after 24 hrs by microtiter plate-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID564284Antimalarial activity against Plasmodium falciparum 3D7 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID575589Antimicrobial activity against Plasmodium falciparum F07-47 harboring pfnhe1 ms4760 haplotype 20 carrying 4 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes afte2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID681127TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID72157In vitro cytotoxic activity tested in mouse mammary tumor FM3A cells2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Pi-delocalized beta-carbolinium cations as potential antimalarials.
AID290776Antimalarial activity against Plasmodium falciparum 3D7 after 48 hrs by pLDH assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
A novel artemisinin-quinine hybrid with potent antimalarial activity.
AID264020Selectivity ratio of EC50s against Plasmodium falciparum FCR3 to mice (Mus musculus) FM3A cells2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Antimalarial effect of bis-pyridinium salts, N,N'-hexamethylenebis(4-carbamoyl-1-alkylpyridinium bromide).
AID322128In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs by SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID575566Antimicrobial activity against Plasmodium falciparum F08B9 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID337535Selectivity index, ratio of ED50 for human LUC1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID682294TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, Quinine: 500 uM) in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID575573Antimicrobial activity against Plasmodium falciparum F09A41 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID337521Cytotoxicity against human LUC1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID158875In vitro antimalarial activity against Plasmodium falciparum W2 in human erythrocytes by [3H]hypoxanthine uptake2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Synthesis and evaluation of new antimalarial analogues of quinoline alkaloids derived from Cinchona ledgeriana Moens ex Trimen.
AID575587Antimicrobial activity against Plasmodium falciparum F08B60 harboring pfnhe1 ms4760 haplotype 14 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes afte2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID417168Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 by SYBR green assay2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Antiproliferative and antimalarial anthraquinones of Scutia myrtina from the Madagascar forest.
AID524781Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by 1536-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID442257Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID554634Antimicrobial activity against Plasmodium falciparum IMT Bres harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID361169Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 by [3H]hypoxanthine uptake2001Journal of natural products, Jun, Volume: 64, Issue:6
Antimalarial compounds from Rhaphidophora decursiva.
AID683682Antiplasmodial against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of [3H]hypoxanthine incorporation after 24 hrs by scintillation counting2012European journal of medicinal chemistry, Nov, Volume: 57The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.
AID564290Antimalarial activity against Plasmodium falciparum HB3 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1145610Dissociation constant, pKa of the compound at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1145689Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as dose required to survivors for period of 60 days1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID554640Antimicrobial activity against Plasmodium falciparum W2 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID554636Antimicrobial activity against Plasmodium falciparum FCM29 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID346864Binding affinity to heme in DMSO assessed as equilibrium constant by UV-visible spectrophotometry2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID158708In vitro inhibitory concentration against ferriprotoporphyrin in biomineralisation assay (FBIT)2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
The imidazo[2,1-a]isoindole system. A new skeletal basis for antiplasmodial compounds.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID755529Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID554641Antimicrobial activity against Plasmodium falciparum IMT K4 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID461617Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as parasitaemia cure at 200 mg/kg, perorally administered 1 day after infection measured after 28 days post infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID159907Effective subcutaneous dose ED90 against Plasmodium yoelii sspNS2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID764200Antileishmanial activity against Leishmania mexicana mexicana MHOM/BZ/84/BEL46 promastigotes assessed as parasite LDH activity by three-fold serial dilution method2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID1436579Antimalarial activity against Plasmodium falciparum2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Synthesis, identification and in vitro biological evaluation of some novel quinoline incorporated 1,3-thiazinan-4-one derivatives.
AID54565Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D3 expressed in Saccharomyces cerevisiae2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
AID1593287Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring V259L mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID575733Antimicrobial activity against Plasmodium falciparum W2 harboring pfnhe1 ms4760 haplotype 1 carrying 2 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86Y 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after 72010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1306794Antimalarial activity against blood stage Plasmodium falciparum 3D7 infected in human erythrocytes assessed as reduction in parasitemia after 72 hrs by SYBR green I fluorescence-based method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Synthesis, antimalarial properties and 2D-QSAR studies of novel triazole-quinine conjugates.
AID1145686Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID360935Cytotoxicity against human KB cells after 72 hrs2001Journal of natural products, Jun, Volume: 64, Issue:6
Antimalarial compounds from Rhaphidophora decursiva.
AID337538Selectivity index, ratio of ED50 for human COL1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID158715Inhibition against Plasmodium falciparum Dd2 in erythrocytes in semiautomated micro dilution assay2003Bioorganic & medicinal chemistry letters, Jul-07, Volume: 13, Issue:13
Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties.
AID1233553Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms by microtiter plate based assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID519977Antimalarial activity against schizont-stage Plasmodium falciparum 3D7 infected in erythrocyte assessed as inhibition of horseradish peroxidase(HRP) uptake after 10 hrs by colorimetric peroxidase assay2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparum.
AID378397Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum D62006Journal of natural products, Aug, Volume: 69, Issue:8
Biological activities and 3D QSAR studies of a series of Delisea pulchra (cf. fimbriata) derived natural products.
AID558826Antimalarial activity against Plasmodium falciparum 3D7 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID679315TP_TRANSPORTER: uptake in Xenopus laevis oocytes1996FEBS letters, Oct-21, Volume: 395, Issue:2-3
Monoamine neurotransmitter transport mediated by the polyspecific cation transporter rOCT1.
AID333897Genotoxicity in CHO cells assessed as chromosomal aberrations at 25 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID116242Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 320 mg/kg subcutaneous dose1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID554627Antimicrobial activity against Plasmodium falciparum IMT 16116 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID575437Antimicrobial activity against Plasmodium falciparum F09A55 harboring pfnhe1 ms4760 haplotype 3 carrying 1 copy of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID681632TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID681642TP_TRANSPORTER: inhibition of Choline uptake (Choline: 10 uM, Quinine: 200 uM) in Xenopus laevis oocytes2001The Journal of biological chemistry, Nov-09, Volume: 276, Issue:45
Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus.
AID764198Selectivity index, ratio of IC50 for human WI38 cells to IC50 for Leishmania mexicana mexicana MHOM/BZ/84/BEL46 promastigotes2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID564301Antimalarial activity against Plasmodium falciparum IMT 16332 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID575571Antimicrobial activity against Plasmodium falciparum F08B72 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID547312Antimalarial activity against Plasmodium falciparum isolate CDA-15532010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID477942Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum PA infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID678794TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in Xenopus laevis oocytes2002Biochemical and biophysical research communications, Aug-23, Volume: 296, Issue:3
Functional characterization of mouse cation transporter mOCT2 compared with mOCT1.
AID420491Antimalarial activity against Plasmodium falciparum K12009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
New antimalarial and cytotoxic 4-nerolidylcatechol derivatives.
AID547307Antimalarial activity against Plasmodium falciparum isolate AK1582010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID159014Minimum inhibitory concentration (IC99) against Plasmodium falciparum K1 infected erythrocytes1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID378398Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum W22006Journal of natural products, Aug, Volume: 69, Issue:8
Biological activities and 3D QSAR studies of a series of Delisea pulchra (cf. fimbriata) derived natural products.
AID575436Antimicrobial activity against Plasmodium falciparum F09A54 harboring pfnhe1 ms4760 haplotype 3 carrying 1 copy of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID764203Cytotoxicity against human WI38 cells by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID575559Antimicrobial activity against Plasmodium falciparum F07-29 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID158035Inhibitory concentration against Plasmodium falciparum D6 infected erythrocytes1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID334842Antimalarial activity after 24 hrs against Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxic and antimalarial alkaloids from the bulbs of Crinum amabile.
AID681157TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes1994Nature, Dec-08, Volume: 372, Issue:6506
Drug excretion mediated by a new prototype of polyspecific transporter.
AID299677Toxicity in human erythrocytes assessed as hemolytic activity at 500 ug/ml after 1 hr2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Synthesis and evaluation of amphiphilic cationic quinine-derived for antibacterial activity against methicillin-resistant Staphylococcus aureus.
AID160056In vitro antimalarial activity against Plasmodium falciparum FCR32004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Pi-delocalized beta-carbolinium cations as potential antimalarials.
AID472367Antimalarial activity against Plasmodium falciparum Nigerian assessed as [3H]hypoxanthine uptake after 48 hrs by liquid scintillation counting2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis and antimalarial activity of new atovaquone derivatives.
AID1899027Antiplasmodial activity against CQ-susceptible Plasmodium falciparum 3D7 infected in human erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by HRP2-ELISA2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1873781Cytotoxicity against human MES-SA cells assessed as cell growth inhibition incubated for 144 hrs by fluorescence microplate reader assay2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines.
AID359667Antimalarial activity against chloroquine-resistant Plasmodium falciparum W21992Journal of natural products, Dec, Volume: 55, Issue:12
Antimalarial activity of sesquiterpenes from the marine sponge Acanthella klethra.
AID554625Antimicrobial activity against Plasmodium falciparum 3D7 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID554638Antimicrobial activity against Plasmodium falciparum IMT A4 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID547323Antimalarial activity against Plasmodium falciparum isolate AK033 D-02010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID1378963Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR Green-1 staining based fluorescence assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Quinoline hybrids and their antiplasmodial and antimalarial activities.
AID554639Antimicrobial activity against Plasmodium falciparum PA harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID361154Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FCB1-R/Colombia by [3H]hypoxanthine uptake2002Journal of natural products, Oct, Volume: 65, Issue:10
Antiplasmodial activity of alkaloids from various strychnos species.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID461602Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 7 days post infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID558831Antimalarial activity against Plasmodium falciparum PA assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID586923Resistant index, ratio of EC50 for tafenoquine-resistant promastigotes of Leishmania major R4 to EC50 for promastigotes of Leishmania major MHOM/JL/80/Friedlin2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
AID547335Antimalarial activity against Plasmodium falciparum harboring pfmdr1-86 mutant gene2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID511252Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum W2 by ELISA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID361168Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum D62001Journal of natural products, Jun, Volume: 64, Issue:6
Antimalarial compounds from Rhaphidophora decursiva.
AID554647Antimicrobial activity against Plasmodium falciparum ms4760-7 assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID396379Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 after 48 hrs by [G-3H]hypoxanthine uptake2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Pharmacophore based discovery of potential antimalarial agent targeting haem detoxification pathway.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID558843Antimalarial activity against Plasmodium falciparum IMT K14 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID564292Antimalarial activity against Plasmodium falciparum IMT Bres assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID547301Antimalarial activity against Plasmodium falciparum isolate AK150 D-422010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID681146TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells1998The Journal of pharmacology and experimental therapeutics, Jul, Volume: 286, Issue:1
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
AID338767Antimalarial activity against Plasmodium falciparum D6 in human erythrocytes after 24 hrs by [3H]hypoxanthine uptake
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID327170Binding affinity to human serum albumin by PAMPA method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.
AID324489Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 6.9 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1145683Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction in growth in presence of 0.001 ug/ml folic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID683686Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 10 days by low oxygen recovery assay2012European journal of medicinal chemistry, Nov, Volume: 57The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.
AID354687Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 as [3H]hypoxanthine uptake1996Journal of natural products, Jun, Volume: 59, Issue:6
Costaricine, a new antiplasmodial bisbenzylisoquinoline alkaloid from Nectandra salicifolia trunk bark.
AID575578Antimicrobial activity against Plasmodium falciparum F09N33 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID402126Antiplasmodial activity against Plasmodium falciparum K1 infected human erythrocytes by [3H]hypoxanthine uptake1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID678996TP_TRANSPORTER: inhibition of TEA uptake (in the absence of bicarbonate) (TEA: 20 uM) in OCT1-expressing HEK293 cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID337669Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes after 24 hrs by [3H]hypoxanthine uptake1994Journal of natural products, Oct, Volume: 57, Issue:10
Thalifaberidine, a cytotoxic aporphine-benzylisoquinoline alkaloid from Thalictrum faberi.
AID337537Selectivity index, ratio of ED50 for human MEL2 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1209583Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID337670Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes after 24 hrs by [3H]hypoxanthine uptake1994Journal of natural products, Oct, Volume: 57, Issue:10
Thalifaberidine, a cytotoxic aporphine-benzylisoquinoline alkaloid from Thalictrum faberi.
AID442258Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes after 96 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID290779Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcB1 after 72 hrs by pLDH assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
A novel artemisinin-quinine hybrid with potent antimalarial activity.
AID575431Antimicrobial activity against Plasmodium falciparum F07-59 harboring pfnhe1 ms4760 haplotype 1 carrying 2 copies of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes aft2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID524784Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by 96-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID754533Inhibition of hemozoin formation by microtiter plate-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID442262Therapeutic index, ratio of IC50 for concanavalin-stimulated BALB/c mice (Mus musculus) splenocytes to IC50 for Plasmodium falciparum W2 after 48 hrs2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID337547Selectivity index, ratio of ED50 for human A431 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID554646Antimicrobial activity against Plasmodium falciparum ms4760-6 assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID477944Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum FCR3 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID417170Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FCM29 by SYBR green assay2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Antiproliferative and antimalarial anthraquinones of Scutia myrtina from the Madagascar forest.
AID402145Cytotoxicity against human KB cells1997Journal of natural products, Apr, Volume: 60, Issue:4
Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives.
AID547316Antimalarial activity against Plasmodium falciparum 3D72010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID558830Antimalarial activity against Plasmodium falciparum FCR3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID581962Antimicrobial activity against leupeptin resistant-Plasmodium falciparum HB3-leuR1 mutant infected in erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I-based fluorescence assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID558827Antimalarial activity against Plasmodium falciparum W2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID754526Inhibition of hemozoin formation in 0.5 M acetate buffer at pH 4.8 after 16 hrs by tube-based high-throughput assay in presence of 0.002 mg/mL phosphatidylcholine2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID337545Selectivity index, ratio of ED50 for mice (Mus musculus) P388 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID511253Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum D6 by ELISA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID1379008Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR Green-1 staining based fluorescence assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Quinoline hybrids and their antiplasmodial and antimalarial activities.
AID1145672Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1434535Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in erythrocytes measured after 48 hrs by Malstat/nitroblue tetrazolium/phenazine ethosulphate reagent based LDH assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
New antiprotozoal agents: Synthesis and biological evaluation of different 4-(7-chloroquinolin-4-yl) piperazin-1-yl)pyrrolidin-2-yl)methanone derivatives.
AID564299Antimalarial activity against Plasmodium falciparum IMT 10354 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID322126In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID547308Antimalarial activity against Plasmodium falciparum isolate AK1212010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID401645Inhibition of beta-hematin formation by BHIA assay2005Journal of natural products, May, Volume: 68, Issue:5
Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.
AID316375Binding affinity to heme in aqueous solution2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis and heme-binding correlation with antimalarial activity of 3,6-bis-(omega-N,N-diethylaminoamyloxy)-4,5-difluoroxanthone.
AID524787Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by 96-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID158849Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Structure-activity relationships of novel anti-malarial agents. Part 2: cinnamic acid derivatives.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID354807Antiplasmodial activity against Plasmodium falciparum D61996Journal of natural products, Jul, Volume: 59, Issue:7
Antimalarial activity: the search for marine-derived natural products with selective antimalarial activity.
AID660168Inhibition of beta-hematin formation after 16 hrs at pH 5.2 by microplate reader2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum.
AID442263Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMTVo1 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID227925The compound was estimated for biosensor analysis2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels.
AID600556Antioxidant activity assessed as DPPH radical scavenging activity at 80 uM after 30 mins2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Antiprotozoal activity of chloroquinoline based chalcones.
AID513176Displacement of [3H]astemizole from free heme crystal at 15 uM after 16 hrs by scintillation counting2006Nature chemical biology, Aug, Volume: 2, Issue:8
A clinical drug library screen identifies astemizole as an antimalarial agent.
AID324578Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 8 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID125784Inhibition of 1'-hydroxybufuralol formation by human liver microsomes1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
AID519974Antimalarial activity against early trophozoite-stage Plasmodium falciparum 3D7 infected in erythrocyte assessed as reduction in parasite hemoglobin content at 5 times IC50 after 8 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparum.
AID679216TP_TRANSPORTER: inhibition of Choline uptake (Choline: 10 uM, Quinine: 200 uM) in Xenopus laevis oocytes2001The Journal of biological chemistry, Nov-09, Volume: 276, Issue:45
Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus.
AID336324Antimalarial activity against chloroquine-resistant Plasmodium falciparum Indochina W2 after 24 to 60 hrs by [G-H3]hypoxanthine uptake 1993Journal of natural products, Nov, Volume: 56, Issue:11
A new antimalarial quassinoid from Simaba guianensis.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID558847Antimalarial activity against Plasmodium falciparum IMT Vol assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID241212Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Defining determinant molecular properties for the blockade of the apamin-sensitive SKCa channel in guinea-pig hepatocytes: the influence of polarizability and molecular geometry.
AID547306Antimalarial activity against Plasmodium falciparum isolate AK2222010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID1873787Cytotoxicity against human MES-SA cells assessed as reduction on calcein accumulation incubated for 15 mins by calcein-AM staining based flow cytometry analysis2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines.
AID299675Toxicity in human erythrocytes assessed as hemolytic activity at 2000 ug/ml after 1 hr2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Synthesis and evaluation of amphiphilic cationic quinine-derived for antibacterial activity against methicillin-resistant Staphylococcus aureus.
AID160054In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCR32002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Rhodacyanine dyes as antimalarials. 1. Preliminary evaluation of their activity and toxicity.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID524780Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by 96-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID564291Antimalarial activity against Plasmodium falciparum 106/1 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1873788Cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as reduction on cell distribution at 20 uM incubated for 15 mins by calcein-AM staining based flow cytometry analysis2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines.
AID1899028Antiplasmodial activity CQ-resistant Plasmodium falciparum W2 infected in human erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by HRP2-ELISA2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID586925Antileishmanial activity against wild type promastigotes of Leishmania major MHOM/JL/80/Friedlin assessed as inhibition of parasite growth after 72 hrs by MTT assay2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
AID755553Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID575435Antimicrobial activity against Plasmodium falciparum F07-13 harboring pfnhe1 ms4760 haplotype 3 carrying 1 copy of DNNND and 2 copies of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID279316Inhibition of Plasmodium falciparum AZ10011017 isolate in HRP2 ELISA2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.
AID564288Antimalarial activity against Plasmodium falciparum FCR3 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID575444Antimicrobial activity against Plasmodium falciparum F07-56 harboring pfnhe1 ms4760 haplotype 6 carrying 2 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID764197Selectivity index, ratio of IC50 for human WI38 cells to IC50 for erythrocytic stage of chloroquine-sensitive Plasmodium falciparum 3D72013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID575574Antimicrobial activity against Plasmodium falciparum F09A61 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID466460Antimalarial activity against cycloguanil-resistant Plasmodium falciparum CDC1 assessed as inhibition of ring stage parasitaemia after 48 hrs by Giemsa staining2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
New anti-malarial phenylpropanoid conjugated iridoids from Morinda morindoides.
AID554631Antimicrobial activity against Plasmodium falciparum IMT 31 harboring Pfcrt, Pfmdr1, Pfmrp, and Pfnhe-1 polymorphisms assessed as growth inhibition after 48 hrs by scintillation counting2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.
AID160053In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCR32000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Synthesis of novel ferrocenyl sugars and their antimalarial activities.
AID442264Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMT10500 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID575583Antimicrobial activity against Plasmodium falciparum Feng harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET infected in human erythrocytes after 72 hrs2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID564294Antimalarial activity against Plasmodium falciparum IMT A4 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1073349Antiviral activity against Chikungunya virus2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Chikungunya virus: emerging targets and new opportunities for medicinal chemistry.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID660169Inhibition of beta-hematin formation after 16 hrs at pH 5.6 by microplate reader2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum.
AID357906Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D62001Journal of natural products, Sep, Volume: 64, Issue:9
Synthesis of new artemisinin analogues from artemisinic acid modified at C-3 and C-13 and their antimalarial activity.
AID764201Selectivity index, ratio of IC50 for human WI38 cells to IC50 for Trypanosoma brucei brucei Lister 427 bloodstream form2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID547324Antimalarial activity against Plasmodium falciparum isolate 89682010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID337513Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Cyclea barbata.
AID1233559Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite viability by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID558835Antimalarial activity against Plasmodium falciparum IMT Guy assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID679159TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes1997DNA and cell biology, Jul, Volume: 16, Issue:7
Cloning and characterization of two human polyspecific organic cation transporters.
AID150735High affinity constant at binding site of human P-Glycoprotein (P-gp) in two-affinity model2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
AID1899029Selectivity index, ratio of IC50 for antiplasmodial activity against CQ-susceptible Plasmodium falciparum 3D7 to IC50 for antiplasmodial activity CQ-resistant Plasmodium falciparum W2 by HRP2-ELISA2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID681581TP_TRANSPORTER: inhibition of Fluo-3-AM efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID333945Genotoxicity in CHO cells assessed as chromosomal aberrations at 100 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID558836Antimalarial activity against Plasmodium falciparum IMT A4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID442259Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in erythrocytes after 96 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID477941Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum L1 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID524785Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by 1536-well format based SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1602675Antibacterial activity against Streptococcus pneumoniae D39 after 20 hrs by CLSI-based microdilution method2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1201061Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D72015European journal of medicinal chemistry, Apr-13, Volume: 94Synthesis of isocryptolepine analogues and their structure-activity relationship studies as antiplasmodial and antiproliferative agents.
AID419115Binding affinity to heme assessed as binding constant for stepwise binding of 2 equivalent of drug to 1 molecule of heme in presence of 40% DMSO by UV-visible spectroscopy2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID151997In vitro antimalarial activity against Plasmodium falciparum W-2 Indochina1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Antimalarial activity of new water-soluble dihydroartemisinin derivatives. 2. Stereospecificity of the ether side chain.
AID575576Antimicrobial activity against Plasmodium falciparum F09N22 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID264018Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCR32006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Antimalarial effect of bis-pyridinium salts, N,N'-hexamethylenebis(4-carbamoyl-1-alkylpyridinium bromide).
AID472819Antiviral activity against Hepatitis C virus H2B2 at 20 uM2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Allosteric inhibitors of hepatitis C virus NS5B polymerase thumb domain site II: structure-based design and synthesis of new templates.
AID419116Binding affinity to heme assessed as binding constant for stepwise binding of 2 molecules of heme to 1 equivalent of drug in presence of 40% DMSO by UV-visible spectroscopy2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID558833Antimalarial activity against Plasmodium falciparum 106/1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID232807Selective toxicity- EC50 value of FM3A / EC50 value of Plasmodium falciparum2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Rhodacyanine dyes as antimalarials. 1. Preliminary evaluation of their activity and toxicity.
AID33558The ability binding to (HSA) human serum albumin (Binding classified based on injection of compound at 80 uM concn.)2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels.
AID564293Antimalarial activity against Plasmodium falciparum IMT Guy assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID547319Antimalarial activity against Plasmodium falciparum isolate AK033 D-492010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID754532Inhibition of hemozoin formation in acetonitrile trophozoite extract by microtiter plate-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID324585Increase in long-lived protein degradation in human H4 cells after 24 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID547334Antimalarial activity against Plasmodium falciparum harboring pfmdr1 gene2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID159900Effective oral dose ED90 against Plasmodium yoelii sspNS2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID600553Toxicity in human RBC assessed as hemolysis at 100 uM after 48 hrs2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Antiprotozoal activity of chloroquinoline based chalcones.
AID575443Antimicrobial activity against Plasmodium falciparum F07-46 harboring pfnhe1 ms4760 haplotype 6 carrying 2 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID337546Selectivity index, ratio of ED50 for human A431 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337516Cytotoxicity against mouse P388 cells1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Cyclea barbata.
AID547338Antimalarial activity against Plasmodium falciparum harboring pfcrt gene with 2 DNNND repeat2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID660171Antimalarial activity against chloroquine resistant Plasmodium falciparum Dd2 after 72 hrs by SYBP Green I dye staining2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum.
AID333947Genotoxicity in CHO cells assessed as mitotic inhibition at 6.3 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID158858Inhibitory concentration against ferriprotoporphyrin in biomineralisation (FBIT)2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
The imidazo[2,1-a]isoindole system. A new skeletal basis for antiplasmodial compounds.
AID682052TP_TRANSPORTER: inhibition of E217betaG uptake in Oatp1-expressing LLC-PK1 cells2002Pharmaceutical research, Feb, Volume: 19, Issue:2
Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.
AID575452Antimicrobial activity against Plasmodium falciparum F07-25 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184F 1034S 1042N 1246D and pfcrt 72-76 CVIET 220S infected in human erythrocytes after2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID772515Antimalarial activity against gametocytic stage of Plasmodium berghei infected in blood assessed as inhibition of ookinete formation at 10 uM after 24 hrs by Giemsa staining-based microscopic analysis relative to control2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID575741Antimicrobial activity against Plasmodium falciparum harboring pfnhe1 ms4760 haplotype 14 carrying 3 copies of DNNND repeat and His/Asp ratio 6:6 infected in human erythrocytes after 72 hrs by SYBR green I-based fluorescence assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID401646Displacement of methyl green dye from DNA2005Journal of natural products, May, Volume: 68, Issue:5
Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.
AID158639Effective dose ED50 against Plasmodium berghei N in mice (Mus musculus) malaria model after peroral administration2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID1593291Antimalarial activity against drug-resistant Plasmodium falciparum 3D7 harboring A82T/V259L double mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID324437Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 6.9 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID575584Antimicrobial activity against Plasmodium falciparum PF18 harboring pfnhe1 ms4760 haplotype 7 carrying 3 copies of DNNND and 1 copy of NHNDNHNNDDD repeats, pfmdr1 86N 184Y 1034S 1042N 1246D and pfcrt 72-76 SVMNT 220S infected in human erythrocytes after 72010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.
AID442267Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCR3 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID755550Cytotoxicity against human EJ cells assessed as cell death up to 20 uM measured within 1 hr by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID1463542Competitive inhibition of human OCT3 expressed in HEK293 cells in presence of varying concentration of MPP+ by Lineweaver-Burk plot analysis2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3).
AID1873783Resistance ratio of IC50 for cytotoxicity against multidrug resistance human MES-SA/Dx5 cells to IC50 for cytotoxicity against human MES-SA cells2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID337543Selectivity index, ratio of ED50 for human KB-V1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID354688Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 as [3H]hypoxanthine uptake1996Journal of natural products, Jun, Volume: 59, Issue:6
Costaricine, a new antiplasmodial bisbenzylisoquinoline alkaloid from Nectandra salicifolia trunk bark.
AID1730953Antimalarial activity against Plasmodium falciparum assessed as parasite growth inhibition2021Bioorganic & medicinal chemistry letters, 03-15, Volume: 36Structure based design, synthesis, and biological evaluation of imidazole derivatives targeting dihydropteroate synthase enzyme.
AID558829Antimalarial activity against Plasmodium falciparum FCM29 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID159892Effective oral dose ED50 against Plasmodium yoelii sspNS2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID333846Phototoxicity against CHO cells assessed as mitotic inhibition at 12 ppm after UV irradiation
AID547330Antimalarial activity against Plasmodium falciparum harboring 2 DNNND repeat2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID564303Antimalarial activity against Plasmodium falciparum IMT K2 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID681163TP_TRANSPORTER: ATP hydrolysis in reconstituted proteoliposomes1996The Journal of biological chemistry, Feb-09, Volume: 271, Issue:6
Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1345181Human Plasma membrane monoamine transporter (SLC29 family)2016Clinical pharmacology and therapeutics, Nov, Volume: 100, Issue:5
The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition.
AID1345181Human Plasma membrane monoamine transporter (SLC29 family)2005Molecular pharmacology, Nov, Volume: 68, Issue:5
Interaction of organic cations with a newly identified plasma membrane monoamine transporter.
AID1346655Human Kv2.2 (Voltage-gated potassium channels)1998The American journal of physiology, 05, Volume: 274, Issue:5
Molecular identification of a component of delayed rectifier current in gastrointestinal smooth muscles.
AID1802150TREK1 Assay from Article 10.1111/cbdd.12810: \\Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.\\2016Chemical biology & drug design, Dec, Volume: 88, Issue:6
Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.
AID654327Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Melodinines M-U, cytotoxic alkaloids from Melodinus suaveolens.
AID654329Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Melodinines M-U, cytotoxic alkaloids from Melodinus suaveolens.
AID654326Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Melodinines M-U, cytotoxic alkaloids from Melodinus suaveolens.
AID654330Cytotoxicity against human SW480 cells after 48 hrs by MTT assay2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Melodinines M-U, cytotoxic alkaloids from Melodinus suaveolens.
AID654328Cytotoxicity against human A549 cells after 48 hrs by MTT assay2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Melodinines M-U, cytotoxic alkaloids from Melodinus suaveolens.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,350)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902782 (43.81)18.7374
1990's1190 (18.74)18.2507
2000's1148 (18.08)29.6817
2010's997 (15.70)24.3611
2020's233 (3.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.36 (24.57)
Research Supply Index8.89 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index190.66 (26.88)
Search Engine Supply Index2.92 (0.95)

This Compound (71.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials398 (5.80%)5.53%
Trials0 (0.00%)5.53%
Reviews370 (5.39%)6.00%
Reviews0 (0.00%)6.00%
Case Studies634 (9.24%)4.05%
Case Studies0 (0.00%)4.05%
Observational12 (0.17%)0.25%
Observational0 (0.00%)0.25%
Other5,445 (79.38%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (44)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Influence of Bitter Substrates on Hunger, Gastrointestinal Hormone Release and Hedonic Food Intake [NCT03985865]Phase 414 participants (Actual)Interventional2017-03-02Completed
Parenteral Artesunate Compared to Quinine as a Cause of Late Post-treatment Anaemia in African Children With Hyperparasitaemic P. Falciparum Malaria [NCT02092766]Phase 4217 participants (Actual)Interventional2014-06-30Completed
A Randomized Clinical Trial to Measure the Impact of Retreatment With an Artemisinin-based Combination on Malaria Incidence and Its Potential Selection of Resistant Strains [NCT01374581]Phase 32,117 participants (Actual)Interventional2012-05-31Completed
A Randomised, Open-label Non-inferiority Trial of Artemether-lumefantrine Versus Quinine for the Treatment of Uncomplicated Falciparum Malaria During Pregnancy, Mbarara, Uganda (2006-2007) [NCT00495508]Phase 4300 participants (Actual)Interventional2006-10-31Completed
Taste Physiology in Healthy, Normal-weight Volunteers [NCT02255812]12 participants (Actual)Interventional2013-03-31Completed
A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions [NCT00727272]Phase 127 participants (Actual)Interventional2004-02-29Completed
Combined Effects of Alcohol and Caffeine [NCT01289561]Phase 120 participants (Actual)Interventional2011-01-31Completed
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease (ROCK-PD) [NCT05931575]Phase 275 participants (Anticipated)Interventional2023-09-11Recruiting
Artemisinin Resistance in Bangladesh [NCT00639873]126 participants (Actual)Interventional2008-06-30Completed
An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults [NCT05808231]100 participants (Anticipated)Interventional2021-04-26Recruiting
A Single-Dose, Open-Label Comparative Study of the Pharmacokinetics, Safety,and Tolerability of Oral Quinine Sulfate in Healthy Volunteers and Adults With Mild and Moderate Renal Impairment [NCT00785551]Phase 15 participants (Actual)Interventional2007-11-30Terminated(stopped due to poor enrollment)
The Effect of Quinine on Food Intake: Oral Sham Feeding Versus Intragastric Delivery [NCT03565133]42 participants (Actual)Interventional2018-08-17Completed
A Pharmacokinetic Drug-Drug Interaction Study to Evaluate the Effect of Steady-State Quinine Sulfate on the Pharmacokinetics of Single-Dose Theophylline in Healthy Adult Males [NCT00779259]Phase 124 participants (Actual)Interventional2007-08-31Completed
A Pharmacokinetic Interaction Study Evaluating the Effect of Qualaquin (Quinine Sulfate) Capsules on Midazolam [NCT00785486]Phase 124 participants (Actual)Interventional2007-03-31Completed
The Role of Bitter Taste Receptors Expressed in the Gastrointestinal Tract in Altering Food Intake and Gastrointestinal Motility [NCT02759926]98 participants (Anticipated)Interventional2011-08-31Active, not recruiting
A Randomized Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon [NCT02563704]Phase 3238 participants (Actual)Interventional2013-09-30Completed
A Randomized, Two-way Crossover Design Used to Compare the Dose Proportionality of Quinine Sulfate Capsules, 324 mg Following a Single Oral Dose of 1 x 324 mg Capsule Versus 2 x 324 mg Capsules in Healthy Adult Volunteers [NCT00726895]Phase 124 participants (Actual)Interventional2004-05-31Completed
Short Course of Quinine Plus a Single Dose of Sulphadoxine-Pyrimethamine for Plasmodium Falciparum Malaria [NCT00167739]Phase 450 participants Interventional2003-04-30Completed
Brain Responses to Intragastric Administration of a Bitter Agonist in Homeostatic and Hedonic Brain Regions [NCT02946970]15 participants (Actual)Interventional2015-09-30Completed
Evaluation of a Compliance Marker A Supplement to: U01DA029580-02 Opioid-Induced Hyperalgesia In Prescription Opioid Abusers: Effects of Pregabalin [NCT02276989]Phase 20 participants (Actual)Interventional2014-12-31Withdrawn(stopped due to poor recruitment)
Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children [NCT00540202]Phase 4302 participants (Anticipated)Interventional2007-09-30Recruiting
An Open-Label Drug-Drug Interaction Study to Investigate the Effects of Steady State Quinine on the Single-Dose Pharmacokinetics of Rosiglitazone Maleate in Healthy Volunteers [NCT00785213]Phase 123 participants (Actual)Interventional2008-09-30Completed
A One-Directional, Open-Label Drug Interaction Study to Investigate the Effects of Multiple-Dose Ciprofloxacin HCl on the Single-Dose Pharmacokinetics of Quinine in Healthy Volunteers [NCT00785980]Phase 124 participants (Actual)Interventional2008-09-30Completed
Taste Physiology in Obese Volunteers Before and After Bariatric Surgery [NCT02902198]16 participants (Anticipated)Interventional2014-12-31Recruiting
Pharmacodynamic and Pharmacokinetic Interactions Between Intravenous Cocaine and Acetazolamide or Quinine [NCT01851473]Phase 114 participants (Actual)Interventional2012-10-24Completed
Effects of Intragastric Quinine, Alone or Combined With L-leucine, on Postprandial Glycaemic Control [NCT05720390]16 participants (Anticipated)Interventional2023-02-02Recruiting
Efficacy and Safety of Adjuvant Topical Irrigation in the Treatment of Acute Exacerbation of Chronic Rhinosinusitis Following Functional Endoscopic Sinus Surgery (FESS) [NCT02630472]Phase 1/Phase 210 participants (Actual)Interventional2015-10-31Terminated(stopped due to Institutional decision)
Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children With Falciparum Malaria [NCT00329134]Phase 256 participants (Anticipated)Interventional2006-07-31Completed
A Relative Bioavailability Study of Quinine Sulfate Capsules 324mg Under Fasting and Fed Conditions [NCT00726414]Phase 122 participants (Actual)Interventional2005-12-31Completed
Very Severe Malaria Treated by Intravenous Artesunate: Epidemiology, Management, Outcome and Prognostic [NCT04516317]578 participants (Actual)Observational2020-08-10Completed
Impact of Different Treatment Modalities on Immunity Against COVID-19 [NCT04553705]Phase 2/Phase 3150 participants (Actual)Interventional2020-09-20Completed
Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial [NCT00124267]Phase 3108 participants Interventional2003-09-30Active, not recruiting
Phase II, Open Label, Randomized Study of Azithromycin Combination Therapy for the Treatment of Acute, Uncomplicated Falciparum Malaria [NCT00299208]Phase 2120 participants InterventionalCompleted
Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine [NCT00000706]12 participants InterventionalCompleted
[NCT00451139]Phase 40 participants InterventionalCompleted
Intravenous Artesunate Versus Quinine in Severe Malaria at Kassla, Sudan [NCT01805232]Phase 480 participants (Anticipated)Interventional2013-03-31Recruiting
Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa [NCT02974348]Phase 3300 participants (Actual)Interventional2013-01-31Completed
A Randomised Safety and Efficacy Trial of Rifampicin/Cotrimoxazole/Isoniazid Versus Mefloquine or Quinine+SP Against Resistant Malaria in Papua New Guinea [NCT00322907]Phase 2330 participants Interventional2000-04-30Terminated
Effects of Intragastric Quinine, Alone or Combined With L-isoleucine, on Postprandial Glycaemic Control [NCT05682339]16 participants (Anticipated)Interventional2023-06-19Recruiting
The Effect of Quinine Hydrochloride on Hedonic Food Intake, Appetite-related Sensations and Gastrointestinal Hormone Release in Overweight Female Subjects [NCT04873011]Phase 140 participants (Anticipated)Interventional2020-10-29Recruiting
An Open Label Randomised Comparative Trial to Establish the Efficacy of 3 mg/kg ArTiMist™ When Compared to Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complicatio [NCT01047436]Phase 231 participants (Actual)Interventional2009-12-31Completed
A Phase III, Randomised, Open Labelled, Active Controlled, Multi Centre, Superiority Trial of ArTiMist™ Versus Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complic [NCT01258049]Phase 3151 participants (Actual)Interventional2010-12-31Completed
A Comparison of the Bioavailability of Quinine Sulfate Capsules Following a 648 mg Dose When Mixed in Chocolate Pudding Relative to That With Intact Capsules in Healthy Adults Under Fasting Conditions [NCT00806078]Phase 118 participants (Actual)Interventional2007-07-31Completed
[NCT02492178]Phase 282 participants (Actual)Interventional2015-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00726414 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)] for Quinine Sulfate
NCT00726414 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Quinine Sulfate
NCT00726414 (3) [back to overview]Maximum Plasma Concentration (Cmax) for Quinine Sulfate
NCT00726895 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]
NCT00726895 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
NCT00726895 (3) [back to overview]Maximum Plasma Concentration (Cmax)
NCT00727272 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
NCT00727272 (3) [back to overview]Maximum Plasma Concentration (Cmax)
NCT00727272 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]
NCT00779259 (5) [back to overview]Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)].
NCT00779259 (5) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
NCT00779259 (5) [back to overview]Electrocardiogram (ECG) Evaluation of the Maximum QT Interval Corrected for Heartrate (QTc), Quinine Study Day 11.
NCT00779259 (5) [back to overview]Maximum Plasma Concentration(Cmax)
NCT00779259 (5) [back to overview]Electrocardiogram (ECG) Evaluation of the Maximum QT Interval Corrected for Heartrate (QTc), Theophylline Co-administered With Quinine, Study Day 12.
NCT00785213 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]
NCT00785213 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
NCT00785213 (3) [back to overview]Maximum Plasma Concentration (Cmax) of Rosiglitazone
NCT00785486 (4) [back to overview]Area Under the Concentration Time Curve From Zero to Infinity (AUC Inf) for Midazolam and 1 Hydroxy Midazolam Before (Day 1) and After (Day 10) Qualaquin (Quinine).
NCT00785486 (4) [back to overview]Area Under the Concentration Time Curve From Zero to T (AUC 0-t) for Midazolam and 1-hydroxy Midazolam at Baseline and With Qualaquin (Quinine) at Steady State.
NCT00785486 (4) [back to overview]Maximum Serum Concentration (Cmax)
NCT00785486 (4) [back to overview]The Area Under the the Concentration Time Curve From Zero to Tau (0-8hrs) for Qualaquin (Quinine) AUC Tau Before and After Midazolam
NCT00785980 (3) [back to overview]Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)].
NCT00785980 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
NCT00785980 (3) [back to overview]Maximum Plasma Concentration(Cmax)
NCT00806078 (3) [back to overview]The Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity. (AUC Inf)
NCT00806078 (3) [back to overview]Area Under the Concentration Time Curve From Zero to t. (AUC 0-t)
NCT00806078 (3) [back to overview]Maximum Observed Plasma Concentration (Cmax)
NCT01047436 (6) [back to overview]Parasitological Success Defined as a Reduction in Parasite Count of ≥ 90% of Baseline at 24 Hours After the First Dose
NCT01047436 (6) [back to overview]Time for Parasite Count to Fall by 50% PCT(50)
NCT01047436 (6) [back to overview]Time for Parasite Count to Fall by 90% PCT(90)
NCT01047436 (6) [back to overview]Parasite Clearance Time
NCT01047436 (6) [back to overview]Parasite Reduction Ratio (PRR) at 12 Hours After the First Dose
NCT01047436 (6) [back to overview]Parasite Reduction Ratio (PRR) at 24 h (Hours) After the First Dose
NCT01258049 (16) [back to overview]Late Parasitological Failure
NCT01258049 (16) [back to overview]Number of Deaths or Neurological Sequelae at Day 28
NCT01258049 (16) [back to overview]Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, of Possible, Probably and Definite Causalities
NCT01258049 (16) [back to overview]Early Treatment Failure
NCT01258049 (16) [back to overview]PCT 50 [MITT Population]
NCT01258049 (16) [back to overview]PCT 90 [MITT Population]
NCT01258049 (16) [back to overview]PRR 12 [MITT Population]
NCT01258049 (16) [back to overview]PRR 24 [MITT Population]
NCT01258049 (16) [back to overview]Time to Return to Full Consciousness
NCT01258049 (16) [back to overview]Parasite Clearance Time (PCT) [MITT Population]
NCT01258049 (16) [back to overview]Complete Cure Rate
NCT01258049 (16) [back to overview]Parasitological Success (MITT)
NCT01258049 (16) [back to overview]Parasitological Success (PP)
NCT01258049 (16) [back to overview]Fever Clearance Time (FCT)
NCT01258049 (16) [back to overview]Late Clinical Failure
NCT01258049 (16) [back to overview]Time to Return to Normal Per os Status

Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)] for Quinine Sulfate

The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant. (NCT00726414)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after drug administration.

Interventionng-hr/mL (Mean)
Quinine Sulfate Under Fasted Conditions52,643.14
Quinine Sulfate Under Fed Conditions54,409.12

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Quinine Sulfate

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT00726414)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after drug administration.

Interventionng-hr/mL (Mean)
Quinine Sulfate Under Fasted Conditions49,484.64
Quinine Sulfate Under Fed Conditions51,228.07

[back to top]

Maximum Plasma Concentration (Cmax) for Quinine Sulfate

The maximum or peak concentration that Quinine Sulfate reaches in the plasma. (NCT00726414)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after drug administration.

Interventionng/mL (Mean)
Quinine Sulfate Under Fasted Conditions3,293.84
Quinine Sulfate Under Fed Conditions3,424.30

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]

The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant. (NCT00726895)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after drug administration.

Interventionng-hr/mL (Mean)
Treatment A - Quinine Sulfate Capsules (1 x 324 mg Dose)35,199.28
Treatment A, Dose Adjusted to 2 x 324 mg70,398.56
Treatment B - Quinine Sulfate Capsules (2 x 324 mg Dose)61,570.10

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT00726895)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after drug administration.

Interventionng-hr/mL (Mean)
Treatment A - Quinine Sulfate Capsules (1 x 324 mg Dose)31,951.03
Treatment A, Dose Adjusted to 2 x 324 mg63,902.06
Treatment B - Quinine Sulfate Capsules (2 x 324 mg Dose)56,198.20

[back to top]

Maximum Plasma Concentration (Cmax)

The maximum or peak concentration that the drug reaches in the plasma. (NCT00726895)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after drug administration.

Interventionng/mL (Mean)
Treatment A - Quinine Sulfate Capsules (1 x 324 mg Dose)2,118.35
Treatment A, Dose Adjusted to 2 x 324 mg4,236.70
Treatment B - Quinine Sulfate Capsules (2 x 324 mg Dose)3,242.92

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT00727272)
Timeframe: serial pharmacokinetic blood samples drawn within one hour prior to dosing (hour 0) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after dose administration.

Interventionng-hr/mL (Mean)
Treatment A - Quinine Sulfate 324 mg Caps, Fasting Conditions32,689.35
Treatment A, Dose Adjusted to 300 mg30,267.96
Treatment B- Quinine Sulphate 300 mg Tabs, Fasting Conditions31,689.32
Treatment C - Quinine Sulfate 324 mg Caps, Fed Conditions34,729.00

[back to top]

Maximum Plasma Concentration (Cmax)

The maximum or peak concentration that the drug reaches in the plasma. (NCT00727272)
Timeframe: serial pharmacokinetic blood samples drawn within one hour prior to dosing (hour 0) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after dose administration.

Interventionng/mL (Mean)
Treatment A - Quinine Sulfate 324 mg Caps, Fasting Conditions2,246.58
Treatment A, Dose Adjusted to 300 mg2,080.18
Treatment B- Quinine Sulphate 300 mg Tabs, Fasting Conditions2,278.46
Treatment C - Quinine Sulfate 324 mg Caps, Fed Conditions2,539.94

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]

The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant. (NCT00727272)
Timeframe: serial pharmacokinetic blood samples drawn within one hour prior to dosing (hour 0) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after dose administration.

Interventionng-hr/mL (Mean)
Treatment A - Quinine Sulfate 324 mg Caps, Fasting Conditions36,132.35
Treatment A, Dose Adjusted to 300 mg33,456.04
Treatment B- Quinine Sulphate 300 mg Tabs, Fasting Conditions34,410.28
Treatment C - Quinine Sulfate 324 mg Caps, Fed Conditions37,550.81

[back to top]

Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)].

The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞)was calculated as the sum of the AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant. (NCT00779259)
Timeframe: Serial pharmacokinetic blood samples for theophylline collected on Days 1 and 12 before dosing and for 48 hours post-dose.

Interventionug-hr/mL (Mean)
Theophylline Alone108.21
Theophylline in Presence of Quinine96.88

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

The area under the plasma concentration versus time curve beginning from the first dose (time 0) to the last measurable concentration (time t), as calculated by the linear trapezoidal method. (NCT00779259)
Timeframe: Serial pharmacokinetic blood samples for theophylline collected on Days 1 and 12 before dosing and for 48 hours post-dose. Serial pharmacokinetic blood samples for quinine collected on Days 11 and 12 before dosing and for 8 hours after the morning dose.

Interventionug-hr/mL (Mean)
Theophylline Alone103.47
Quinine Alone45.17
Theophylline in Presence of Quinine92.72
Quinine in Presence of Theophylline51.68

[back to top]

Electrocardiogram (ECG) Evaluation of the Maximum QT Interval Corrected for Heartrate (QTc), Quinine Study Day 11.

The QT interval assesses cardiac repolarization and risk for arrhythmias. It is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. QTc is the QT interval corrected for heartrate. (NCT00779259)
Timeframe: 5 hours - measured 1 hour pre-dose and then at 4 hours after the morning dose on Day 11

Interventionmsec (Number)
1 Hour Before Morning Dose of Quinine on Study Day 11453.33
4 Hours After Morning Dose of Quinine on Study Day 11451.33

[back to top]

Maximum Plasma Concentration(Cmax)

The maximum or peak concentration that the drug reaches in the plasma. (NCT00779259)
Timeframe: Serial pharmacokinetic blood samples for theophylline collected on Days 1 and 12 before dosing and for 48 hours post-dose. Serial pharmacokinetic blood samples for quinine collected on Days 11 and 12 before dosing and for 8 hours after the morning dose.

Interventionug/mL (Mean)
Theophylline Alone9.58
Quinine Alone6.63
Theophylline in the Presence of Quinine9.81
Quinine in the Presence of Theophylline7.47

[back to top]

Electrocardiogram (ECG) Evaluation of the Maximum QT Interval Corrected for Heartrate (QTc), Theophylline Co-administered With Quinine, Study Day 12.

The QT interval assesses cardiac repolarization and risk for arrhythmias. It is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. QTc is the QT interval corrected for heartrate. (NCT00779259)
Timeframe: 5 hours - measured 1 hour pre-dose and then at 4 hours post-dose on Day 12

Interventionmsec (Number)
1 Hour Before Co-Administered Dose of Theophylline/Quinine452
4 Hours After Co-Administered Dose of Theophylline/Quinine455.33

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]

The area under the plasma concentration versus time curve from time 0 to infinity. [AUC(0-∞)] was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant for rosiglitazone. (NCT00785213)
Timeframe: serial pharmacokinetic blood samples drawn prior to dosing on Days 1 and 7 and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 20 and 24 hours after dose administration.

Interventionug-hr/mL (Mean)
Rosiglitazone Alone1.99
Rosiglitazone With Quinine Sulfate2.10

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

The area under the plasma concentration versus time curve from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule for rosiglitazone. (NCT00785213)
Timeframe: serial pharmacokinetic blood samples drawn prior to dosing on Days 1 and 7 and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 20 and 24 hours after dose administration.

Interventionug-hr/mL (Mean)
Rosiglitazone Alone1.96
Rosiglitazone With Quinine Sulfate2.07

[back to top]

Maximum Plasma Concentration (Cmax) of Rosiglitazone

The maximum or peak concentration that rosiglitazone reaches in the plasma. (NCT00785213)
Timeframe: serial pharmacokinetic blood samples drawn prior to dosing on Days 1 and 7 and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 20 and 24 hours after dose administration.

Interventionug/mL (Mean)
Rosiglitazone Alone0.41
Rosiglitazone With Quinine Sulfate0.43

[back to top]

Area Under the Concentration Time Curve From Zero to Infinity (AUC Inf) for Midazolam and 1 Hydroxy Midazolam Before (Day 1) and After (Day 10) Qualaquin (Quinine).

AUC inf for Midazolam and hydroxy-midazolam on day 1 (midazolam alone) and day 10 (midazolam with steady state Qualaquin(quinine)- the sum of AUC0-t plus the ratio of the last measured plasma concentration to the elimination rate constant to determine whether a significant drug interaction occurs between midazolam and quinine (NCT00785486)
Timeframe: Days 1 and 10 at 0.167, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 7.917, 12, 15 and 24 hours

Interventionng·h/mL (Mean)
Midazolam - Midazolam Alone31.324
1-Hydroxy-Midazolam - Midazolam Alone11.669
Midazolam - Midazolam With Qualaquin (Quinine)28.771
1-Hydroxy-Midazolam -Midazolam With Qualaquin (Quinine)11.447

[back to top]

Area Under the Concentration Time Curve From Zero to T (AUC 0-t) for Midazolam and 1-hydroxy Midazolam at Baseline and With Qualaquin (Quinine) at Steady State.

Area under the concentration time curve(AUC 0-t) calculated by the linear trapezoidal method from time 0 to 24 hours, for Midazolam and 1-hydroxy-midazolam on day 1 (midazolam alone) and day 10 (midazolam with Qualaquin -(quinine) at steady state to determine if a significant drug interaction occurs between midazolam and quinine (NCT00785486)
Timeframe: Days 1 and 10 at 0.167, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 7.917, 12, 15 and 24 hours

Interventionng•h/mL (Mean)
Midazolam - Midazolam Alone30.076
1-Hydroxy-Midazolam - Midazolam Alone10.780
Midazolam - Midazolam With Qualaquin (Quinine)27.242
1-Hydroxy-Midazolam -Midazolam With Qualaquin (Quinine)10.454

[back to top]

Maximum Serum Concentration (Cmax)

Maximum serum concentration(Cmax) (NCT00785486)
Timeframe: Day 1 (Midazolam Alone), Day 9 (Qualaquin (quinine) Alone), Day 10 Midazolam with Qualaquin (quinine)

Interventionng/ml (Mean)
Midazolam - Midazolam Alone12.0435
1-Hydroxy-Midazolam - Midazolam Alone4.6907
Quinine - Qualaquin(Quinine) Alone4432.4089
Midazolam - Midazolam With Qualaquin(Quinine)12.5585
1-Hydroxy-Midazolam -Midazolam With Qualaquin(Quinine)4.8605
Quinine - Qualaquin (Quinine) With Midazolam4399.7690

[back to top]

The Area Under the the Concentration Time Curve From Zero to Tau (0-8hrs) for Qualaquin (Quinine) AUC Tau Before and After Midazolam

Qualaquin (quinine) - AUC tau alone at steady state (day 9) and in the presence of coadministered midazolam 2 mg (day 10) over the dosing interval (0 - 8 hours), as calculated by the linear trapezoidal method. (NCT00785486)
Timeframe: Days 9 and 10 at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, and 7.917 hours

Interventionng•h/mL (Mean)
Qualaquin (Quinine) Alone30455.4
Qualaquin (Quinine) With Midazolam30568.7

[back to top]

Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)].

The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞)was calculated as the sum of the AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant. (NCT00785980)
Timeframe: Serial pharmacokinetic blood samples for quinine sulfate collected on Days 1 and 11 before dosing and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 36 hours post-dose.

Interventionng-hr/mL (Mean)
Quinine Sulfate Alone67,694.99
Quinine Sulfate With Ciprofloxacin77,439.24

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

The area under the plasma concentration versus time curve beginning from the first dose (time 0) to the last measurable concentration (time t), as calculated by the linear trapezoidal method. (NCT00785980)
Timeframe: Serial pharmacokinetic blood samples for quinine sulfate collected on Days 1 and 11 before dosing and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 36 hours post-dose.

Interventionng-hr/mL (Mean)
Quinine Sulfate Alone63,415.67
Quinine Sulfate With Ciprofloxacin68,572.17

[back to top]

Maximum Plasma Concentration(Cmax)

The maximum or peak concentration that the drug reaches in the plasma. (NCT00785980)
Timeframe: Serial pharmacokinetic blood samples for quinine sulfate collected on Days 1 and 11 before dosing and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 36 hours post-dose.

Interventionng/mL (Mean)
Quinine Sulfate Alone4,240.65
Quinine Sulfate With Ciprofloxacin4,521.20

[back to top]

The Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity. (AUC Inf)

AUC inf is calculated as the sum of the AUC 0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant.It is calculated to evaluate the bioequivalence of the two dosing methods (NCT00806078)
Timeframe: After dosing at time points 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, and 48 hours

Interventionng-h/ml (Mean)
Quinine Alone61887.4
Quinine With Chocolate Pudding60764.9

[back to top]

Area Under the Concentration Time Curve From Zero to t. (AUC 0-t)

The area under the plasma concentration versus time curve from zero to the last measurable plasma concentration as calculated by the linear trapezoidal method. Calculated to determine whether the 2 methods of administration are bioequivalent. (NCT00806078)
Timeframe: After dosing at time points 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, and 48 hours

Interventionng·h/mL (Mean)
Quinine Alone555973.3
Quinine With Chocolate Pudding56008.6

[back to top]

Maximum Observed Plasma Concentration (Cmax)

The highest concentration of drug in plasma after a dose. Measured to evaluate the bioequivalence of the two dosing methods (NCT00806078)
Timeframe: After dosing at time points 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, and 48 hours

Interventionng per mL (Mean)
Quinine Alone3291.411
Quinine With Chocolate Pudding3439.867

[back to top]

Parasitological Success Defined as a Reduction in Parasite Count of ≥ 90% of Baseline at 24 Hours After the First Dose

(NCT01047436)
Timeframe: 24 hours after first dose

Interventionparticipants (Number)
ArTiMist14
Intravenous Quinine10

[back to top]

Time for Parasite Count to Fall by 50% PCT(50)

The time taken for the parasite count to fall 50% from baseline (NCT01047436)
Timeframe: 3 h (hours) , 6h, 12h, 18h, 24h, 30h, 36h, 48h, 54h, 60h

Interventionhours (Mean)
ArTiMist12.0
Intravenous Quinine10.8

[back to top]

Time for Parasite Count to Fall by 90% PCT(90)

The time taken for the parasite count to fall 90% from baseline (NCT01047436)
Timeframe: 3h (hours), 6h, 12h, 18h, 24h, 30h, 36h, 48h, 54h, 60h

Interventionhours (Mean)
ArTiMist17.6
Intravenous Quinine19.8

[back to top]

Parasite Clearance Time

Time in hours from the initiation of therapy until the first of two successive parasite-negative smears were obtained (NCT01047436)
Timeframe: 3h (hours), 6h, 12h, 18h, 24h, 30h, 36h, 48h, 54h, 60h

InterventionHours (Mean)
ArTiMist35.7
Intravenous Quinine51.2

[back to top]

Parasite Reduction Ratio (PRR) at 12 Hours After the First Dose

Reduction in parasitaemia from baseline at 12 hours after the first dose of study medication (NCT01047436)
Timeframe: 12 h (hours) after first dose

InterventionPercent reduction (Median)
ArTiMist79.6
Intravenous Quinine75.9

[back to top]

Parasite Reduction Ratio (PRR) at 24 h (Hours) After the First Dose

Reduction in parasitaemia from baseline at 24 h after the first dose of study medication (NCT01047436)
Timeframe: 24 hours after first dose

InterventionPercent reduction (Median)
ArTiMist100.0
Intravenous Quinine96.9

[back to top]

Late Parasitological Failure

o Parasitaemia on any day from Day 7 to Day 28 and tympanic temperature ≤ 38.0°C (NCT01258049)
Timeframe: 28 days after the start of treatment

Interventionparticipants (Number)
ArTiMist12
Quinine14

[back to top]

Number of Deaths or Neurological Sequelae at Day 28

(NCT01258049)
Timeframe: 28 days after start of treatment

Interventionparticipants (Number)
ArTiMist0
Quinine0

[back to top]

Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, of Possible, Probably and Definite Causalities

(NCT01258049)
Timeframe: 28 days after start of treatment

Interventionparticipants (Number)
ArTiMist5
Quinine6

[back to top]

Early Treatment Failure

"Early treatment failure is indicated by one or more of the following:~Parasite count on Day 2 > Day 0, irrespective of temperature~Parasite count on Day 3 > 0 with tympanic temperature ≥ 38.0°C~Parasite count on Day 3 ≥ 25% of baseline~Administration of rescue antimalarial treatment" (NCT01258049)
Timeframe: Three days after the start of treatment

Interventionparticipants (Number)
ArTiMist0
Quinine14

[back to top]

PCT 50 [MITT Population]

Time for parasite counts to fall by 50% (NCT01258049)
Timeframe: 28 days after start of treatment

Interventionhours (Mean)
ArTiMist9.42
Quinine18.58

[back to top]

PCT 90 [MITT Population]

Time for parasite counts to fall by 90% (NCT01258049)
Timeframe: 28 days after start of treatment

Interventionhours (Mean)
ArTiMist15.02
Quinine27.93

[back to top]

PRR 12 [MITT Population]

The percentage reduction in parasite counts 12 hours after first dose (NCT01258049)
Timeframe: 28 days after start of treatment

Interventionpercentage of baseline (Mean)
ArTiMist47.6
Quinine-132.2

[back to top]

PRR 24 [MITT Population]

The percentage reduction in parasite counts 24 hours after first dose (NCT01258049)
Timeframe: 28 days after start of treatment

Interventionpercentage of baseline (Mean)
ArTiMist98.2
Quinine44.5

[back to top]

Time to Return to Full Consciousness

"Time in hours to return to full consciousness (Blantyre Coma Scale = 5), if level of consciousness is reduced (Blantyre Coma Scale <5) prior to dosing or within 24hours of first dosing.~For the Blantyre Coma Scale~Total - maximum 5, eye movement - maximum 1, best motor response - maximum 2, best verbal response - maximum 2" (NCT01258049)
Timeframe: 28 days after start of treatment

Interventionhours (Mean)
ArTiMist20.8
Quinine23.0

[back to top]

Parasite Clearance Time (PCT) [MITT Population]

Parasite clearance time (PCT). Time in hours from the initiation of therapy until the first of two successive parasite negative smears (zero parasite counts) are obtained (NCT01258049)
Timeframe: 28 days after start of treatment

Interventionhours (Mean)
ArTiMist30.29
Quinine68.30

[back to top]

Complete Cure Rate

The complete resolution of clinical signs and symptoms, malaria-related laboratory abnormalities, and elimination of asexual parasites by Day 7, with no recurrence up to Day 28 (+/- 2 days), and the 48h parasite count to be < 25% of baseline with no clinical deterioration (NCT01258049)
Timeframe: 28 days after the start of treatment

,
Interventionparticipants (Number)
CureNo Cure
ArTiMist4114
Quinine4617

[back to top]

Parasitological Success (MITT)

Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose (NCT01258049)
Timeframe: 24 hours after start of treatment

,
Interventionparticipants (Number)
SuccessNot Success
ArTiMist664
Quinine2843

[back to top]

Parasitological Success (PP)

Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose (NCT01258049)
Timeframe: 24 hours after start of treatment

,
Interventionparticipants (Number)
SuccessNot Success
ArTiMist653
Quinine2841

[back to top]

Fever Clearance Time (FCT)

Time in hours from the initiation of therapy until the disappearance of fever (tympanic temperature < 38.0) that lasted at least 24 hours. (NCT01258049)
Timeframe: 28 days after start of treatment

Interventionhours (Mean)
ArTiMist42.6
Quinine41.6

[back to top]

Late Clinical Failure

"Signs of severe malaria on any day between Day 4 and Day 28 in the presence of parasitaemia, without previously meeting any of the criteria of early treatment failure~Presence of parasitaemia and tympanic temperature ≥ 38.0°C (or history of fever), on any day between Day 4 and Day 28, without previously meeting any of the criteria of early treatment failure" (NCT01258049)
Timeframe: 28 days after the start of treatment

Interventionparticipants (Number)
ArTiMist3
Quinine1

[back to top]

Time to Return to Normal Per os Status

Time in hours to return to normal per os status. Normal per os was when the investigator considered the patient to be able to eat and drink normally. (NCT01258049)
Timeframe: 28 days after start of treatment

Interventionhours (Mean)
ArTiMist22.1
Quinine25.3

[back to top]